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Abstract 
Recent statistics show that approximately 415 million people worldwide have 
diabetes.  Glycated haemoglobin (HbA1c) measurements were introduced many 
years ago as the gold standard tool for detecting and monitoring treatment as well as 
making management decisions for diabetic patients. Glycated haemoglobins are 
formed by the non-enzymatic glycation of haemoglobin molecules. This non-
enzymatic glycation process has been strongly related to pathogenesis of chronic 
complications associated to diabetes. It was suggested that this glycation process 
may be moderated by an enzymatic deglycation process thought to involve a 
deglycating enzyme known as Fructosamine-3-kinase (FN3K), an enzyme that 
deglycates the glycated haemoglobin in erythrocytes and other glycated proteins in 
other tissues.  
FN3K acts through phosphorylation of fructosamines on the third carbon of their 
sugar moiety, making them unstable and consequently causing them to detach from 
the protein. The degree of deglycation is thought to depend on the activity of the 
FN3K enzyme. Moreover, variation in the activity of FN3K between individuals is 
hypothesised to lead to apparent differences in glycated haemoglobin levels: some 
individuals have high rates of deglycation so that they tend to have lower  average 
glycaemia than actually  the case, while others with low rates of deglycation appear 
to have higher  than actual glycaemia (known as the glycation gap, G-gap). The G-
gap has been reported to be associated with alteration of diabetic complications risk. 
The G-gap reflects the discrepancy between average glycaemia as determined from 
glycated haemoglobin (measured as HbA1c) and that from the determination of 
fructosamine. The positive G-gap is defined as a higher level of glycation of proteins 
than expected whereas a negative G-gap means a lower level of glycation than 
expected. To explore the role of FN3K in diabetes and other associated morbidities, 
we decided to divide our research into 3 studies. Each study was categorised 
according to the type and the source of samples involved.  
The first study explored the correlation between FN3K activity and protein level with 
G-gap data; it involved 148 diabetic patients who were recruited at New Cross 
Hospital, Wolverhampton, selected as having a consistent positive G-gap > +0.5 and 
a consistent negative G-gap > -0.5 over a minimum of 2 estimations. Age, gender, 
race and BMI were collected from patients in this study. Blood samples were also 
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collected to measure FN3K activity, protein levels, and markers of CVD in relation to 
G-gap.  
The second study involved 23 AECOPD patients who were recruited from St 
George’s Hospital (London) and were treated with either metformin or a placebo. 
Serum samples were collected from these patients for a larger study: we assayed 
those 23 serum samples for FN3K protein levels to explore any possible correlation 
between FN3K with metformin therapy in COPD patients.   
The third study utilised 36 human peripheral lung samples from healthy individuals, 
asymptomatic smokers and stable COPD patients (GOLD 2) who were recruited at 
The Section of Respiratory Medicine, University Hospital of Ferrara, Italy. Those 
samples were assessed for FN3K expression by means of immunohistochemistry to 
explore the difference in FN3K activity between those three categories.    
It was found that the intracellular activity and protein expression of the FN3K 
enzyme in diabetic patients negatively correlated with the values of G-gaps where 
FN3K activity was high in patients with negative G-gap. FN3K serum protein levels 
were shown to be enhanced with metformin administration in COPD diabetic 
patients, suggesting a protective role for FN3K enzyme against protein damaged 
caused by the non-enzymatic glycation of proteins. Therefore, patients with positive 
G-gap have lower FN3K activity than those with negative G-gap, and in turn they are 
more susceptible to diabetes related complications.  Our data also indicate that 
metformin has a beneficial effect in reducing damage caused by carbonyl stress from 
cigarette smoking in COPD patients by the action of FN3K.  
Our research has demonstrated that FN3K contributes to the protein repair 
system which protects against damage caused by non-enzymatic glycation. The high 
activity for the FN3K enzyme was associated with low levels of AGEs and low 
carbonyl stress levels in observed among patients with diabetes and COPD. In 
contrast, COPD patients tend to have low FN3K-mediated protection against protein 
damage in comparison to the normal population. These patients tend to be at risk for 
developing more complications, particularly CVD complications, than normal, healthy 
individuals. Treatment with metformin enhances FN3K action in COPD diabetic 
patients, possibly as a protective enzyme against the damaged caused by the non-
enzymatic glycation. 
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1.1 Diabetes 
Diabetes mellitus is a chronic condition characterised by an abnormal elevation of 
glucose in the blood (hyperglycaemia) due to an absolute or relative deficiency of 
insulin. It is associated with reduction in life expectancy, significant morbidity, 
increased risk of macro-vascular complications, and low quality of life (World Health 
Organisation (WHO), 1999). 
1.1.1 Epidemiology of Diabetes 
In 2015, it was estimated that approximately 415 million people around the world are 
living with diabetes, and it is predicted that this number will continue to increase, 
reaching approximately 642 million people by the year 2040 (International Diabetes 
Federation (IDF), 2015). The WHO anticipate that the number of deaths attributed to 
diabetes will double between the years 2005 and 2030 (WHO, 2011). A further 193 
million diabetics are undiagnosed and are at risk of developing complications (IDF, 
2015). Diabetes can be classified into two main types: Type 1 (insulin-dependent 
diabetes mellitus) and Type 2 (non-insulin-dependent diabetes mellitus) (Williams, 
2002). 
It was estimated that there are 3.8 million people living with diabetes in the UK 
alone, and according to the NHS, the total direct cost of diabetes was £9.8 billion in 
2010-2011 (£1 billion for Type 1 and the remaining £8.8 billion for Type 2 diabetes). 
Approximately 80% of this cost can be attributed to complications associated with 
diabetes (Diabetes UK, 2014). In addition, the indirect costs associated with diabetes 
from 2010-2011 were calculated to be £13.9 billion (comprising £0.9 billion for Type 
1 diabetes and £13 billion for Type 2). The estimated projected cost for this disease 
is expected to rise to £39.8 billion by 2035-2036: £16.9 billion of this is assigned for 
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direct costs (£1.8 billion for Type 1 and £15.1 billion for Type 2 diabetes, 
respectively), and the remaining £22.9 billion for indirect treatment (£2.4 billion to be 
spent on Type 1 diabetes and £20.5 billion on Type 2 diabetes) (Hex et al., 2012). 
  In 2012, The American Diabetes Association (ADA) reported that the total 
expenditure for diabetes had exceeded their $174 billion budget for 2007 and $245 
billion budget for 2012, excluding unforeseen social costs. These include factors 
such as “pain and suffering, additional care provided by nonpaid caregivers, excess 
medical costs associated with undiagnosed diabetes, and diabetes-attributed costs 
for health care expenditures categories excluding health care system administrative 
costs, over-the-counter medications, clinician training programs, and research and 
infrastructure development” (ADA, 2012).  
Zhuo et al. (2014) concluded that patients with diabetes are subjected to a 
lifetime of costly medical expenditures and a lower life expectancy compared with 
the non-diabetic population. They proposed that a reduction in long-term medical 
costs associated with diabetes could be achieved if preventive costs were kept low.  
Diabetic patients usually fail to control their blood glucose, lipid, and/or blood 
pressure levels. This is because the majority of diabetic adults seek their treatments 
from primary care and physicians (Crosson et al., 2010). This failure to control blood 
glucose leads to an increased risk for cardiovascular diseases and other related 
complications (American Heart Association, 2016). The prevention of cardiovascular 
diseases can be achieved by providing optimal control for glycaemia, blood pressure 
and lipids, which is itself an important step in managing diabetes since much of 
diabetes-related morbidity and mortality is the result of cardiovascular disease 
(Crosson et al., 2010).  
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1.1.2 Glycaemic control 
The main therapeutic objective for prevention of acute and chronic diabetes and 
other associated complications is thought to be glycaemic control (Koro et al., 2004). 
Many randomised control trials have shown that a reduction in glycaemia, lipids and 
blood pressure levels has a positive outcome for diabetes-related complications 
(Skyler, 2004). A number of studies have shown that a major decrease in glycaemic 
levels reduces the risk of cardiovascular disease and death (Cefalu and Watson, 
2008). There is growing recognition that an improvement in intensive blood glucose 
monitoring will reduce the progression of diabetic macro-vascular diseases (UKPDS, 
1998). Furthermore, Mazzone (2010) reported that intensive glycaemic control can 
be conductive to preventing long-term cardiovascular complications among diabetic 
patients.  
According to Chan et al., (2000) several independent factors contribute to 
poor glycaemic control: inappropriate treatment in relation to pancreatic -cell 
function, increasing insulin resistance, lack of therapeutic patient education and 
smoking. A study conducted by Murata et al. (2003) involved a large cohort of Type 
2 diabetic veterans who underwent stable insulin treatment. It was shown that 
intensive self-blood glucose monitoring (SBMG) improved glycaemic control level 
among each test subject, which in turn leads to a sustained decrease in glycated 
haemoglobin levels. 
Type 2 diabetes, however, is characterized by peripheral insulin resistance 
and deterioration in β-cell function (Kahn, 2003). Insulin resistance can be described 
‘as the inability of insulin hormone to be biologically effective at circulating 
concentrations as in normal individuals’ (Goke, 1998, s18).  The core metabolic 
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defect in Type 2 diabetic patients is insulin resistance and it presents as 
hyperglycaemia (Taylor, 2012). It was estimated that up to 90% of Type 2 diabetic 
patients have a combination of insulin resistance and inadequate compensatory 
insulin secretion (Colberg et al., 2010). Numerous cardiovascular risk factors are 
associated with Type 2 diabetes (Martín-Timón et al., 2014) which are caused by 
insulin resistance (Steinberger and Daniels, 2003). According to Henry (1996), it was 
reported that intensive insulin therapy can be associated with improvement in 
glycaemic control in patients with Type 2 diabetes. This can be achieved by 
decreasing hepatic glucose output and improving its uptake. It may also improve 
insulin resistance and secretion by decreasing the glucotoxicity that results from 
hyperglycaemia. 
One factor that contributes to -cell dysfunction is glucokinase (GCK) gene 
dysfunction. GCK is encoded in mitochondrial DNA and is a pro-hormone 
convertase. Glucokinase is an important regulatory enzyme that plays a crucial role 
in regulation of glucose metabolism by maintaining insulin secretion in pancreatic b-
cells and hepatocytes, and is referred to as the “glucose sensor’’ (Osbak et al., 
2009). However, the frequency of mutations in GCK is low compared with other 
causes of Type 2 diabetes (Goke, 1998). 
There is a growing acceptance that for hyperglycaemia to present in Type 2 
diabetes, pancreatic -cell dysfunction must exist. The relationship between reduced 
-cell secretory function and a fast-rising glucose level can be described as an 
inverse nonlinear relationship (Kahn, 2001).  
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1.1.3 Diagnosis of Diabetes 
Davidson (2001) stated that “In 1979 the criteria for diagnosis of diabetes were 
based on levels of glycaemia during an oral glucose tolerance test (OGTT) 
associated with the subsequent development of retinopathy”. Later, glycated 
haemoglobin (HbA1c) measurements were introduced and became the gold 
standard tool for detecting and monitoring treatment, as well as making management 
decisions regarding diabetic patients (WHO, 2011). HbA1c levels are a preferable 
measure for glucose levels over OGTT because firstly they reflect the overall mean 
blood glucose level during the preceded period of 6 to 8 weeks rather than a single 
instance of time (Nathan et.al., 2007). Secondly, many studies have reported an 
association between HbA1c and microvascular complications in diabetics (Davidson, 
2001).  WHO recommends the use of HbA1c as a diagnostic test for diabetes 
because it ensures that “stringent quality assurance tests are in place and assays 
are standardised to criteria aligned to the international reference values, and there 
are no conditions present which preclude its accurate measurement” (WHO, 2011, 
p.6). 
Many studies were carried out to show the association between glycated 
haemoglobin levels and glycaemic control. A study carried by Koenig et al., (1976) 
involved five poorly controlled diabetic patients to determine whether changes in 
glycaemic control were associated with changes in glycated haemoglobin levels. It 
was found that the reductions in glycated haemoglobin levels were associated with 
improved glycaemic control.  The above finding is consistent with Ditzel and 
Kjaergaard (1978) who focused on 10 newly-diagnosed non-acidotic diabetic 
patients initially exhibiting elevated levels of HbA1c.  They observed a gradual 
decrease in HbA1c in the weeks following weeks of initiation of dietary and insulin 
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therapy. It can therefore be concluded from both studies that glycated haemoglobin 
is an indicator for the long-term average blood glucose concentrations. To detect a 
significant concentration for blood glucose for diabetes an HbA1c value ≥6.5 % (48 
mmol/mol) was introduced as a preferred diagnostic test for diabetes (WHO, 2011).  
ADA (2010) established a diagnostic range of 5.7-6.4 % for HbA1c to identify 
subjects at risk of developing diabetes in the future. 
Glycated haemoglobins are “haemoglobins with an attached sugar moiety, 
they constitute the HbA1 fraction of the adult haemoglobin (HbA). HbA1c is the 
predominant fraction of HbA1 and gives an estimate of the blood sugar levels of an 
individual over the last three months’’ (Nitin, 2010). They are formed by the 
glycosylation of haemoglobin molecules. Haemoglobin A (HbA) is the most common 
type of haemoglobin; it accounts for more than 95% of haemoglobin in adults and it 
is typically present in both healthy adults and those with certain diseases such as 
severe thalassemia (Yudkin et al., 1990, The London North West Healthcare NHS 
Trust, 2015). HbA1c is typically present in non-diabetic individuals and comprises 
approximately 4-6%, of total haemoglobin (Yudkin et al. 1990). However, several 
factors have been reported to affect measurements of HbAc1 levels such as: the age 
of an individual, decreased survival rate of red blood cells, haemoglobinopathies and 
a lack of standardised method for measuring HbA1c level (Kilpatrick, 1997).  In a 
study conducted in Japan by Tsuki and Kobayashi (1995), it was demonstrated that 
glycated haemoglobin values in non-diabetic individuals appeared to increase with 
age, as well with diseases of the liver and kidneys. In addition, Soranzo (2011) 
showed that HbA1c levels vary among individuals without diabetes due to both 
biological and hereditary factors. Additionally, Simonos et al., (2008) indicated that in 
healthy non-diabetic adults, the genes controlling HbA1c and FPG reflect different 
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aspects of glucose metabolism, and also reported that 75% of HbA1c level was 
heritable. Leslie and Cohen (2009) reported that differences in the survival rates of 
red blood cells, due to genetic and ethnic causes, can alter the HbA1c level by more 
than 1%. Furthermore, Soranzo (2011) stated that the utility of HbA1c in diagnosing 
diabetes can also be altered by inherited haemoglobinopathies. HbA1c level was 
found to be influenced by ethnic factors. In a study conducted by Herman et al. 
(2007), racial and ethnic differences in glycated haemoglobin levels were studied 
among people with impaired glucose tolerance (IGT). It was reported that the mean 
of HbA1c levels was 0.4% higher in Afro-Caribbeans compared with white 
Europeans exhibiting the same glucose tolerance. Similarly, Likhari and Gamma 
(2009) also reported that the mean HbA1c levels are higher in South Asians than in 
whites living in the UK. Therefore, it can be concluded that age and ethnic factors 
need to be taken into consideration when using HbA1c diagnosis for diabetes. 
Despite these discoveries, HbA1c measurements are not appropriate for the 
diagnosis of diabetes in all cases John (2012).  This method of diagnosis is not 
advised for: 
 Children and young people 
 People suspected of having Type 1 diabetes  
 Patients exhibiting diabetic symptoms for less than two months 
 Patients at high risk for diabetes who are acutely ill 
 Patients taking medication that may cause rapid increases in glucose 
levels, e.g. the use of steroids and antipsychotics  
 Patients with acute pancreatic damage or those who have undergone 
pancreatic surgery 
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 Individuals who exhibit haemoglobinopathies (e.g. Hbs, Hbc, etc.) 
 Those who suffer from anaemia (haemolytic and iron deficiency) 
 Persons experiencing renal failure 
 Individuals infected with HIV infection and finally 
 Women who have recently been or are currently pregnant 
Glycated haemoglobin concentration can be used to predict the risk of developing 
cardiovascular diseases in people living with and without diabetes (Khaw & 
Wareham, 2006). It can also be used to identify people who are at high risk for 
cardiovascular diseases and in need of imminent medical intervention. Moreover, the 
same study found that a 10-20% increase in cardiovascular disease was correlated 
with a 1% increase in mean HbA1c concentration. It was also reported that a 
reduction of 14% of the incidences involving acute myocardial infarction among Type 
2 diabetic patients   can be attributed to only a 1% reduction in their glycated 
haemoglobin levels (Syed and Khan, 2011). In summary, Khaw and Wareham 
(2006) and Syed and Khan (2011) showed that efforts to reduce glycated 
haemoglobin, not only in diabetic patients but also within the general population, 
could be considered important in decreasing the risk of mortality (Diabetes.co.uk, 
2013). 
Paynter et al., (2011) confirmed these findings, and also reported HbA1c levels 
alongside scores obtained for the risk of likelihood of suffering from cardiovascular 
diseases. They showed that it could be possible to predict which patients at the 
baseline are most susceptible to developing diabetes when this disease is 
considered a derivative of cardiovascular disease. 
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1.2 Glycation 
Glycation is defined as a non-enzymatic reaction by which carbohydrates (such as 
glucose) bind to proteins (such as haemoglobin). This reaction was first studied by 
Louis Camille Maillard in the early 1900s and later came to be known as the Maillard 
reaction (Popova et al., 2010). In this reaction, sugars spontaneously react with the 
NH2 terminal residue of the f3 chain (f3-NA1 valine) in proteins, lipids and nucleic 
acids to form the advanced glycation end products (AGEs) (Schalkwijk et al., 2004).  
The process can be summarised in 3 stages: (See figure 1.2.1): 
Stage (1): This involves the formation of a sugar- protein complex which is called the 
Amadori rearrangement. It is considered a precursor to all later compounds.  
Stage (2): This stage includes the formation of numerous intermediate compounds, 
some of which very reactive and others that are not. The reactive compounds 
continue to take part in the reaction, advancing to the third and final stage.  
Stage (3): the reaction products that were formed in the previous stage undergo 
polymerisation, which results in the formation of the AGEs (Miller et al., 1980).  
 The initial step of the first stage of this reaction includes the formation of a 
compound called a “Schiff base’’, which undergoes spontaneous rearrangements to 
form the “Amadori product’’, a keto-amine (Popova et al., 2010). The initial step  is 
rapid and highly reversible. The speed with which the reaction occurs depends on 
the concentration of the reactant (glucose). For instance, when glucose levels are 
low, this results in the breaking apart of the bonds between the sugar molecules and 
the amino groups that are attached to them. In contrast, when the glucose level is 
high, this will result in the opposite effect (Peppa et al., 2003). Peacock (1984) 
reported that glycation begins during the erythropoiesis process and occurs slowly 
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during the life cycle of haemoglobin in the circulation.   
 
Figure 1.2.1: The initial steps of glycation (Millard reaction) (Schalkwijk et al.,2004).
Lysine or Arginine
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glucose-lyine
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As discussed above, the glycation reaction can occur in proteins, lipids and nucleic 
acids. Glycation also occur in plasma; where glucose glycates proteins including 
albumin (50% of the plasma protein), immunoglobulin, and fibrinogen, and in the 
extracellular matrix (ECM) where glucose glycates collagen (the predominant protein 
in ECM) (Wautier & Schmidt, 2004). In blood the glycation of haemoglobin can be 
summarised by the simple equation below: 
 
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 + 𝐻𝑏 ↔ 𝐴𝑙𝑑𝑖𝑚𝑖𝑛𝑒(𝑆𝑐ℎ𝑖𝑓𝑓 𝑏𝑎𝑠𝑒) → 𝐻𝑏𝐴1𝑐 
The following steps briefly describe the synthesis of glycated haemoglobin as 
discussed by Hinzman et al., (2012): 
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1. The first step of this reaction is a reversible step (Peppa et al., 2003). It includes 
the formation of a compound identified as aldimine (also known as the Schiff base) 
which results when glucose reacts with an amino-group (–NH2) of a valine residue 
located at the N-terminal of a globin chain (Lazareva et al., 2008).  
2. The second step is irreversible. The aldimine undergoes spontaneous self-
rearrangements to yield a stable keto-amine [1 -deoxy- 1 (N-valyl-f-globin) fructose] 
which persists for the duration of the protein’s lifespan (Figure 1.2.2): 
slow
Aldimine
(Schiff Base)
Glucose
Figure 1.2.2 : The initial steps of  glycated haemoglobin formation  
from D glucose (Hinzmann et al.,2012).
Rapid
(hours) Days(Amadori-rearrangements)
Ketomine
protein 
protein 
protein 
 
 
1.2.1 Advanced Glycation End Products  
AGEs can be defined succinctly as a heterogeneous group of compounds 
formed via non-enzymatic glycation between reducing sugars and free amino group 
of proteins, lipids and nucleic acids (Ahmed et al., 2005). Since these complex 
groups of compounds are formed slowly, it was once believed that AGEs 
accumulated solely from long lived extracellular proteins (Goh and Cooper, 2008). 
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However, by the mid-1990s it was reported that AGEs often accumulate 
intracellularly. AGEs can also originate from exogenous sources such as tobacco 
smoke and food (Giardino et al., 1994). Uribarri et al., (2010) state that AGEs can 
originate either from endogenous or exogenous sources. Although AGEs are known 
as products of hyperglycaemia, they can be formed from food during cooking. A 
number of studies have reported that dietary AGEs can be partially absorbed and 
excreted in the urine, and they are considered as a major source of circulating AGEs 
in the body (Uribarri et al., 2003; Vlassara et al., 2002). Furthermore, smoking is 
considered as one of the main exogenous source of dietary AGEs (Uribarri et al., 
2003). 
Sustained hyperglycaemia contributes to many of the complications 
associated with diabetes (Brownlee et al., 1984, Cerami et al., 1987 and Merimee et 
al., 1990). AGEs Chronic hyperglycaemia has been reported to cause the 
accumulation of non-enzymatic glycated products in which glucose initially forms the 
Amadori product, then after a series of chemical reactions some of these Amadori 
products are converted to AGEs. The AGEs were reported to accumulate more in 
the tissues of diabetic patients where they are found to be connected to a number of 
complications (Brownlee et al., 1988. Vishwanath et al., 1988 and Monnier et al., 
1984). 
          Brownlee (2001) reported that the formation of AGEs in vivo can result from 
highly reactive carbonyl groups called alpha-dicarbonyls or oxoaldehydes, including 
3-deoxyglucosone, glyoxal, and methylglyoxal.  According to Hammes et al. (1999) 
AGEs accumulate within various sites where diabetic complications readily develop. 
These include the kidney, retina and atherosclerotic plaques. The rate at which these 
AGEs accumulate is accelerated by hyperglycaemia. Moreover, it has been reported 
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that the increase in diastolic and systolic hypertension seen among diabetic patients 
is caused by AGEs. 
             The UK Prospective Diabetes Study (UKPDS) (1998) established that 
hyperglycaemia is the main instigator of tissue damage in Type 2 diabetic patients. 
However, this process is dependent on individual variation and genetic factors, 
taking into consideration that AGEs formed by the non-enzymatic glycation are also 
promoted by hyperglycaemia (Fowler, 2008). Moreover, the intracellular formation of 
AGEs can be detrimental to the normal functioning of cells, whereas tissue 
alterations by AGEs can result from the modification of proteins. This can occur by 
stimulating the formation of cross-links between molecules in the membrane of 
extracellular matrices and by the involvement of receptors for advanced glycation 
end-products (RAGE receptors). These phenomena can serve to explain the 
contribution of AGEs in micro and macrovascular complications (Tan et al., 2007).  
It has been suggested that AGEs are essential pathogenic mediators of most 
complications that are related to diabetes. For example, they can be found in the 
retinal vessels of diabetic patients and the severity of retinopathy is correlated with 
their levels in retinal vessel levels, in addition to their levels in serum (Peppa et al., 
2003). The extent to which AGEs are formed depends on two key factors: the degree 
of hyperglycaemia and the degree of oxidative stress in the environment (Goldin et 
al., 2006). More recent research provides increasing evidence that hyperglycaemia 
is the initiator of tissue damage such as macrovascular and microvascular 
complications in patients with diabetes either via long-term accumulation of glycated 
products and AGEs, or through severe changes in glucose metabolism in cells 
(Stirban et al., 2014; Gkogkolou and Böhm, 2012; Schurman et al., 2008). 
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           Some mechanisms in which AGEs contribute to diabetic complications, 
particularly the vascular effects of AGEs, are related to tissue inflammation and 
oxidative stress, as well as the increased glycation of LDL and HDL (Cai et al., 
2002). Such mechanisms can be summarised into the following steps: 
1. Cellular proteins such as those involved in the regulation of gene transcription 
are modified (Giardino et al., 1994). 
2. Precursors of AGEs diffuse from cells and modify nearby ECM thus modifying 
the signalling between matrix and cells and resulting in cellular dysfunction 
(Charonis et al., 1990). 
3. AGEs alter circulating proteins in the bloodstream, thereby modifying their 
function (Tan et al., 2007).  
4. Finally, these modified circulating proteins bind to RAGEs, altering the 
production of inflammatory cytokines and growth factors, which in turn leads 
to tissue damage (Vlassara, 2001; Goldin et al., 2006). 
Nevertheless, measurements of glycated haemoglobin levels do not give a strong 
indication of mean plasma glucose levels as is often assumed. This is because there 
are numerous analytical problems associated with glycated haemoglobin 
measurements, such as the lack of assay standardisation, various problems that 
affecting HbA1c measurement, haemoglobinopathies, fetal haemoglobin, renal 
failure, and haemolytic diseases (John, 2012). It has also been proven that there are 
discrepancies between estimates of the average glycaemia levels when calculated 
from glycated haemoglobin levels or from fructosamine measurements (Kilpatrick, 
2000; Nayak et al., 2011).         
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It can be concluded from the above observations that acceleration of the 
glycation process and increased incidences of diabetes related complications are 
strongly linked to the damaged protein by glycation reaction (Brownlee et al., 1984). 
Fructosamine is an index of the glycated fraction of all plasma proteins, 
predominantly albumin. Glycated albumin is considered to be the main glycated 
protein that is related to extracellular fructosamine in the circulation while HbA1c is 
the main intracellular fructosamine by product of the glycation reaction (Cohen et al., 
2003). 
 1.2.2 Glycation Gap 
There are discrepancies between estimates of the average glycaemic levels when 
calculated from glycated haemoglobin levels or from using fructosamine 
measurements. A study by Cohen et al., (2003) was conducted to test whether this 
discrepancy between HbA1c and an integrated measure of plasma glucose was a 
reliable indicator of physiological processes that cause variations between 
individuals. It was also conducted to determine whether these factors demonstrated 
a relationship with the frequency of diabetic nephropathy. The authors developed a 
measure of discordance between HbA1c and circulating fructosamine (FA) which 
they gave the name ‘’glycation gap’’ in order to conduct a systematic evaluation. It 
was concluded that the glycation gap may be a useful tool in clinical research for 
estimating the physiological reasons behind the variation in diabetic complications 
among the individuals. 
              Glycation gap (G-gap) is defined as “the difference between measured 
HbA1c and HbA1c predicted from the FA based on the HbA1c-FA regression 
equation G-gap = measured HbA1c - predicted HbA1c’’ Cohen et al., (2003). 
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However, several authors reported that the G-gaps varied among individuals. Hempe 
et al., (2002) investigated the individual differences in the relationship between 
glycated haemoglobin (HbA1c) and mean blood glucose (MBG) levels among 
diabetic participants. They reported that these differences in the relationship 
between MBG and HbA1c were not due to the age of erythrocytes but rather that 
these differences were related to differences in the rate of glycation of haemoglobin, 
resulting in the categorisation of patients according to their G-gaps as high and low 
glycators. In addition, the research studies carried out by Hempe et al. (2002), Gould 
et al., (1997) and Yudkin et al. (1990) showed that 42 out of 223 non-diabetic 
participants were categorised as high and low glycators based on the discrepancy 
between the centile ranking of their mean glycated haemoglobin and their mean 
blood glucose level after OGTT. Nayak et al., (2013) proposed that the G-gap 
explained differences in the incidence of diabetic complications such as 
(nepthropathy, neuropathy, retinopathy, CVD and mortality); the concept of G-gap 
has also received more interest in recent decades from many researchers since this 
discordance is between the two principal methods of estimating glycaemic levels, 
HbA1c and FA (Nayak et al., 2011; Kilpatrick, 2000). 
 1.2.3 Deglycation 
Szwergold et al., (2002) proposed that intracellular non-enzymatic glycation is 
controlled by an enzymatic process thought to involve a key enzyme called 
Fructosamine-3-Kinase (FN3K). FN3K can deglycate the glycated haemoglobin in 
erythrocytes and also other glycated proteins in other tissues. Thus, the variations in 
the activity of FN3K between individuals may lead to the apparent differences in 
glycated haemoglobin levels. Some individuals have a high rate of deglycation and 
tend to have low glucose levels, whilst those with a low rate of deglycation tend to 
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have high glucose levels (Mohas et al., 2010).  
The concept of enzymatic deglycation catalysed by the FN3K enzyme can be 
illustrated by Figure 1.2.3.3: FN3K phosphorylates fructoselysine (FL) into 
fructoselysine-3-phosphate (FL3P), which is naturally unstable. This molecule then 
spontaneously decomposes into unmodified lysine, inorganic phosphate and 3-
deoxglucosone (3DG) (Delpierre et al., 2000 & Szwergold et al., 2001).   
Unlike the non-enzymatic glycation reaction which is slow and dependent on 
glucose levels, the rate of the deglycation reaction greatly depends on the activity of 
deglycating enzymes (Delpierre et al., 2006).  As the glycation reaction is 
accompanied by the accumulation of the AGEs and carbonyl stress which are likely 
to have a deleterious impact on tissues (Arasteh et al., 2014), a natural defence 
mechanism is initiated to protect the body’s tissues against the excessive build-up of 
AGEs. This is accomplished by degylcation enzymes (Monnier and Sell, 2006). 
Popova et al., (2010) described three types of deglycating enzymes. The first 
group is made up of enzymes called amadoriases, while the second group called 
fructosamine-3-kinases. The third group consists of fructose lysine-6-kinase and 
fructose-lysine-p-deglycase. 
According to Takahashi et al., (1997) the role of the amadoriase enzymes is 
to block the glycation reaction from moving forward during the early stages via 
oxidative deglycation of Amadori products yielding glucosone, a primary amine, and 
hydrogen peroxide (H2O2) (Figure 1.2.3.1). After undergoing oxidation, the Amadori 
product spontaneously decomposes by way of hydrolysis in the presence of fructosyl 
amine oxidases (isolated by Horiuchi and Kurokawa (1991) from Corynebacterium 
spp. and Aspergillus spp.). Two deglycating enzymes were named amadoriase I and 
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amadoriase 2 and identified by growing Aspergillus spp on minimal medium that 
contained Amadori products as the sole carbon source. Their activities varied from 
one individual to another, depending on the size and charge status of the substrate 
(Zhanglin and Zheng, 2010). 
 
O2 H2O
H2O2
R
GLUCOSONE
Figure 1.2.3.1 Role of oxidases in degradation of the Amadori product
R-CH2-NH2
Ketoamine bond
CH2
AMADORI PRODUCT
CH2R
 
 
 
The second group of deglycating enzymes was identified by Wiame et al., (2002) as 
fructoselysine-6-kinase and fructoselysine-p-deglycase. The authors discovered that 
fructoselysine was capable of sustaining the growth of Escherichia coli and that its 
uptake and metabolism could be controlled by a bacterial operon. These enzymes 
belong to the PFK/ribokinase family. This kinase catalyses the ATP dependent 
phosphorylation of fructoselysine to fructoselysine-3-phosphate whereas the 
deglycase enzyme catalyses the formation of lysine and glucose-6-phosphate from 
fructose lysine -3- phosphate in the presence of H2O (Figure 1.2.3.2).  
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The third group of deglycating enzymes consists of the enzyme fructosamine 3-
kinase (FN3K) (Figure 1.2.3.3), which was discovered by Delpierre et al., (2000). 
Based on early NMR research carried out by Szwergold et al. in 1990, they reported 
the presence of fructose 3-phosphate, a novel monosaccharide phosphate, in the 
lens of diabetic rats, as well as an enzyme that catalyses the phosphorylation of the 
Amadori product into fructosamine 3-phosphate.  Delpierre et al., (2000) also cloned, 
characterised, and identified the FN3K enzyme in erythrocytes. It is suggested that 
FN3K maintains deglycating activity by catalysing the phosphorylation of both low 
molecular mass and protein-bound fructosamines. This leads to the formation of 
fructosamine 3-phosphate which is unstable and decomposes spontaneously to yield 
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3-deoxyglucosone and inorganic phosphate while generating a free lysine residue.  
Szwergold et al., (2001) suggested that protein bound FL can be a relevant substrate 
for the FN3K enzyme because of its high affinity for FL and other glycated protein 
that was detected in vivo. The subsequent phosphorylation of the third carbon for 
fructosamines by FN3K leads to the destabilization of the molecule and its partial 
removal from protein (Delpierre et al., 2000). 
In addition to these observations, studies conducted by Collard et al., (2004) and 
Fortpied et al., (2005) reported the existence of another deglycating enzyme called 
fructosamine-3-kinase-related protein(FN3K-RP). FN3K-RP is also found in human 
erythrocytes and other vertebrates. This enzyme can phosphorylate psicosamines 
and ribulosamines located on the third carbon of the sugar moiety into psicosamine-
3-phosphates and ribulosamine-3 phosphates. These products are both unstable 
and decompose at a pH of 7.1 and 370C to form allose and free lysine. Psicosamine-
3- phosphates and ribulosamine-3-phosphates have half-lives of 8.8 h and 25 min, 
respectively.  
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The physiological presence of enzymatic deglycation was demonstrated by 
showing that the decrease in FN3K activity leads to an increase in intracellular 
protein glycation (Delpierre et al., 2002). This also was confirmed by Veiga-da-
Cunha et al., (2006) who demonstrated that the concentrations of haemoglobin-
bound fructosamine and other intracellular proteins within the tissue and erythrocytes 
of FN3K-deficient mice were 2.5 times higher than those of healthy control mice. 
Additionally, haemoglobin-bound fructosamine was approximately 1.8-2.2 times 
higher in FN3K- deficient mice than other control intracellular proteins compared with 
healthy controls. These results show that fructosamines are removed from 
intracellular proteins by FN3K in vivo.  
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1.2.4 FN3K 
 
Fructoseamine 3 Kinase (FN3K) is an enzyme that was first identified by Szwergold 
and colleagues (Szwergold et al., 2001) from its ability to phosphorylate 
fructosamines that are formed by the non-enzymatic glycosylation of D-glucose 
(Ahmed and Furth, 1992).  Given that its enzymatic product, fructose-3-phosphate 
(F3P) is a key marker of the onset of diabetes, by virtue of its appearance within the 
lens of diabetic rats (Szwergold et al., 1990), its role as a key enzyme within the 
aetiology of human diabetes has become of substantial interest within the field 
(Szwergold and Beisswenger, 2003).  This is especially pertinent given that F3P 
spontaneously degrades to form 3-Deoxyglucosone (3DG), a highly reactive sugar 
which is produced by the body both when excessive sugar is consumed and in 
diabetes (Singh et al., 2014), and which has been identified as a key metabolic 
precursor in the formation of AGEs (Dyer et al., 1991; Kostolanská et al., 2009), 
which have been implicated in the onset of diabetic.   
Szwergold et al. (1997) subsequently observed deglycating enzymatic activity within 
human erythrocytes, thereby identifying an enzyme that is capable of metabolizing 
protein-bound Amadori products. This discovery implied that in vivo glycation is, in 
essence, reversible owing to the existence of an ATP-dependent mechanism which 
is catalysed by deglycating enzymes, thereby preventing glycated proteins from 
further reaction processes which lead to the formation of AGEs.  Taken together 
these findings, the discovery of the deglycating enzyme FN3K by Delpierre et al. 
(2000) opened an entirely new window into our understanding of cellular metabolism 
and shed light upon the enzymatic role of protein glycation in the aetiology of 
diabetes. It also identifies  a direct link between glucose  metabolism and key 
complications in advanced diabetes, as FN3K is an enzyme that is uniquely capable 
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of the phosphorylation of the Amadori product into fructosamine 3-phosphate.  
Delpierre and colleagues (2000) went on to clone, characterise, and identify the 
presence of FN3K enzyme within erythrocytes.  Further, FN3K was proposed to 
maintain deglycating activity by catalysing the phosphorylation of both low molecular 
mass and protein bound fructosamines (Delpierre et al., 2000). The phosphorylation 
of fructosamine, catalysed by FN3K, has a km 4-5 mmol/L, which is an order of 
magnitude lower than that for fructose at 50-100 mmol/L (Delpierre et al., 2000). This 
suggests that this is a highly specific reaction and one which occurs naturally in 
healthy cells.  In 2006, Krause and coworkers measured FN3K activity within human 
erythrocytes by means of a reverse-phase high-performance liquid chromatography 
(RP-HPLC).  Their assay used an erythrocyte lysate that was diluted without enzyme 
purification and which was based upon the FN3K-dependent conversion of the 
synthetic substrate Nα-hippuryl-Nε-(1-deoxy-D-fructosyl) lysine (BzGFruK) to the Nα-
hippuryl-Nε-(phosphofructosyl) lysine (BzGpFruK) (Krause et al., 2006). 
 
FN3K activity was consequently found to be high in erythrocytes isolated from 
humans, mice and rats, but was barely measurable in erythrocytes derived from 
chicken and pig haematocrit.  Intriguingly, this variation in distribution correlated with 
the low intracellular concentrations of glucose that were present within erythrocytes 
in these animals.  FN3K activity was subsequently found to be highest in the brain, 
heart, kidneys and skeletal muscles (Delplanque et al., 2004).  FN3K mRNA was 
also detected in numerous human and rodent tissues, especially within the bone 
marrow, brain, kidneys and spleen, and was also present at lower levels in other 
tissues, including the heart, liver and skeletal muscle (Monnier , 2006). 
 
40 
 
Given the role of FN3K in the enzymatic conversion of fructose into fructose-
3-phosphate in the lens and erythrocytes of diabetic rats, its role in the production of 
deoxyglucosone, and the presence of fructose-3-phosphate in both human and 
animal tissues (Petersen et al., 1990), a possible causal link between FN3K activity 
and the level of glycation of proteins was explored. It was found that, when the FN3K 
gene was silenced in animal models, levels of protein glycation increased (Veiga da-
Cunha et al., 2006).  This is of special interest given the role of non-enzymatic 
glycation in the pathogenesis of the complications of diabetes.  As FN3K plays a 
pivotal role in the removal of fructosamine from proteins, it has been postulated that 
it may serve to protect again diabetes (Mosca et al., 2011) and even the aging 
process (Chondrogianni et al., 2014) under certain metabolic conditions, especially 
given the predisposition of the FN3K ‘knockout’ mouse to developing symptoms 
which are characteristic of diabetes (Monnier, 2006).   
The metabolic intermediates and glycated products are inherently complex, 
especially given that FN3K also catalyses the synthesis of Fructoselysine 3-
phosphate from fructoselysine, a compound which then decomposes to 3DG.  This 
has led to the proposition that 3DG production might in theory be reduced by the 
specific inhibition of FN3K (Brown et al., 2003).      
A study carried out by Delpierre et al., (2006) examined the relationship 
between FN3K activity and the levels of glycated haemoglobin in 57 individuals, 31 
of whom were Type 1 diabetics while the remaining 26 were normo-glycaemic. This 
study aimed to determine whether variations in FN3K activity among individuals 
existed, what genetic factors might affect variability in FN3K activity and to determine 
whether there was an inverse association with HbA1c. A non-significant difference 
was discovered in the mean erythrocyte FN3K activity between subjects with Type1 
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diabetes and the control group. However, there was a wide inter-individual variation 
in both groups ranging from 1 to 4mU/g of haemoglobin (=0.8031). Furthermore, 
there was no inverse correlation between FN3K activity and levels of glycated 
haemoglobin. These findings may be due to the fact that a substantial fraction of the 
fructosamines found in haemoglobin is bound to the N-terminal valine of the β-chain. 
Like free fructosevaline and other α-glycated amino acids, the N-terminal 
fructosevaline residue is a poor substrate for FN3K, and therefore it escapes 
deglycation.  Moreover, an earlier study by the same group (Delpierre et al., 2002) 
showed that HbA1c is a poor substrate for FN3K.  Therefore, this substrate is 
classified as being deglycation-resistant.  The authors also reported that 
fructoselysine, which is poorly utilized by erythrocytes, is not likely to be a substrate 
for FN3K, but rather a substrate for other glycated proteins.  
              Recently, research conducted by Avemaria et al., (2015) confirmed that free 
fructosevaline behaved much more poorly as a substrate for FN3K than free 
fructoselysine. On the other hand, Delplanque et al., (2004) disagree with the results 
presented by Delpierre et al., (2002) and reported that FN3K plays an extremely 
active role in the erythrocytes of human, rat and mouse when the intracellular 
glucose concentration is equal to the concentration of plasma. This is due to the fact 
that the protein is poorly or not renewed in the presence of an aggravating agent, 
which is identified as glucose. Thus, FN3K activity in erythrocytes was found to be 
non-essential when glucose was absent. 
                  The presence of FN3K was shown by Szwergold et al., (1990) who 
demonstrated the occurrence of fructose-3-phosphates (F3P) in the lens of diabetic 
rats. They reported that the development of some diabetic complications could be 
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partially attributed to an increase in the concentration of F3P and its hydrolysis to (3-
deoxyglucosone) in the lens of diabetic rats.  
Identification of FN3K was initially achieved through studies in human 
erythrocytes. Its capacity to phosphorylate fructose and sorbitol substrates, thereby 
producing F3P and sorbitol-3-phosphate, made its detection possible (Payne et al., 
2008).  Since FN3K was purified, sequenced and cloned, the idea of enzymatic 
deglycation received an additional confirmation (Szwergold et al., 2002). In fact, the 
whole concept of protein deglycation began when F3P was first identified by 
Szwergold and colleagues in 1990. By conducting NMR analyses of tissue extracts, 
Petersen et al. (1990) revealed the presence of F3P in the lenses of diabetic animals 
and in erythrocytes of both diabetic and non-diabetic subjects. Later, Petersen et al. 
(1992) reported that F3P could be induced by incubating erythrocytes with fructose, 
or by incubating fructose with erythrocyte lysates in the presence of ATP. Due to the 
high km values the fructose-3-kinase had shown for fructose, the lower enzymatic 
activity it exhibited in comparison to other enzymes involved in fructose metabolism, 
and the lack of information about additional metabolic activities for F3P, the theory 
that fructose-3-kinase was able to metabolize fructose was rejected.  This led 
Szwergold et al., (1990) and Schaftingen et al., (2007) to assume that fructose-3-
kinase was instead capable of catalysing the phosphorylation of fructosamines since 
they are similar to fructose in terms of molecular structure, apart from having an 
amino-group present on the first carbon of the hexose sugar fructose instead of a 
hydroxyl group. For this reason, Delpierre et al., (2000) chose to use Fructosamine-
3-kinase as the indicator of choice for the putative fructose -3-kinase.  Moreover, 
FN3K strongly prevents the conversion of fructose to F3P and bears a km lower than 
that of fructose-3-kinase.  
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Owing to the apparent contribution that FN3K makes to the process of non-
enzymatic glycation, the enzyme was purified and characterised to using a human 
erythrocyte model (Szwergold et al., 2001). For the past decade, human erythrocytes 
have been used as a convenient model system for the purification of FN3K. The 
reasons for this owe to the fact that they are readily obtained, easy to incubate, 
extremely permeable to glucose (Lacko et al., 1973), and contain relatively high 
amounts of FN3K (Szwergold et al., 2002).  Using electrospray tandem mass 
spectrometry (MS/MS), an analytical method used to detect molecules such as 
amino and fatty acids, the functionality and sequence of the FN3K enzyme was 
characterised by Szwergold et al., (2001).   
FN3K is a 35-KDa monomeric enzyme consisting of 309 amino acids that are 
able to phosphorylate fructose, fructoselysine and protein-bound Amadori products. 
However, it has a much higher affinity for Amadori products than for fructose as the 
relative km values range from 10µM for fructoselysine to more than 50mM for 
fructose (Delpierre et al., 2000). The FN3K enzyme shares no significant homology 
with any other known proteins except with FN3K-RP. In humans FN3K appears to be 
encoded by genomic sequences that are located on chromosomes 1 and 17 
(Szwergold, 2002).  
Szwergold et al. (2001) reported that the FN3K enzyme may be part of an 
ATP-dependent system for removing carbohydrates from non-enzymatically glycated 
proteins due to its high affinity for fructoselysine on proteins and the liability of 
fructoselysine-3-phosphate.  Deppe et al. (2011) also indicate that the FN3K enzyme 
and its homologue FN3K-RP might overcome protein damage arising from 
intracellular glycation by conferring protective and repair functions in E. coli and B. 
subtilis. To test whether pancreatic β-cell functions can be protected from 
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glucotoxicity by FN3K, Pascal et al. (2010) carried out a study to investigate the 
possible effects of FN3K deficiency on the function and survival of mouse pancreatic 
islets after prolonged culture in high glucose or ribose concentrations. They assumed 
that FN3K might play a partial role in protecting pancreatic β-cells from glucotoxic 
alterations so as to maintain their survival and functionality.  Pascal et al., (2010) 
found that FN3K is capable of decreasing the rate of glycation of intracellular islet 
proteins, but cannot protect β-cells from glucotoxicity. They also discovered that 
FN3K is not involved in maintaining the survival and function of β-cells under control 
conditions.  Nevertheless, they demonstrated that a reduction in FN3K levels was 
the result of an increase in glycated ketoamines in the pancreatic islets of FN3K-
deficient mice. Therefore, this argument supports the concept that FN3K is acting as 
a deglycating agent in the pancreas and in the other tissues (Veiga-da-Cunha et al., 
2006). 
With regards to the genomic context of the FN3K and FN3K-RP sequences, 
Delplanque et al., (2004) reported that the human genome contains two genes that 
are related to FN3K and FN3K-RP.  They also found that these genes were 
presented in a tandem repeat in the telomeric region of chromosome 17q. 
A small number of studies have reported a relationship between genetic 
variants in FN3K and its enzymatic activity.  Delpierre et al. (2006) mentioned an 
association between the enzymatic activity of FN3K in erythrocytes and some 
polymorphisms in the FN3K gene in a Belgian cohort that included 31 Type 1 
diabetic patients and 26 controls. They identified two single nucleotide 
polymorphisms (SNPs) in addition to other gene variants. The CC of the c.900C/G 
(rs1056534) in exon 6 and the G-gap of the c.–385A/G (rs3859206) in the promoter 
region were related to the low enzymatic activity exhibited by FN3K measured 
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erythrocytes. Nonetheless they could not find any correlation between FN3K SNPS 
and HbA1c concentrations. In a later study by Mohas et al., (2010) involving a larger 
cohort of Type 2 diabetic subjects, the authors reported that the C allele of 
polymorphism c.900 C/G (rs1056534) in exon 6 was associated with lower glycated 
haemoglobin levels and a later onset of the Type 2 diabetes mellitus disease in 
comparison to the G allele, but they failed to find an association between this variant 
and diabetic complications such as nephropathy, neuropathy or retinopathy. 
Furthermore, a study was carried out in 2014 that involved 314 subjects with Type 2 
diabetes who were screened for a total of 19 SNPs in six candidate genes encoding 
enzymes of metabolic pathways. The aim was to investigate whether genetic 
variability in such genes might stimulate the progression of diabetic nephropathy and 
the morbidity and mortality associated with diabetes. The authors discovered an 
association between the polymorphism in exon 6 (rs1056534) with the progression of 
diabetic nephropathy and cardiovascular morbidity and mortality (Tanhäuserová et 
al., 2014). 
Recently, Skrha et al., (2014) conducted research to investigate the association 
between FN3K polymorphisms (rs1056534, rs3848403) and glyoxalase I 
polymorphisms (rs 4746) with soluble RAGE and parameters of endothelial 
dysfunction involving 595 diabetic and non-diabetic subjects. Skrha et al. (2014) 
found significant differences existed in s-RAGE of diabetic subjects in relation to their 
rs1056534 and rs3848403 genotypes. GG and CG genotypes of rs1056534 with 
mutated G allele were associated with a significant decrease of sRAGE 
(GG=1055±458 and CG= 983±363 vs. CC= 1796±987 ng/l, p <0.0001). On the other 
hand, the rs3848403 polymorphism, presented s-RAGE levels that were significantly 
increased (TT=1365±852 vs. CT= 1016±401 and CC= 1087±508 ng/l, p =0.05). 
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Significant differences in endothelial dysfunction markers were observed in genotype 
subgroups of GLO1 rs4746 polymorphism (p< 0.05).  
Glyoxalase I (GLO1) is an enzyme that removes the AGE methylglyoxal and is 
involved in the detoxification pathway which breaks down toxic reactive dicarbonyls 
to prevent the development of carbonyl stress. This prevents the formation of AGEs 
in proteins, lipids and nucleic acids. However, methylglyoxal, the primary substrate of 
glyoxylase, is generated mainly by the triose phosphate and pentose phosphate 
pathways rather than from glycated proteins, therefore there is no molecular link 
between FN3K and GLO1, each enzyme has its own independent mechanism in 
preventing formation of AGEs. GLO1 can be found in humans, mice, yeast, plants, 
insects, protozoa, fungi, and many bacterial strains (Thornally, 2003; Rabbani and 
Thornalley, 2011). In our project, we focused on the FN3K enzyme which acts on 
ketoamines in glycated proteins, rather than GLO1.  
Unlike previous findings (Delpierre et al., 2006; Tanhäuserováa et al., 2014; 
Skrha et al., 2014), Avemaria et al., (2015) did not observe any significant 
associations between certain SNPs and diabetic conditions, although they found that 
the genotype containing c.900 CC alleles (rs1056534) was associated with low 
concentrations of HbA1c. 
As discussed earlier in this chapter, the FN3K enzyme appears to catalyze a 
repair mechanism for protein damage caused by glucose. An association between 
high levels of fructosamine in serum and colorectal adenomas was observed by 
Misciagna et al., (2004). Additionally, Ross et al., (2001) reported an existence of a 
common pathogenic pathway between diabetes and cardiovascular diseases 
coupled with colorectal cancer. To investigate such a pathway, Caruso et al., (2007) 
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included 31 patients with colorectal cancer (CRC) in their study to evaluate FN3K 
gene expression via Reverse Trasncriptase-PCR. They found a significant decrease 
in FN3K gene expression when compared with its expression in the surrounding 
healthy mucosa. Later it was reported that when 30 CRC patients underwent colon 
surgery, the FN3K activity and mRNA FN3K levels were downregulated in tumors 
located on the left side of colon compared to tumors situated on the right side 
(Notarnicola et al., 2010).  A year later in 2011, the same research group carried out 
a study that involved examining FN3K activity in erythrocytes obtained from patients 
with colorectal adenomas and cancer.  Of the 33 individuals enrolled, 16 of them 
were diagnosed as having colorectal cancer (non-adenomatous),  7 had adenomas, 
while 11 patients served as the control group; exhibiting normal colonoscopy results. 
The activity of FN3K was measured by means of radiometric assay; it was found that 
FN3K activity was significantly lower in patients with non-adenomatous tumors than 
in patients with adenomas (19.55 ± 6.4 pmol/min per ml in patients with colorectal 
cancer, whereas 31.7 pmol/min per ml of red blood cells in adenoma, p = 0.04, 
Tukey’s test. (Notarnicola et al., 2011)). 
1.3 Cardiovascular diseases 
Cardiovascular disease (CVD) is defined according to NHS (2014) as ‘’ a general 
term that describes a disease of the heart or blood vessels’’. The main types of 
CVDs are: coronary heart disease (angina and heart attack), congenital heart 
disease, stroke and peripheral arterial and aortic diseases.  
1.3.1 Epidemiology of Cardiovascular diseases 
The WHO states that: 17.5 million people die each year from CVD, which accounts 
for 31 % of all deaths worldwide. More than 75% of deaths from CVD occur in low 
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and middle income countries. Furthermore 80% of all deaths caused by CVD are 
due to heart attacks and strokes (WHO, 2014).  
Fuster and Kelly (2010) reported that the total number of deaths caused by 
CVD (mainly coronary heart disease, stroke, and rheumatic heart disease) in 2005 
had increased from the estimated 14.4 million in 1990 to 17.5 million. 7.6 million of 
these deaths were attributed to coronary heart disease and 5.7 million to stroke. 
In the United Kingdom, a report by the British Heart Foundation (BHF) (2015) 
stated that more than 27% of all deaths in the UK (approximately 155,000 deaths 
annually) are due to CVD. In addition to the 7 million people living in the UK with 
CVD, the BHF also estimated that the economic burden of CVD would generate 
indirect costs caused by premature death and disability amounting to approximately 
more than £15 billion each year, despite the fact that healthcare alone costs up to 
£11 billion. 
1.3.2 Pathophysiology of CVD 
The majority of CVD is attributable to coronary heart disease (CHD) and stroke 
(Bhatnagar et al., 2015). CHD accounts for 45% of CVD while stroke accounts for 
30% (Fuster and Kelly, 2010). It can be concluded that, as most CVD pathology is 
within the arteries that are lined by endothelial cells, any decline in endothelial cell 
function leads to ‘’endothelial cell dysfunction’’, a well-recognized response to 
cardiovascular risk factors (Hadi et al., 2005; Libby and Theroux, 2005). 
The thin layer of endothelial cells lining blood vessels is called the endothelium and 
produces both vasodilators and vasoconstrictors. In normal conditions, continuous 
regulatory nerve signals and a continual supply of vasodilating nitric oxide are sent 
from the endothelium to the vascular smooth muscles (Lewis, 1998). It was proposed 
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that the endothelium enables the normal homeostasis of vessels via production of 
extracellular matrix components such as collagen, mediators of regulatory 
processes, nitric oxide, endothelin-1 (ET-1), Von Willebrand factor (VWF), 
angiotensin II, tissue-type plasminogen activator (t-PA), plasminogen activator 
inhibitor-1 (PAI-1), prostanoids and tumour necrosis factor (TNF) (Ambrose and 
Barua, 2004). Barrett et al., (2010) also reported that the fibrinolysis process is 
controlled by the endothelium throughout its function in sustaining the integrity of the 
vascular wall. This can be achieved by producing t-PA and PAI-1, and in addition the 
endothelium altering the function of heparin sulphates/anti-thrombin, 
thrombomodulin/protein C and tissue factor/tissue factor inhibitor interactions, all of 
which limit the coagulation cascade. Moreover, it was found that vascular 
remodelling can be affected by endothelium through the release of factors that 
promote/inhibit the growth of blood vessels such as TIMPs and MIMPs, platelet-
derived growth factor (PDGF) and angiotensin II (ANG II). A balance between 
MIMPs can influence the repair and maintenance of the extracellular matrix 
throughout breakdown of the ECM and the TIMP that inhibits MIMPs (Libby and 
Theroux, 2005). Furthermore, Betsy (2008) reported a contribution of diabetes in the 
defects in the autonomic nervous system, the endothelium, and local metabolism, all 
of which can result in microvascular disease. In conclusion, any decline or defects in 
endothelial cells normal function of endothelial cells may lead to cardiovascular 
disease (Hadi et al., 2005). The endothelium mediates several vasoprotective effects 
such as vasodilation and suppression of smooth muscle cell growth and inhibition of 
inflammation via nitric oxide (NO). Any defect in the production of NO can lead to 
endothelial dysfunction and may initiate atherosclerosis (Feldman et al., 2000). 
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1.3.3 Diabetes as a risk factor for CVD  
The major risk factors for CVD are: diabetes mellitus, ethnic background, family 
history of heart disease, hypertension, high blood cholesterol levels, lack of exercise, 
smoking and obesity/being overweight (Grundy et al., 1999). According to the 
American Heart Association (2016), people with diabetes are at high risk for CVD 
because diabetic patients, especially those with Type 2 diabetes may additionally 
have other risk factors for CVD. These include hypertension, abnormal cholesterol 
and high triglycerides levels, obesity and lack of exercise. Nathan et al., (2005) found 
that hyperglycaemia in diabetic adults increases the risk of heart attack, stroke, 
angina, and coronary artery disease. In addition, Betsy (2008) also mentioned that 
hyperglycaemia as a symptom of diabetes is a factor that contributes to myocardial 
damage after ischemic events. Moreover, it was reported by The Center for Disease 
Control and Prevention (CDC, 2014) that death rates from CVD among adults aged 
18 years or older with diagnosed diabetes were about 1.7 times higher than rates 
among adults without diagnosed diabetes. The risk of CVD in people with diabetes 
can further be doubled by smoking (NDEP, 2007). 
Intensive glycaemic control in diabetic patients has been reported to reduce 
the risk of any CVD event by up to 42% and the risk of heart attack, stroke and death 
from CVD by 57% (Nahtan et al. 2005). In addition, the risk of any diabetic 
complications can be reduced by 12% with a reduction of 10mm Hg in systolic blood 
pressure (Adler et al., 2000).  Poornima et al., (2006) indicate that the risk for 
development of CVD is elevated 2-4 times in diabetic patients. 
It was reported by Ewing et al., (1980) that diabetes contributes to defects in 
the autonomic nervous system as well as in the endothelium and in all conditions 
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that result in microvascular disease. They also describe a factor called diabetic 
autonomic neuropathy (DAN) that is associated with impaired autoregulation of blood 
flow in a variety of vascular beds such as the skin and heart.  A year later Smith et 
al., (1981) added that patients with diabetic autonomic neuropathy were reported to 
have an increase in the rate of sudden cardiac death and had a higher 
cardiovascular mortality rate than those without. Moreover, in patients with diabetes, 
a decrease in the bioavailability of NO, which acts as a potent vasodilator, was seen, 
in addition to an increase in the secretion of vasoconstrictor endothelin-1 (Koh et al., 
2005). This decrease in the bioavailability of NO in diabetic patients might be due to 
insulin deficiency or resistance in endothelial cells, plus hyperglycaemia was proven 
to inhibit NO production in arterial endothelial cells (Williams et al., 1998).  
1.3.4 AGEs and CVDs   
AGEs were found to accumulate at a much higher rate in individuals suffering from 
diabetes than among the non-diabetic population (Peppa et al., 2003). Kilhovd et al., 
(1999) found that serum AGEs were significantly increased in patients with diabetes 
and  CHD compared with diabetic patients without CHD (8.1U/ml vs 7.1 U/ml, 
respectively). In another study related to AGE levels in tissue, Makita et al., (1991) 
reported a significantly higher level of AGE content in the arterial wall collagen of 
patients with diabetes in comparison to samples from non-diabetic individuals. In 
addition to this study, the same group reported that the AGE content found in the 
renal tissues of diabetic patients with end-stage renal disease was approximately 
double the AGE content for diabetic patients without renal disease (21.3± 2.8 U/mg 
vs 11.5 ± 1.9 AGE U/mg).  
Pentosidine is a biomarker for AGEs that is constantly being formed under 
normal circumstances and more rapidly under a variety of situations that pose stress, 
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for example oxidative stress and hyperglycaemia (Dyer et al., 1991). Yoshida et al., 
(2005) observed that serum levels of pentosidine in patients with diabetes were 
significantly higher than those in nondiabetic individuals (64.4 ± 21.0 μg/L vs 22.8 ± 
7.0 μg/L).  Furthermore, in diabetic patients with CVD, the pentosidine serum levels 
were significantly higher than those without CVD (72.3 ± 23.7 μg/L vs 62.3 ± 19.8 
μg/L). These serum levels for pentosidine were correlated with arterial wall stiffness 
in diabetic patients.  
More recent findings by Koyama et al. (2007) investigated 141 patients with 
heart failure and 18 control subjects. This study reported that serum pentosidine 
levels were higher in patients with heart failure than those without ( <0.001). This 
suggests that serum pentosidine can be considered as an important risk factor in 
predicting of heart failure as it relates to the severity of heart failure. Likewise, 
Lapolla et al., (2007) examined the association between AGEs, malondialdehyde, 
total reactive antioxidant potentials (TRAPs), and vitamin E in Type 2 diabetic 
patients with and without peripheral artery disease. They found that the levels of 
AGEs, pentosidine and malondialdehyde were significantly higher in patients with 
peripheral artery disease than in patients without and compared with control 
subjects. In conclusion, this study demonstrated that pentosidine can be considered 
a good predictor for peripheral artery disease in diabetes, although it would be 
essential to perform an appropriately-designed longitudinal study to further support 
this finding.  
As discussed, many studies have investigated the association between AGEs 
and diabetes-related macro- and microvascular complications, in order to understand 
how AGE levels correlate with the development of diabetes related cardiovascular 
complications. Obayashi et al., (1996) reported the presence of AGEs in 
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atheromatous lesions located in the coronary arteries of patients with diabetes. They 
proposed that AGEs can accelerate the development of atherosclerosis as was 
reported for patients diagnosed with diabetes. In support of this finding, Yeboah et al. 
(2004) showed that the levels of serum AGEs in Type 2 diabetic patients can be 
considered biomarkers for detecting the severity of coronary artery atherosclerosis. 
Moreover, Kiuchi et al., (2001) reported the detection of higher levels of AGEs in 
Type 2 diabetics with obstructive coronary artery disease with respect to diabetic 
patients who did not exhibit obstructive coronary disease. A correlation between 
levels of AGEs and the degree of coronary atherosclerosis in the patients with 
obstructive coronary disease was also observed. Furthermore, it was reported that 
increased levels of AGEs in the serum of patients who underwent percutaneous 
coronary intervention served as an independent risk marker for restenosis in patients 
with diabetes (Choi et al., 2005). 
Hartog et al., (2007), detected an association between serum AGEs levels 
and the development and progression of heart failure whereby increased serum 
levels of AGEs in diabetic patients accelerated the severity and development of heart 
failure. This can be utilized via two pathways. The first is the indirect pathway that 
occurs via their vascular effects (coronary dysfunction, atherosclerosis, and 
thrombosis). The second pathway occurs through direct actions on the myocardium. 
In contrast, Zieman and Kass (2004) and Bidasee et al., (2004) reported that AGEs 
directly impacted the myocardium independent of effects imposed by the vascular 
tree. This is partially caused by cross linking of extracellular cardiac proteins and via 
actions utilized by RAGEs expressed on the myocardium. 
However, endothelial dysfunction is considered to be an independent key 
predictor of side events associated with cardiac trauma and the hospitalization of 
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patients with CHF, and possible death (Fischer et al., 2005). AGEs are known to 
impair the vascular functions of diabetic patients by influencing both endothelial 
function and vascular compliance (Fischer et al., 2005); for example, endothelial 
dysfunction can be triggered by AGEs by reducing the availability of the vasodilator 
nitric oxide (Quehenberger et al., 2000). Moreover, the production of endotheline-1, 
a potent vasoconstrictor, might also be enhanced by AGEs (Quehenberger et al., 
2000 & Sanders et al., 2000). A correlation was observed between the levels of 
circulating AGEs and arterial compliance (Yoshida et al., 2005). In general, it has 
been reported that for patients that exhibit vascular stiffness, treatment with AGE 
breaking medication such as ALT-711 can improve arterial compliance (Kass et al., 
2000). 
1.3.5 Endothelial dysfunction  
Endothelial dysfunction is a condition where the endothelium of blood vessels 
functions abnormally (Endemann and Schiffrin, 2004). The endothelium is “a thin 
monocellular layer that covers all the inner surface of the blood vessels, separating 
the circulating blood from the tissues. It works as a receptor-effector organ and 
responds to each physical or chemical stimulus with the release of the correct 
substance with which it may maintain vasomotor balance and vascular-tissue 
homeostasis'' (Esper et al., 2006). The endothelium plays a role in controlling vessel 
tone, haemostasis, fluid filtration, immune cell recruitment and transportation of 
hormones to the target organs and is a vital part of vascular system (Endemann and 
Schiffrin, 2004). 
Endothelial dysfunction is characterised by an imbalance between 
vasodilative and vasoconstrictive agents (Muniyappa and Sowers, 2013). According 
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to Fieldman et al., (2000) the endothelium mediates many vasoprotective effects 
such as vasodilation, suppression of smooth muscle cell growth and inhibition of 
inflammation via nitric oxide (NO). Defective production of NO can result in 
endothelial dysfunction. A reduction bioavailability of NO, an increased oxidative 
stress, an elevation in expression of pro-inflammatory and pro-thrombotic factors, 
and abnormal vasoreactivity are all characteristics of endothelial dysfunction (Barac 
et al., 2007). Endothelial dysfunction is considered an important incident in an array 
of cardiovascular disorders (Ramesh and Shenovy, 2003). It is associated with many 
cardiovascular complications such as coronary artery diseases, coronary heart 
failure, coronary renal failure, hypertension and peripheral artery disease 
(Endemann and Schiffrin, 2004). Endothelial cells play a major role in 
vasoconstriction and vasodilation of blood vessels: they secrete several mediators 
that can induce both vasoconstriction, such as endothelin-1 and thromboxane A2, 
and vasodilation, such as endothelium-derived hyperpolarizing factor, NO and 
prostacyclin (Avogaro et al., 2011). NO is one of the most important substances 
released by the endothelium; it has anti-aggregation effects on platelets and can 
inhibit growth and inflammation (Esper et al., 2006). According to Muniyappa and 
Sowers (2013), NO is an important vasodilator that causes a relaxation of vascular 
smooth muscle, reducing intracellular Ca2+ levels in response to vasoconstricting 
agents such as angiotensin II. The intracellular concentration of Ca2+ increases and 
this increase promotes binding of calmodulin and activation of endothelial NO 
synthase to increase NO production.  
Endothelial dysfunction also appears to be an important, consistent finding in 
diabetic patients: impairments to NO production and activity can result from 
hyperglycaemia and diabetes (Avogaro et al., 2011). Brownlee (2001) and Meigs, et 
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al. (2004) both describe endothelial dysfunction as a defining event that precedes 
cardiovascular pathology such as atherosclerosis, and so it is considered a 
precursor of future pathogenic cardiovascular events. Endothelial dysfunction has 
proved some prognostic value for these events. Fischer et al., (2005) also report that 
endothelial dysfunction is an independent key predictor for cardiac side events, 
hospitalization in patients with CHF and death.  
Fischer et al. (2005) reported that AGEs can impair vascular function of 
diabetic patients by influencing both endothelial function and vascular compliance. 
Endothelial dysfunction can be induced by AGEs by reducing the availability of the 
NO (Quehenberger et al., 2000). It was reported by Falk et al. (2008) that tobacco 
smoking, obesity and sleep disorders together contribute to endothelial dysfunction 
and atherosclerosis, creating a high risk for CVD in patients with COPD and 
diabetes. The contribution of smoking to cardiovascular events is believed to occur 
via induction of endothelial dysfunction; as well as the fact that cigarette smoking 
itself is linked to oxidative stress, widely considered to be a mediator of endothelial 
dysfunction (Morrow et al., 1995; Cai and Harrison, 2000; Sambola et al., 2003). 
Additionally, AGE was shown to bind with endothelial RAGE resulting in endothelial 
dysfunction (Schmidt et al., 1994). According to Muniyappa and Sowers (2013), 
many methods have been used to assess both endothelial function and dysfunction, 
either directly or indirectly. 
Indirect measurement involves measuring levels of markers of endothelial 
dysfunction, whereas direct measurement involves imaging techniques such as PET, 
which have been used to assess changes in capillary blood flow in response to 
intravenous infusion of vasodilatory agents, although these techniques are 
considered less reliable (Muniyappa and Sowers, 2013). Nadar et al., (2004) and 
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Muniyappa and Sowers, (2013) have found indirect assessment of endothelial 
dysfunction to be more reliable as it requires less patient contact, less complicated 
procedures and is relatively cheaper than direct assessment.  
1.3.5.1 Thrombomodulin as a marker of endothelial dysfunction 
Thrombomodulin is "a glycoprotein that can bind to thrombin and activate protein C, 
thus mitigating the effects of cytokines produced by inflammatory and immunological 
processes'' (Califano et al., 2000).  It is one of the important markers for endothelial 
dysfunction with antithrombotic action mediated via the thrombin-thrombomodulin 
complex. An increase in thrombomodulin levels can be observed in many neoplastic 
diseases (lymphoma, leukaemia and cancer) and in hepatitis (Takahashi et al., 
1992). Thrombomodulin levels are quantified in plasma by using ELISA techniques 
in patients with collagen disease, diabetes, haematological malignancies, liver 
disease and thrombotic disease (Takahashi et al., 1992; Eng et al., 2000).  
Thrombomdulin is a key molecule as an anticoagulant in the blood vessel wall 
(Jansson et al., 1996). 
 1.3.5.2 E-selectin as a marker of endothelial dysfunction 
E-selectin (CD62E) is a member of the selectin family of cell surface glycoproteins. It 
is an endothelial cell-specific adhesion protein involved in the initial vessel wall 
binding and rolling of polymorphonuclear leukocytes (Pober and Cotran, 1990). E-
selectin production occurs during stimulation of TNF-
endothelial cells, and thus takes around two hours to be expressed on the cell 
surface, with its peak expression lasting up to 12 hours after stimulation (Fries et al., 
1993). Expression of E –selectin is a result of cytokine activity such as tumor 
necrosis factor (TNFα) and interleukin 1β (Bevilacqua et al., 1989). Rahman et al. 
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(1998) concluded that TNFα induces generation of ROS, which in turn mediates E-
selectin mRNA expression. Furthermore, Ley et al. (1998) showed that the 
expression of E-selectin is induced by TNF- -selectin is widely recognised as an 
important endothelial cell product which leads to plaque formation in atherosclerosis 
and some other CVD events (Malatino et al., 2007). 
             Harari et al., (2001) speculated that the induction of E-selectin expression in 
endothelial cells might be a protective response to endothelial damage, in this case 
the levels of cytokines are increased and this stimulates the expression of E-selectin. 
The stimulation attracts leukocytes to move to the site of the damage and to bind to 
E-selectin on the surface of endothelial cells in a protective role. However, this only 
occurs when the inflammation is acute: if the inflammation becomes chronic then a 
negative response might develop. When endothelial injury occurs, E-selectin is more 
likely to be expressed at high levels, so that it can be considered as an indicator of 
endothelial damage and oxidative stress. It was reported that when there is 
endothelial dysfunction, there are alterations in E-selectin levels (Muniyappa and 
Sowers, 2013). As the level of NO is reduced in the presence of endothelial damage, 
endothelial cell adhesion molecules increase as a result of cytokine induction, and 
therefore the risk of developing CVD increases. In addition, any reduction in NO level 
causes constriction of blood vessels which in turn increases the probability of having 
an injury from high blood pressure (Vachharajani and Granger, 2009). 
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1.3.5.3 Plasminogen activated inhibitor (PAI-1)  
Fibrosis is an abnormal fibroblast activation-related or fibroproliferative disease. Any 
deregulation in the process of wound healing can result in hyperactivation of 
fibroblasts and extra accumulation of ECM proteins in the wound area, which is 
recognised as the pathophysiological manifestation of fibrosis (Nadar et al., 2004). It 
is considered as a final common stage of the pathological manifestation of several 
diseases such as alcoholic liver disease, cardiac and pulmonary hypertension, 
myocardial infarction, and non-alcoholic steatohepatitis (Brunt, 2004; Berk et al., 
2007; Ellmers, 2010; Ghosh, 2010; Mastuzaki, 2010; Yang et al., 2010). 
PAI-1 is a member of the serine protease inhibitor (serpin) gene family and is 
recognised as a major physiologic inhibitor of the serine proteases, uPA and tPA 
(tissue plasminogen activator) (Potempa et al., 1994). According to Barrett et al. 
(2010) endothelium sustains the integrity of the vascular wall, which controls 
fibrinolysis when it produces tPA and PAI-1, which blocks tPA. Moreover, it was 
found that the endothelium affects the function of heparin sulphate with antithrombin, 
thrombin/protein C and tissue factor, with tissue factor inhibitor interactions resulting 
in limitation of the coagulation cascade. PAI-1 is therefore widely considered as a 
marker of endothelial damage and is also linked to thrombosis as it is partially 
responsible for inhibition of fibrinolysis (Nadar et al., 2004). 
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COPD: Chronic obstructive pulmonary disease 
1.4.1 Introduction 
COPD is a major public health problem that is defined as a preventable and 
treatable entity which is usually progressive. Its main feature is a systemic 
inflammatory response of the airways and lungs to noxious gases, such as tobacco 
and biomass fuel smoke, that are associated with a poorly and progressively 
irreversible obstruction of airflow particles and causes an accelerated decline in 
ability of the lungs to function (GOLD, 2015). 
1.4.2 Epidemiology of COPD  
The prevalence of COPD, morbidity and mortality varies from country to country and 
from group to group within the general population (Vermeire, 2002).  A direct 
association between the prevalence of COPD and tobacco smoking has been 
reported; in addition to outdoor and indoor air pollution that results from the burning 
of fuels and woods. These issues are classified as the major COPD risk factors 
(Salvi and Barnes, 2009). The burden and prevalence of COPD are likely to increase 
in the next decades as a result of continuous exposure to risk factors associated with 
COPD and the aging global population (Chan-Yeung et al., 2004). Meta-analysis and 
systematic review of previous studies conducted by Helbert et al., (2006) revealed 
that the remarkable variation in COPD prevalence can be attributed to differences in 
survey methods, diagnostic criteria and analytic approaches. Several studies 
conducted across countries such as Asia and Latin and Meso-America, showed that 
the use of biomass fuel for cooking has increased the prevalence of COPD and has 
also resulted in a greater decline in lung function in women compared with women 
who do not use biomass fuel (Dutt et al., 1996; Dossing et al., 1994; Sungu et al., 
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2001; Regalado et al., 2006; Pandey, 1984). A report by the Global Burden of 
Disease Study states that COPD will be ranked the fourth leading cause of death 
worldwide by 2020; it was ranked as the sixth leading cause of death in 1990 
(Mathers et al., 2006). 
1.4.3 Pathophysiology of COPD 
              The main signs and symptoms of COPD are limited airflow, chronic 
coughing, increased sputum production and dyspnoea. In general, the progression of 
COPD is strongly associated with a thickening of the walls of the small airways as a 
result of an increase of epithelium, lamina propria and muscle tissues and adventitial 
compartments (Chung, 2005).  
Despite the fact that cigarette consumption is considered the number one risk factor 
for acquiring COPD, evidence showed that non-smokers can also develop chronic 
airflow limitation. Nevertheless, not all smokers develop COPD. The reasons for this 
irregularity are not yet clear. However, this is likely due to genetic differences and 
other exposure to dissimilar environmental settings (Celli et al., 2005; Behrendt, 
2005). Smokers inherently have a higher predisposition for lung abnormalities and 
prevalent respiratory symptoms, not to mention higher rates of decline in FEV1 
(forced expiratory volume1) than non-smokers (Kohansal et al., 2009). 
Chronic inflammation of the lungs can result from inhaling particles of smoke, air 
pollutants or other comparable sources. This type of inflammation is present among 
individuals who develop COPD. An inflammatory response of this nature can trigger 
destruction of the parenchymal tissue which, in turn, causes a disruption in normal 
repair and defence mechanisms. Disturbances of this type may lead to small areas 
of fibrosis that cause air trapping and airflow limitation (Chung, 2005).  Chronic 
62 
 
inflammation of the lungs and the narrowing of peripheral airways cause a decrease 
in FEV1. In the case of emphysema, parenchymal destruction occurs, which results 
in reduced elastic recoil. Subsequently, this results in the limitation of airflow 
together, inflammation, the narrowing of peripheral airways, and parenchymal 
destruction, leading to a progressive trapping of gas during expiration and 
consequent hyperinflation (Hogg et al., 2004). 
1.4.4 Oxidative stress and COPD pathogenesis 
          Smoking is known to contribute to the development of COPD and studies have 
demonstrated its effects on systemic inflammation and oxidative stress (Yanbaeva et 
al., 2007).  It is widely accepted that oxidative stress is a major aetiological factor in 
the pathogenesis of COPD. Oxidative stress results from impaired or overwhelmed 
endogenous antioxidant defences caused by the presence of reactive oxygen 
species (ROS), such as those found in cigarette smoke (Mirrakhimov, 2012).  Recent 
evidence suggests that an increase in oxidative stress may pose a risk by initiating 
Type 2 diabetes; at the same time, it can be considered a consequence of Type 2 
diabetes. This increase in oxidative stress can be due to the generation of ROS that 
results from hyperglycaemia (Evans et al., 2002).  Stapleton et al., (2008) reported 
that when there is oxidative stress, an increase in the generation of oxidants occurs 
which can result in either a failure to repair oxidative damage or a reduction in 
antioxidant damage due to the generation of ROS. Several other risk factors that are 
linked with oxidative stress are cigarette smoking, dyslipidemia, insulin resistance 
and inflammation.  
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There is also considerable evidence that injury is found to be caused or 
exacerbated by pro-inflammatory cytokines that occur through many different 
mechanisms; including enhancement of vascular permeability, apoptosis, and 
recruitment of invasive leukocytes and promotion of ROS (Chung and Barnes, 1999). 
The term ROS refers to a subset of molecules that are identified as free radicals. 
These free radicals are defined as any molecule that has unpaired electrons in the 
outer orbital shell. Each unpaired electron is responsible for making each molecule 
highly reactive rendering it capable of donating an electron to another molecule or 
compound, or withdrawing a proton from another molecule or compound to gain 
stability. The highly reactive molecule results in the formation of bonds between the 
ROS and other compounds and thus leads to impairment of tissue function 
(Cheeseman and Slater, 1993). Under normal situations ROS are manufactured by 
the immune system to overcome or destroy pathogens. Normal metabolism also 
produces ROS, but oxidative stress is presented only when the production of ROS 
exceeds the capacity of cellular antioxidant defences. Several findings proved that 
chronic oxidative stress in patients with diabetes is related to an excess of substrates 
in the metabolism (i.e. glucose and fatty acids). In addition, an association between 
mitochondrial dysfunction and insulin resistance was discovered (Nourooz-Zadeh et 
al., 1997). As the majority of ROS are derived from mitochondria, any defect in 
mitochondrial function can increase the risks of developing diabetes-related 
complications; since the aetiology of insulin resistance and diabetes are related to 
mitochondrial dysfunction (Blake and Trounce, 2014). In brief, oxidative stress 
originates from the overproduction of ROS and is recognised as a main unifying 
factor for developing of complications associated with diabetes.  
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Many studies have explored possible correlations between oxidative stress and 
biomarkers of COPD. Most of these COPD biomarkers were found in highly 
significant levels among patients with COPD and in individual smokers compared 
with healthy individuals (Rezaeetalab et al., 2014). As discussed, oxidative stress 
results from impaired or overwhelmed endogenous antioxidant defences caused by 
the existence of ROS. Consequently, this leads to the development of “carbonyl 
stress’’ in which oxidants damage the surrounding tissues and in turn forms highly 
reactive organic molecules that are responsible for modifying proteins. This occurs 
through a non-enzymatic pathway, forming carbonyl adducts, more commonly known 
as AGEs on the surface of proteins (Yao and Rahman, 2011). The formation of 
AGEs is historically linked to high glucose levels and the presence of oxidative stress 
in diabetes through a process known as glycation. In diabetes, an increase in 
carbonyl stress can be due to oxidative stress which is expressed as an increase in 
the levels of reactive carbonyls which are linked to the severity of COPD which leads 
to the formation of AGEs (Kirkham and Barnes, 2013). 
1.4.5 Carbonyl Stress 
In vivo, modified AGEs were reported as being involved in the development of 
vascular lesions, which contribute to macro and microvascular pathologies (DCCT, 
1993). HbA1c is widely considered the gold standard tool for diagnosing diabetes 
and measuring glycaemia (Genuth, 2002). α-oxoaldehydes are recognised as potent 
glycating agents that play a key role in creating carbonyl stress. These compounds 
are produced endogenously (Thorpe et al., 2000). An imbalance between the 
formation of carbonyl intermediates and the effectiveness of scavenger pathways 
leads to the formation of carbonyl stress (Miyata et al., 1999). While dicarbonyls 
such as α-oxoaldehydes are considered as AGE precursors, they form in one of 
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three ways: as glycolytic intermediates by conversion of glucose via metabolic 
pathways, by Millard reaction via degradation of glycated protein, or by peroxidation 
of lipids (Thornalley, 2005). Figure 1.4.5 shows that the α-oxoaldehydes compounds 
are potent glycating agents with extremely high chemical activity, up to 50,000-fold 
as reactive glucose. Therefore, they can form AGEs even at low concentrations 
(Latruffe et al., 1982). In fact, during the process of the glycation reaction glucose is 
manufactured into the amino group of lysine and N-terminal amino acids from 
proteins that react with glucose.  In the case of dicarbonyls the glycation product is 
presented as an arginine residue (Thornalley, 2005).   
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Figure 1.4.5:  Pathways for reactive carbonyl compounds biogenesis. 
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1.4.6 AGE and RAGE and the association with COPD 
As mentioned in section 1.2.1, AGEs are the final products of the non-enzymatic 
glycation and the oxidation of proteins and lipids (Goldin et al., 2006). Their 
production is accelerated in the presence of hyperglycaemia and oxidative stress 
(Schmidt et al., 2001). Forbes et al., (2001) reported that AGEs accumulate in the 
brain and contribute to the development and progression of Alzheimer’s disease via 
cellular responses to ROS. 
           The two major risk factors of COPD are smoking and ageing, although it is 
unclear exactly how these two factors contribute to the development of COPD 
(Fletcher and Peto, 1977). It is known, however, that they may accelerate the 
formation of AGEs (Nicholl et al., 1998). The binding of AGEs to RAGEs activate NF-
B (nuclear factor kappa- B cells) and enhances inflammation so that AGEs can play 
an important role in the development and progression of COPD (Bierhaus et al., 
2000).  Demling et al. (2005) reported the expression of RAGE at low levels in 
tissues and blood vessels, although its expression becomes high in sites where its 
ligand accumulates.  The same research group found that RAGE is well expressed 
in normal lung tissue. RAGE was identified as a specific differentiation marker of 
human ATI cells by analysing the alveolar epithelial Type 2 cells. In addition, 
Demling et al., (2005) noted that RAGE was expressed in endothelia and alveolar 
macrophages. RAGEs also promote the adherence of epithelial cells to collagen. 
Despite these findings, the role of AGEs in the development of COPD has not yet 
been fully investigated (Mukherjee et al., 2008).  
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1.4.7 COPD comorbidity with Diabetes 
Several studies have reported an association between diabetes and COPD. It has 
been estimated that the prevalence of diabetes amongst stable COPD patients is as 
high as 18% (Cazzola et al., 2010). This number rises to 30-34% in acute 
exacerbating COPD patients (Kinney et al., 2014), with the risk of developing 
diabetes increasing along with disease severity in COPD (Mannino et al., 2008). It 
has been reported that for women with COPD, the presence of Type 2 diabetes is 
1.8 times higher than for women without COPD; when age, activity, MI, diet and 
exercise, family history and smoking status are taken into consideration (Rana et al., 
2004). Moreover, the presence of diabetes in COPD patients has been associated 
with worse lung function (Van den Borst et al., 2010), with smoking being a known 
risk factor for developing Type 2 diabetes in the absence of COPD (Xie et al., 2009). 
The interaction between diabetes and COPD was shown throughout demonstrating 
that the decline in lung function is a risk factor for the development of diabetes 
(Lazarus et al., 1998; Engstrom et al., 2003). In fact, smoking has been considered a 
risk factor for diabetes (Manson et al., 2000& Rimm et al., 1995).  
Both COPD and diabetes are influenced by inflammation and oxidative stress 
after exposure to tobacco. The net outcome is downstream complications that are 
often associated with these diseases; particularly after an exacerbation in COPD, 
namely vascular complications brought about by high levels of AGEs (Lavi et al., 
2007).  
In fact, in stable COPD patients it was reported that the levels of pro-
inflammatory cytokines IL-6, IL-1, TNF- and IL-8 are increased in sputum (Chung, 
2001). In COPD, the cytokine mediators are increased chronically and are thought to 
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contribute to the development of COPD. It was reported that in diabetic individuals, 
the TNF-, IL-6 and C reactive protein (CRP) levels were higher than in non-diabetic 
individuals and can be considered predictors for risk of diabetes (Hu et al., 2004). In 
addition, insulin resistance was found to be increased in patients with COPD than 
those without and this increase was related to plasma IL-6 and TNF-levels (Bolton et 
al., 2007). However, the relationship between increased insulin resistance and 
chronic inflammation may be due to disruption of insulin receptor signaling by 
inflammatory mediators (Grimble, 2002). Such a relationship was demonstrated by 
Liu et al. (1998). In their research study, they cultured human adipocytes and noted 
that TNF- caused a decrease in the insulin-stimulated autophosphorylation of the 
insulin receptor, which blocked the signaling of insulin.  
Treatment of COPD with glucocorticoids has impacted on diabetes 
management. Diabetes control also affects COPD outcomes; although it is currently 
unclear whether improving glycaemic control can improve COPD outcomes (Luijks et 
al., 2015).  The use of systematic corticosteroids as a form of therapy for COPD 
affects glucose intolerance and diabetes mellitus. A study carried out on patients 
with COPD (Wood-Baker et al., 2007) compared patients treated with oral 
corticosteroids and those who received a placebo. Results indicated that those who 
received oral corticosteroid therapy were 7.7 times more likely to experience adverse 
effects than those who received the placebo.  The adverse effects mostly commonly 
experienced were glucose intolerance and mild hypertension. In addition to these 
findings, other studies have also shown that inhalation of steroids can have slight 
negative effects on glucose metabolism. In a large, randomised control study, it was 
shown that patients who inhaled budesonide 400µg bid were more susceptible to 
developing diabetes within three years of follow up than those who received placebo 
70 
 
(Canis et al., 2007; Faul et al., 2009). Additionally, mortality rates were reported to 
be significantly higher in patients with poor glycaemic control who were admitted to 
hospital for acute exacerbation of COPD (Baker et al., 2006). Even after discharge, 
hyper glycaemia remained as a risk factor for increasing the death rate for diabetic 
patients. It is still unclear whether improvement in glycaemic control can improve 
COPD outcomes (Gudmundsson et al., 2006). 
1.4.7.1 Metformin as an antidiabetic drug in COPD 
Metformin treatment is well known for improving the outcomes of 
complications associated with COPD. During COPD, exacerbated glucose tolerance 
worsens because of the physiological stresses of acute illness including an increase 
in inflammation, acidosis and corticosteroids therapy. Thus, most COPD patients 
with diabetes are found to be overweight and insulin resistant (Baker et al., 2009). 
Such patients are required to be treated with drugs that increase insulin sensitivity 
and encourage weight loss, for example metformin.  
  Metformin (dimethylbiguanide) is an anti-diabetic drug that is administrated 
orally. It lowers blood glucose levels in Type 2 diabetic patients due to its role in 
improving insulin sensitivity, which in turn decreases insulin resistance. It also 
causes a significant reduction in plasma fasting insulin levels and so is widely 
considered as an insulin sensitizer (Violet et al., 2012). It can be administered alone 
as an initial therapy to lower glucose or with sulphonylureas as an additional therapy 
(Bailey et al., 1996). Metformin’s main effect is reducing the production of hepatic 
glucose. This can be due to its action in activation of AMP-activated protein kinase 
(AMPK). AMPK is a major cellular regulator of lipid and glucose metabolism. This 
activation of AMPK stimulates glucose uptake in muscle, fatty acid oxidation in 
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muscle and liver, and results in reduced production of hepatic glucose, cholesterol 
and triglyceride (Zhou et al., 2001).  
 Several studies show that administration of metformin has beneficial effects 
on cardiovascular events (Sasali and Leahy, 2003; Inzucchi, 2005; Lamanna et al., 
2011).  Yin et al. (2011) reported that, in Sprague-Dawley rats, metformin treatment 
improves cardiac function and decreases the size of infarct after myocardial 
infarction. In addition, it was found that administration of metformin alone or with 
sulphonylurea can decrease mortality and morbidity rate in patients with Type 2 
diabetes and heart failure, compared to administration of sulphonylurea alone 
(McDonald et al., 2010, Eurich and McAllister, 2010). Metformin was also found to 
decrease the rate of atherothrombosis in a cohort of patients with atherothrombosis 
for continued health (REACH) Registry (Roussel et al., 2010).  
AGEs which result from non-enzymatic glycation are formed in vivo from 
highly reactive carbonyl groups called alpha-dicarbonyls or oxoaldehydes, including 
3-deoxyglucosone, glyoxal, and methylglyoxal (Brownlee et al., 2006). Several 
studies have shown that methylglyoxal (MG) is significantly increased in the plasma 
of diabetic patients (Knecht et al., 1992; McLellan et al., 1992) and that this increase 
in plasma MG levels correlates with glycaemic control (Beisswenger et al., 1995). 
MG levels can cause increases in AGEs levels as they are one of the main source 
for AGEs. This has been proven to correspond to occurrences of diabetic vascular 
and neuropathic complications and diabetic nephropathy (Beisswenger et al., 1995, 
Monnier et al., 1986 and Biesswenger et al., 1997).  
 Many investigators have shown that metformin has beneficial effects in 
reducing vascular risks associated with diabetes; alongside its main role as an anti-
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hyperglycaemic drug (Beisswenger et al., 1999). In addition, metformin has shown 
reductions in MG levels in the tissues of diabetic patients (Beisswenger et al., 1999), 
which in turn reduce AGEs levels in the lens, kidney, and nerves of diabetic animals 
(Tanaka et al., 1999). This reduction of MG levels by metformin occurs via formation 
of specific condensation products that result from the reaction of metformin with MG. 
One example of those compounds is triazepinone (TZP) (Ruggiero-Lopez et al., 
1999).   Regan et al., (2001) reported that functional and structural alterations of 
diabetic myocardium associated with glycation can be prevented by metformin 
treatment. They also reported that metformin can completely prevent myocardial 
AGE formation.  
1.4.8 COPD, Diabetes and CVD 
 Diabetes, hypertension, ischaemic heart disease and heart failure are the 
main comorbidities that are linked to COPD (Moussas et al., 2008). Cardiovascular 
disease (CVD), cancer, chronic obstructive pulmonary disease (COPD) and diabetes 
mellitus (DM) are listed as the most prevalent among chronic morbidities; it was 
reported that hyperglycaemia, infections and cardiovascular complications are linked 
with exogenous hypercorticism which is most frequent among patients suffering from 
extra severe lung disease with endocrine alteration (Martin et al., 2009).  
Several studies have reported that Type 2 diabetes is a risk factor for 
macrovascular disease (Fowler, 2008). Some of the side effects of diabetes may 
alter the outcomes for COPD. These effects of diabetes may be related to an 
increase in cardiovascular morbidity and mortality, taking into account that the lung 
itself is targeted by microvascular diseases (Mirrakhimov, 2012). Weynand et al. 
(1999) showed that the thickening of alveolar epithelial and endothelial capillary 
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basal lamina can be observed in the lungs of patients with diabetes when compared 
to healthy people; using electron microscopy. Moreover, the lung’s capacity is 
reduced in patients with diabetes mellitus and is expected to further diminish when 
coupled with macrovascular complications. The presence of pulmonary 
microvascular disease in patients with COPD and diabetes may lead to respiratory 
impairment (Strojek et al. 1992; Mori et al., 1992). 
The relationship between cardiovascular diseases and respiratory diseases 
has received much attention (Sin and Man, 2005; Curkendall et al., 2006). The 
reason for this association is unclear but may be due to systemic inflammation, 
chronic infections, shared risk factors (i.e. smoking) or other unknown factors (Le 
Jemtel et al., 2007; Naunheim et al., 2006). The Atherosclerosis Risk in 
Communities Study (ARIC) data demonstrate that respiratory impairment predicts 
the progression and development of cardiovascular disease.  It was also discovered 
that this relationship decreases when fibrinogen, a marker of systematic 
inflammation is accounted for. This finding proposes that the association between 
COPD and cardiovascular disease may be partially related to other factors (Johnston 
et al., 2008).  
In patients with COPD, the plasma fibrinogen levels were increased. It is 
possible that this rise in fibrinogen levels may lead to an increased CVD morbidity 
and mortality rate among patients with COPD. As serum IL-6 levels rise in COPD 
patients, plasma fibrinogen levels increase in response. In turn, this increase in 
plasma fibrinogen results in the development of acute infection which plays a role in 
pre-occurrence of coronary heart disease (CHD) and stroke (Wedzicha et al., 2000).  
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 Furthermore, smoking may increase susceptibility to infection and causes the 
levels of inflammatory markers to intensify (Arcavi and Benowitz, 2004; Gan et al., 
2005). 
In fact, relevant features in their development and their course of action 
demonstrated similarities between diabetes and COPD. These similarities include 
hypoxia, insulin resistance, inflammation and oxidative stress. Collectively, tobacco 
smoking, obesity and sleep disorders promote endothelial dysfunction and 
atherosclerosis, thereby placing diabetic and COPD patients at high risk (Falk et al, 
2008). As mentioned in section 1.4.4, this phenomenon may be caused by an 
increase in carbonyl stress brought on by oxidative stress. The latter may be 
expressed as levels of reactive carbonyl that are linked to the severity of COPD, 
which results in the formation of AGEs (Kirkham and Barnes, 2013). Oxidative stress 
is the result of free radicals present in cigarette smoke; the levels of isoprostanes, a 
marker of oxidative stress, were notably increased in smokers (Seet et al., 2011).  
The mechanism behind the contribution of smoking to cardiovascular events 
may be explained through the catabolic pathway of induction of endothelial 
dysfunction. Cigarette smoking is linked to oxidative stress; which is widely 
considered a mediator of endothelial dysfunction.  In the presence of oxidative 
stress, the inflammatory response as well as blood thrombogenicity (both features of 
endothelial dysfunction) increase (Morrow et al., 1995; Cai & Harrison, 2000; 
Sambola et al., 2003). Due to the apparent contribution of FN3K in the process of 
non-enzymatic glycation and the assumed effect it has on the formation of AGEs, it 
was proposed that the enzyme might play a role in the association between COPD, 
CVD and diabetes.  Figure 1.4.8 provides a summary of these possible links. 
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In contrast, it has been shown that AGEs in the circulatory system bind with 
endothelial RAGE, thereby causing endothelial dysfunction. This can be explained 
by the activation of a variety of signaling pathways, such as nicotinamide adenine 
dinucleotide phosphate oxidase activation, which stimulates the manufacturing of 
ROS (Schmidt et al., 1994). In support of this finding, Evans et al., (2002) reported 
that ROS contribute to majority of the cardiovascular damage seen in patients with 
diabetes mellitus by modifying and altering the structure of cellular lipids, nucleic 
acids and proteins, ultimately affecting the physiological functions of these 
constituents.  
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1.5 Summary of Gaps in the Previous Studies 
1. Most of the previous studies have reported the presence of FN3K in animal models 
but very few of them have examined human models. Many have looked at 
whether HbA1c levels reflect mean blood glucose (MBG) levels in Type 2 
diabetes. 
2. Previous studies have neglected to look at the relationship between the FN3K 
activity and glycated haemoglobin levels in human models. 
3. No studies have investigated the presence and activity of the FN3K enzyme 
and its relation to G-gap values.  
4. Studies have failed to look at any possible relationships between plasma AGEs 
and the activity and/or expression of FN3K enzyme in human erythrocytes. 
5. Very few studies have clarified the role of AGEs in aging and diabetic 
complications.  
6. No studies have been conducted to measure FN3K levels in human 
erythrocytes of patients with variety of G-gap values.  Thus, there have 
been no reports on any association between Human FN3K levels and its 
activity in erythrocytes with the markers of endothelial dysfunction. 
7.  Few studies have considered the association between COPD, diabetes and 
CVD and even fewer studies have clarified how these comorbidities are 
linked together.  
8. There are no studies that investigate the role of FN3K enzyme in patients with 
COPD, diabetes and/ or CVD. 
9. Minimal studies have explored whether the discrepancies in FN3K activity 
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and/or concentration may affect the outcomes of diabetes in the presence 
or absence of accompanying complications.   
10. There is no research to possible links between metformin therapy and FN3K 
enzyme activity and/or expression.  
11. Past studies have overlooked the possibility for associations between 
carbonyl stress and the role of FN3K enzyme in patients with COPD and 
diabetes. 
12. A limited number of studies have investigated the occurrences of isoenzymes 
for FN3K exhibiting different kinetic properties. 
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1.6 Research Questions, Aims and Objectives 
1.6.1 Research Questions 
The questions below have been formulated based on the gaps created in previous 
studies: 
1. Is the FN3K enzyme responsible for deglycating the glycated haemoglobin within 
erythrocytes?  
2. Are the differences in G-gap levels related to FN3K activity and/or levels in human 
erythrocytes or vice versa? 
3. Can variations in the FN3K activity affect the levels of AGEs in individuals that 
display discrepancies in glycation gaps? 
4. Are markers of endothelial dysfunction affected by FN3K enzyme activity and/ or 
levels in erythrocytes? 
5. Does FN3K enzyme expression control the levels of carbonyl stress and AGEs in 
COPD patients with diabetes? If so, does it affect the occurrence of 
associated CVD complications? 
6. What are the factors behind the discrepancies in FN3K levels among individuals?  
7. Does FN3K activity in human erythrocytes associate with FN3K levels inside and 
outside erythrocytes?  
8.  Is the FN3K the only enzyme responsible for the deglycation of glycated     
haemoglobin in erythrocytes and are polymorphisms in the FN3K genes 
associated with this event? 
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1.6.2 Research Hypothesis 
The following hypotheses were developed from the above research questions: 
1. FN3K deglycates glycated haemoglobin in erythrocytes of diabetic patients 
2. FN3K is an important enzyme that plays a role in maintaining of blood glucose 
levels in humans 
3. Variations in the activity of FN3K between individuals may lead to apparent 
discrepancies in glycated haemoglobin levels, causing people with high FN3K 
activity to have low glucose levels while those with low FN3K activity present 
high glucose levels 
4. Patients with positive G-gaps are assumed to exhibit lower FN3K activity in 
comparison to patient with negative G-gaps and are expected to have higher 
activity of FN3K enzyme 
5. Patients with low G-gaps and high FN3K activity are assumed to be less at risk for 
developing diabetic complications, such as cardiovascular events, while those 
with a high G- gap value and low FN3K activity are expected to be at high risk 
for developing complications associated with diabetes 
6. High FN3K activity plays a role in decreasing the levels of AGEs as well as 
decreasing carbonyl stress levels in patients with diabetes and COPD 
7. Metformin, an antidiabetic drug, can have positive and beneficial effects in the 
frequency and severity of diabetic complications.   
Validation of the above hypotheses would serve to pave the way for further 
complementary investigations to take place in the future. Such studies may 
contribute to improving the managements of diabetes. More research on this area of 
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diabetes is needed to achieve a better understanding of the FN3K enzyme and its 
possible clinical utilities regarding the management of patients with diabetes. 
1.6.3 Aims of the Research  
The aim of this research is to investigate possible associations between differences 
in G-gap values among diabetic individuals with the individual discrepancies in their 
FN3K activity and levels as presented by each case.  Furthermore, this study also 
aims to look at whether these discrepancies impact the risk of developing diabetes-
related complications and to assess whether the G-gap could be used to predict 
whether complications associated with diabetes will arise. This possible association 
is examined by measuring the amount of FN3K activity and level in diabetic patients 
and correlating the results with their G- gaps levels; whilst measuring markers of 
endothelial dysfunction, since it is known as an important precursor for other 
cardiovascular complications in diabetic patients (Green and Turner, 2017; Meigs, et 
al., 2004; Sena et al., 2013; Hadi and Al Suwaidi, 2007).  In summary, this research 
seeks to: 
1. To test the hypothesis that the enzyme fructoseamine-3-kinase is responsible for 
the deglycation of glycated haemoglobin in erythrocytes and to obtain a better 
understanding of its potential and physiological role of in this process;  
2. Investigate any associations between the activity and levels of the FN3K enzyme 
both erythrocytes and plasma with the G-gap value in each individual; 
3. Examine whether the rate of deglycation reaction influences differences in the 
occurrence of diabetic complications between subjects with high G- gap 
values and those with low G-gap values. If so the FN3K enzyme could be 
considered as an important enzyme for maintaining glucose levels in patients 
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as it catalyses the phosphorylation of glycated proteins, such as glycated 
haemoglobin, since the variations in the activity of FN3K between individuals 
may lead to apparent discrepancies in the glycated haemoglobin levels; 
4. Investigate the relationship between the variations in G-gaps with FN3K levels in 
diabetic patients and the possibility of assessing development endothelial 
dysfunction by measuring markers of endothelial dysfunction in each of those 
patients;  
5. Determine whether variations in G-gap values affect the levels of AGEs in diabetic 
patients and the involvement of FN3K enzyme in this association; 
6. Understand the concept of oxidation/carbonyl stress and its association with FN3K 
levels in patients who have COPD and diabetes  
7. Investigate the impact of metformin treatment therapy on FN3K levels in COPD 
patients with diabetes; 
8. Investigate the impact of smoking on FN3K expression in COPD diabetic patients 
as FN3K may control the levels of carbonyl stress and AGEs formation, along 
with the vascular complications that can arise in COPD and diabetes. 
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1.6.4 Objective of Studies 
 
To achieve the above aims for this research, this work was divided into three 
separate studies, each study was categorised according to the type and the source 
of samples involved:  
1. The first study: fructosamine-3-kinase (activity and protein levels) in relation to G-
gap and AGEs in diabetic patients. This study was divided into five parts: 
I. Study 1 Part 1:  FN3K enzyme activity in Erythrocyte lysate: The 
purpose of this part of the study is to compare FN3K enzyme 
activity between subjects with high G-gap values to those with low 
G-gaps values; using human erythrocytes from those subjects for 
this assay (Krause et al., 2006).                               
II. Study 1 Part 2:  FN3K levels in erythrocyte lysate. The purpose of 
this study is to know if there are differences in the levels of FN3K 
enzyme between those with high and low G-gap values and if these 
differences in FN3K protein levels are correlated with its activity.  
III. Study 1 Part 3: Plasma FN3K protein levels in relation to G-gap.  
This part was set to investigate whether FN3K enzyme is presented 
in plasma and if it can deglycate glycated proteins in plasma such 
as glycated albumin. 
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IV.  Study 1 Part 4: Plasma AGEs levels in relation to G-gap. This part 
was aiming to investigate whether there is an association between 
differences in glycation gaps value and plasma levels of AGE. And 
to find out if there is a link between difference in plasma AGEs 
levels and the activity and levels of FN3K enzyme.  
V. Study 1 Part 5: The association between endothelial dysfunction 
and G-gap. The objective behind this part is to investigate whether 
any changes in G-gap values are associated with presence of 
endothelial dysfunction. 
VI. Study 1 part 6 Plasminogen activated inhibitor (PAI-1) relation as a 
marker of thrombosis and endothelial dysfunction to G-gap. The 
objective of this part is to explore whether changes in the G-gap 
values are associated with any risk of both thrombosis and 
endothelial dysfunction.  
In summary, the objectives of this study comprise: 
A. FN3K enzyme levels were measured in plasma from the same diabetic 
patients who displayed difference in glycation gap levels. 
B. With regards to the possibility of having endothelial dysfunction in individuals 
with high glycation gap values, markers of endothelial dysfunction, such as, 
thrombomodulin and E-selectin molecules were measured in plasma samples 
obtained from the same patients using the ELISA technique (Eng et al., 2000, 
Meigs et al., 2004 & Nadar et al., 2004). In case of fibrinolysis and endothelial 
dysfunction, the plasminogen activator inhibitor 1 (PAI-1), a protein primarily 
produced by the endothelium which is partially responsible for the inhibition of 
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fibrinolysis and thus is linked to thrombosis that contributes to endothelial 
dysfunction, was also measured using the ELISA technique (Nadar et al., 
2004). 
C. AGEs levels in plasma were measured by performing a competitive ELISA 
technique on the same diabetic patients who exhibited high and low glycation 
gaps values. 
2. The second study involved measuring of FN3K levels in acute exacerbating 
COPD (AECOPD) patients treated with metformin and placebo) the reason behind 
this study is to examine the association between COPD and diabetes and the 
impact of metformin therapy. This was achieved by investigating whether 
metformin treatment can enhance FN3K expression compared with placebo 
treatment in subjects with AECOPD. Serum FN3K enzyme levels were measured 
using the ELISA techniques in serum samples obtained from patients with 
AECOPD who were admitted to hospital and treated with either metformin or 
placebo.  
 
3. The third study involves measurement of FN3K protein levels in COPD airways.  
The reasoning behind this study is to investigate whether the presence of COPD 
may enhance the expression of FN3K enzyme and to examine the impact of 
smoking on FN3K expression in COPD patients. 
FN3K expression was assessed by examining bronchial biopsies from smokers, 
stable COPD patients, and healthy individuals using immunohistochemistry on 
paraffin-fixed biopsies; obtained following lung resection surgery. 
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Chapter 2  
Materials and Methods 
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2.1 Study 1: FN3K, AGEs and Markers of Endothelial Dysfunction Assay  
2.1.1.1 Study Design   
A double blind and single-centre study was conducted using 148 plasma samples 
and 100 samples of erythrocytes obtained from patients diagnosed with diabetes. 
Samples were collected from New Cross Hospital (Wolverhampton, UK), a member 
of the West Midlands NHS trust. 
2.1.1.2 Ethical Approval 
Ethical approval was obtained from the University of Wolverhampton and the local 
UK Health Service Research Ethical Committee - West Midlands prior to the 
collection of test samples.  
2.1.1.3 Selection of Patients and Data Collection 
After receiving ethical approval for conducting this study, glycated haemoglobin and 
fructosamine measurements were taken from carefully selected patients over a 
three-year period (2006-2009) at New Cross Hospital. These patients were adults 
who had been recruited for a wider range of diabetes research which involves the 
investigation of glycated haemoglobin and various elements of G-gaps (Nayak et al., 
2013). In total, 148 samples were gathered from the corresponding number of 
patients involved in this study. 
These patients were subjected to two different tests that involved taking two 
measurements for the levels of glycated haemoglobin and two for G-gaps which 
were presented as consistent. These values were categorised as positive or 
negative for G-gaps.  
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Of the 147 patients who met the inclusion criteria (one sample was excluded 
due to mishandling), 80 were found to have negative G- gaps while the remaining 67 
had positive G-gaps. These patients had been diagnosed with either Type 1 or Type 
2 diabetes although the majority of them had Type 2 diabetes.  The 150 patients 
selected were made of the first 75 had 2 pairs of simultaneous estimations of HbA1c 
and  2 calculated G-gaps that were consistently positive and the first 75 patients that 
had 2 pairs of simultaneous estimations of HbA1c and 2 calculated G-gaps that were 
consistently negative and not from random selections. 
The only known information during the analysis process at the time 
experiments were   conducted was each patient’s gender and ethnicity as the study 
was double-blinded (Table 2.1a and 2.1b). Variables, such as age and length of 
disease were unknown.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glycation gap 
values 
Gender  Ethnicity  
 
Male  
 
Female  
 
White  
 
Black  
 
Asian  
Negative G 
gaps 
(n=80) 
52 29 58 7 10 
Positive  G  
gaps 
(n=67) 
40 27 48 3 16 
Table 2.1a: The known variables in the cohort in each glycation gap 
group of (Study 1). 
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Gap Category>  Negative  
(mean ± 
SD)  
Positive  
(mean ± 
SD)  
P  
(unpaired t)  
P (MWU)  P  
µ2  
n  81  67     
Age (years)  61.3±10.4  64.4±9.3  ns  ns   
Gender (% 
male)  
64%  60%    ns  
Ethnicity (% 
white)  
72%  72%    ns  
Smoking status 
(% never 
smoked)  
56%  49%    ns  
Body mass 
index (kg/m2)  
30.2±5.2  35.4±6.7    <0.001   
Weight (kg)  87.8±18.3  99.1±21.4   <0.01   <0.01   
Type of 
Diabetes (% 
type 2)  
84%  91%    ns  
Duration of 
Diabetes (years)  
15±10  15±9  ns  ns   
Insulin therapy 
(% yes)  
69%  81%    ns  
Retinal status 
(% with any 
retinopathy)  
72%  71%    ns  
Urinary albumin 
creatinine ratio 
 
4.4±18.5  9.7±29.7  ns   <0.05   
Creatinine (umol 
/l)  
86±22  82±21  ns  ns   
Vascular status 
(% 
macrovascular 
disease)  
29%  31%    ns  
Cholesterol 
(mmol /l)  
4.3±1.2  4.2±1.3  ns  ns   
HbA1c (% 
glycated)  
7.4±1.9  9.7±1.7   <0.001   <0.001   
Fructosamine  332±86  302±60   <0.05   <0.05   
Fructosamine 
derived HbA1c 
(% glycated 
HbA1c)  
8.8±1.9  8.2+-1.3   <0.05   <0.05   
Glycation gap 
(% glycated 
HbA1c)  
-1.4±0.7  +1.5±0.7   <0.001   <0.001   
Table 2.1b: Descriptive characteristics of patients involved in (study 1).  
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Tables 2.1a and 2.1b show that the total number of male participants was higher 
than females. Despite this observation, their G-gap numbers are approximately 
equal for both genders. Moreover, the distribution of ethnic groups appeared to be 
unequal with most patients being white, followed by Asians and blacks. This 
discrepancy might be because patients were recruited from a single area: the study 
is single centred in its design. 
2.1.1.4 Inclusion and Exclusion Criteria 
For individuals to be selected into this study they were required to meet the 
following criteria: 
1. Be diabetic patients 
2. Consistently produce measures for G-gaps that fall between ≥0.5% or ≤-0.5% 
3. They should be 18 years of age or older 
4. Should demonstrate variation in their glycated haemoglobin (HbA1c) levels. 
Patients were excluded from this study if they were: 
1. Non-diabetic 
2. Displayed abnormal haemoglobin 
3. Patients with electrophoretic pattern or were pregnant women 
4. Patients with previously prescribed drugs affecting glucose levels, such as 
corticosteroids, for example 
5. Patients under 18 years old 
6. Patients with haemoglobinopathy  
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7. Patients with elevated creatinine levels of more than 200 μmol/L. 
2.1.1.5 Consent Forms and Information Sheets: 
Each patient recruited was provided with information pertinent to this study, such as 
the research title, background information about the study and the research team, as 
well as the tasks to be carried out. Each participant was clearly informed about his/ 
her right to withdraw from the study at any time without providing a reason, and 
assured that his/her privacy would be protected. Their written consent to willingly 
participate in this study was obtained before samples were collected. 
2.1.1.6 Samples 
Patients were given advance notice of the dates on which blood samples would be 
collected.  Blood samples were collected by venepuncture using a safe vacutainer 
system. The heparinized blood samples were all taken at New Cross Hospital 
(Wolverhampton, UK). Samples were then centrifuged to separate plasma from the 
erythrocyte fraction and both fractions stored at -80˚C in order to maintain their bio-
stability over a long period.  Plasma samples were prepared using heparin, an 
anticoagulant, and then centrifuged at 1,000xG for 30 minutes after collection. These 
plasma and erythrocytes samples were then aliquoted to avoid repeated freeze-thaw 
cycles and stored for assays that were to be conducted later. All aliquoted samples 
were then moved and stored at -20 ˚C in the Diabetes Research Group laboratory at 
the University of Wolverhampton under the care of Dr Simon Dunmore’s research 
group. 
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2.1.1.7 Analysis of Samples 
In order to conduct this study, FN3K activity levels, AGE levels, and levels of 
markers of endothelial dysfunction were compared between subjects with positive 
and negative G-gap values. The following information was used as standards for 
evaluating these variables: 
 
1. The normal range of glycated haemoglobin (HbA1c) is 4-6 %( 20-42 
mmol/mol); individuals with values higher than this range (> 6.5%; 
48mmol/mol) were deemed diabetics (DCCT, 1993). 
 
2. The identification of positive and negative G-gaps should fall within a range 
of >0.5% and> -0.5% (Cohen et al., 2003).  HbA1c level was measured using 
high performance liquid chromatography (HPLC) (Nayak et al., 2013).   
 
The performance scores used by the UK National External Quality Assurance 
Scheme (UK NEQAS) were applied to this study and are as follows: A (accuracy) 
score <100 and B (bias) score <2%, which are within the acceptable limits of the UK 
NEQAS standards for glycated haemoglobins (maximum limits: A score <200 and B 
score less than ± 7.5%), whereas the between batch coefficient of variation was 1.8 
for an HbA1c of 5.7% and 1.4% for an HbA1c of 9.5%. This was achieved in 
collaboration with Nayak et al., (2011). Fructosamine was measured by 
nitroetrazolium blue reduction (Nayak et al., 2013).  
Since HbA1c is the key element of this analysis, any factors and/or conditions 
that altered its level were noted and excluded from the study.  Examples of such 
anomalies include: 
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1. Abnormal haemoglobin levels. This can be due to high levels of Hbs in 
diseases such as sickle cell anaemia or deficiency of HbA in conditions such 
as thalassemia (Mediterranean anaemia). 
 2. Any changes in HbA levels can affect the glycation process since HbA 
accounts for 95% of all types of haemoglobin. Thus, if HbA levels are low, this 
leads to a reduction in the formation of HbA1c which in turn affects the 
glycation process. Alternatively, an increase in HbA level can lead to an 
increase in the levels of glycated haemoglobin (HbA1c), which requires that 
haemoglobin electrophoresis be carried out (Hempe et al., 2002). 
3. Many drugs, such as corticosteroids, β-blockers, diuretics, etc. affect blood 
glucose levels (Ginsberg, 2009). As glycated haemoglobin levels reflect the 
levels of glucose in blood, any medications that increase or decrease blood 
glucose levels should be considered. Corticosteroids, for instance, are well 
known to cause hyperglycaemia, while some -blocker drugs can mask 
hypoglycaemia, which in turn, affects the degree of glycation and affects the 
results. Therefore, any patients undergoing treatment with such medication 
were excluded from the study (Ginsberg, 2009; Unnikrishnan et al., 2012). 
 2.1.1.8 Calculations of Fructosamine-predicted HbA1c (FHbA1c) and the G-gap 
Nayak et al., 2013 stated that the predicted FHbA1c was calculated from 
simultaneously measuring fructosamine that was standardized to the distribution of 
HbA1c. This is illustrated by the equation below: 
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𝐹𝐻𝑏𝐴1𝑐 =  (
𝑓𝑟𝑢𝑐𝑡𝑜𝑠𝑎𝑚𝑖𝑛𝑒 − 𝑚𝑒𝑎𝑛 𝑓𝑟𝑢𝑐𝑡𝑜𝑠𝑎𝑚𝑖𝑛𝑒
𝑆𝐷 𝑓𝑟𝑢𝑐𝑡𝑜𝑠𝑎𝑚𝑖𝑛𝑒
×  𝑆𝐷𝐻𝑏𝐴1𝑐)  + 𝑚𝑒𝑎𝑛 𝐻𝑏𝐴1𝑐 
According to (Nayak et al., 2013) the glycation gap can be calculated as follows: 
𝐺𝑔𝑎𝑝 =  𝐻𝑏𝐴1𝑐 −  𝐹𝐻𝑏𝐴1𝑐  
which simply means the true HbA1c value minus the predicted HbA1c. According to 
this equation, a negative G-gap means that the true HbA1c value is lower than the 
value for FHbA1c, while a positive G-gap means that the value of the true HbA1c 
reading is higher than that for FHbA1c. For those results with a second paired 
HbA1c-fructosamine estimation, a consistent G-gap was identified by calculating the 
product of two G-gaps (if consistent) so that the G-gap product would be positive 
(positive x positive or negative x negative). However, any discordance in the G-gap 
direction among the pairs, with increasing time, would be considered negative; the 
negative G-gap would be negative x positive. 
In order to categorise the G-gap values, the G-gap (unit = HbA1c %) was 
categorized as negative when less than or equal to −1, neutral if greater than −1 and 
less than +1, or positive when greater than or equal to +1. 
The use of G-gap in this study is based on Nayak et al., (2003) to measure 
the deviation of HbA1c from its expected value: a negative G-Gap means lower level 
of glycation than expected whereas a positive G-gap relates to a higher level of 
glycation of proteins. An increase in the level of glycation is linked to hyperglycaemia 
in patients with diabetes and hyperglycaemia is assumed to be a strong predictive 
indicator for diabetes complications (Nayak et al., 2013).  
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2.1.2 Study 1:  Materials and Methods 
2.1.2.1 Part 1: Determination of FN3K Activity in Erythrocytes 
Based on previous studies, human erythrocytes were selected as a suitable model 
for detecting FN3K activity due to the fact that erythrocytes are easily obtained, 
incubated and are extremely permeable to glucose. Also, there are easy and robust 
methods exist for measuring glycated haemoglobin (Lacko et al., 1973). 
Furthermore, the presence of FN3K in human erythrocytes could be detected at high 
levels as reported by many previous studies (Delplanque et al., 2004; Miller et al., 
1980). The activity was measured by means of HPLC, following the protocol of 
Krause et al. (2006) with a few slight modifications to fit with our HPLC machine. The 
activity of FN3K was measured following the formation of a product, BzGpFruK (Nα-
hippuryl-Nε-(3-phosphofructosyl)-lysine) from the substrate, BzGFruK (Nα-hippuryl-
Nε-fructosyl-lysine). This assay is based on FN3K-dependent conversion of the 
synthetic UV-active fructosamine Nα-hippuryl-Nε-(1-deoxy-Dfructosyl) lysine 
(BzGFruK) to Nα-hippuryl-Nε-(phosphofructosyl) lysine (BzGpFruK). The assay was 
performed on lysates of erythrocytes collected from diabetic patients exhibiting 
strongly positive and negative G-Gaps (Krause et al., 2006). The chemicals and 
parts required for this assay were ordered according to Krause et al., (2006). 
Chemicals used for preparation of hypotonic lysis buffer which used for lysis of 
erythrocytes, were purchased from Sigma-Aldrich Company Ltd. Dorset, England 
(for more details about manufacturers of these chemicals see Appendix I): 
 HEPES Buffer (pH=7.5): (5 mM 4-(2-hydroxyethyl)-piperazine-1-
ethanesulfonic acid) 
 Dithiothreitol (DTT):  1 Mm (HPLC grade) 
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 Leupeptin hemisulfate salt (1 μg/ml) (HPLC grade) 
 Antipain (1 μg/ml) (HPLC grade) 
Consumables needed to prepare the HEPES-buffered erythrocyte lysate were 
sodium chloride powder.  
Chemicals required for final preparation of the product (Nα-hippuryl-Nε-(3-
phosphofructosyl)-lysine (BzGpFruK) were  
 25 μL of 22 mM ATP solution 
 170 mM of sodium chloride 
 10% (w/v) trichloracetic acid (diluted in H2O). 
 The substrate, Nα-hippuryl-Nε-fructosyl-lysine, was gift from Dr Anne Hellwig 
from the Institute of Food Chemistry (Technische Universität Dresden, 
Dresden, Germany).  
Two mobile phases were used to run the HPLC system:  mobile phase A, a 0.02M 
ammonium acetate buffer at pH 6.5 and mobile phase B, methanol (HPLC gradient, 
both purchased from Sigma-Aldrich Company Ltd. Dorset, England). A stainless-
steel column from Knauer Eurospher (Aberdeen, UK) was used to separate out the 
product, BzGpFruK.) 
A stainless-steel column from Knauer Eurospher (Aberdeen, UK) was used to 
separate out the product, BzGpFruK: a Vertex Plus Column (250 x 4.6 mm; 
Eurospher II 100-5 C18A) was filled RP18 material of 5 μm particle size, with 
integrated pre-column (5 mm × 4 mm) filled with the same material. 
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The injection volume of the prepared sample was 25μl rather than 50 μl as in Kraus 
et al., (2006) as a different injection loop was used (Rheodyne/Loops/8125 / 8126 
25μl SS Loop for 8125/8126 (EA) from Kinesis Company). A MBI Refrigerated 
Centrifuge (max 24 x 2.0 Ml, Montreal, Biotech, Inc), and a micro Centrifuge (PT. 
Nutrilab Pratama, Indonesia) were also used. 
2.1.2.1.1 Preparation of HEPES-buffered Erythrocyte Lysate 
This assay was set up with advice from Dr Anne Hellwig (Institute of Food 
Chemistry, Technische Universität Dresden, Dresden, Germany). The was as 
follows: 
1. Preparation of erythrocyte lysate: the lysis process was performed according to 
Krause et al., (2006) and Hellwig et al., (2014) with some minor modifications. From 
each sample, 0.2 ml of erythrocyte isolate was mixed with 0.8ml of hypotonic lysis 
buffer, consisting of (5 mM 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid 
(HEPES), pH=7.5, 1 mM dithiothreitol, 1 μg/ml leupeptin, and 1 μg/ml antipain). This 
was stored for 10 minutes in ice. The mixed solution was centrifuged for 10 minutes 
at 4C at a RCF 4500g; the membrane pellet was then discarded and the 
supernatant was then diluted 1:1 (v/v) with 200mM HEPES buffer (pH=7.5) 
containing 170 mM NaCl, resulting in HEPES-buffered erythrocyte lysate. 
2. To assay FN3K activity, a 500-μL aliquot of HEPES-buffered erythrocyte lysate 
was mixed with 25 μL of 22mM ATP solution + 25 μL BzGFruK (substrate) solution 
(11 mM in HEPES buffer). Then the resulting mixture (550 μL) was incubated in a 
water bath at 37°C for 120 minutes with its final concentration being 0.5 mM 
BzGFruK, 2 mM ATP, erythrocyte dilution 1:11. This reaction was stopped by adding 
550 μL 10% trichloroacetic acid to the same volume of the incubated sample. After 
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vigorous shaking, the samples were stored for one hour in the fridge and then 
centrifuged (3000 g, 20C, 10 min), and then the supernatant was membrane-filtered 
using a regenerated cellulose filter of 0.45 μm. After that 0.25 μl of the prepared 
sample was then injected immediately into the HPLC system. 
Separation of the assay products (including BzGpFruK) was performed by using 
PerkinElmer Series 200 HPLC Systems UV/Vis Detector. This incorporated a 
stainless-steel column (250X4.6 mm) filled with Knauer Eurospher 100, RP18 
material of 5-μm particle size, with integrated guard column 5×4 mm filled with the 
same material purchased from (Knauer UK). 
The mobile phase A used 0.02 M ammonium acetate buffer, pH=6.5 and the mobile 
phase was 100% methanol. The injected volume was 25 μL, column temperature 
was set to 20 °C and ultraviolet detection was performed at λ=230 nm.  
The elution gradient programme was set as in the two following tables (2.1.2.1.1a 
and 2.1.2.1.1b) for both the product and the substrate (as standard), following 
recommendations from Dr Ann Hellwig (personal communication): 
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Time (minute)  Mobile phase B % Flow rate (ml/min) 
0 5 0.5 
0-15  5 0.5 
15-15.1  5 0.3 
15.1-37 11 0.3 
37-37.1 11 0.5 
37.1-40 80 0.5 
4--45 80 0.5 
45-48 5 0.5 
48-57 5 0.5 
 
 
 
 
 
Time (minute)  Mobile phase B (%) Flow rate (mL/min) 
0 14 0.5 
0-15 14 0.5 
15-15.1  14 0.3 
15.1-37 20 0.3 
37-37.1 20 0.5 
37.1-40 80 0.5 
40-45 80 0.5 
45-48 14 0.5 
48-57 14 0.5 
 
 
 
Table 2.1.2.1.1 b: Gradient Program for BzGFruK (substrate and calibrant) 
according to Krause et al., (2006), with 250 mm x 4.6 mm column: with same 
eluents, peak of BzGFruK at 14.5 minute.  
Table 2.1.2.1.1a:  shows gradient Programme for BzG-phospho-FruK 
(Product) according to Krause et al., (2006). 
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2.1.2.1.2 Determination of Haemoglobin 
According to Krause et al., (2006), the activity of FN3K enzyme is usually expressed 
as (mU/g) of haemoglobin, in which each 1 unit (U) represents the amount of FN3K 
enzyme that catalysed the formation of 1 μmol BzGpFruK/min. To know the amount 
of haemoglobin into each sample, we measured the amount of haemoglobin using 
the procedure described by Oshiru et al., (1980) with slight modifications as 
recommended by Dr James Vickers (Diabetes research group, University of 
Wolverhampton). The equipment and reagents used were:  
 Spectrophotometer (Model: SB038, Cadex, Quebec, Canada) available at 
School of Biomedical science, University of Wolverhampton  
 SLS buffer (700 mg sodium dodecyl sulphate, 1 ml Triton X-100 in 1 litre 
0.033 M phosphate buffer) 
 Haemoglobin standard (a gift from Dr James Vickers) 
 Sample: Blood or erythrocyte isolate 
 
The procedure can be summarized as follows. Two tubes were labelled for each of 
the following standard concentrations of haemoglobin, and two tubes for each 
unknown (patient) sample. The standards were prepared by using a stock solution of 
200 mgml-1 haemoglobin: 
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Tube 
number 
Concentration of 
Hb (mgml-1) 
Volume Hb 
stock (ml) 
Volume diluent (SLS 
buffer, ml) 
 1 200 mgml-1 4 ml 0 ml 
 2 150 mgml-1 3 ml 1 ml 
 3 100 mgml-1 2 ml 2 ml 
 4 50 mgml-1 1 ml 3 ml 
 5 0 mgml-1 0 ml 4 ml 
 
Each patient sample was prepared by adding 20 µl blood (erythrocyte isolate) to 4 ml 
diluent (SLS buffer). The tube was stopped and inverted gently several times to mix 
and left for 5 mins. The absorbance was read at 540 nm against a reagent blank in 
the spectrophotometer.  
A standard curve for haemoglobin measurements was plotted from the mean 
of duplicate measurements. The absorbance of the patient sample was measured (in 
duplicate) and the haemoglobin concentration was read from the curve (figure 
3.1.1b). 
2.1.2.2 Study 1, part 2: Measurement of FN3K levels in Human Erythrocytes 
In this part of the study, FN3K enzyme protein levels were measured in human 
erythrocytes; complementary to part 1 of this study. The FN3K assay was performed 
by using FN3K sandwich ELISA Kit (SEJ094Hu) manufactured by Cloud-Clone 
Corp/USA, purchased from (Hölzel Diagnostika/50672 Cologne-Germany). The 
procedure can be summarised as follows. 
This ELISA assay was a sandwich ELISA; a series of five ELISAs were run 
according to the protocol supplied.  All reagents, wash buffer, reagent diluents were 
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supplied and the microtiter plate provided in this kit had been pre-coated with an 
antibody specific for the FN3K enzyme.  
The three reagents supplied in the kit, detection Reagent A (Detection 
Reagent A: biotin-conjugated antibody), detection antibody B (Avidin conjugated to 
Horseradish Peroxidase), and the standard (recombinant human FN3K), were all 
reconstituted and stored according to the instructions in the manual and were used 
within 60 days (storage time limit as instructed).    
 Eight standard solutions of recombinant human FN3K were made via a serial 
dilution: 10 ng/ml, 5ng/ml, 2.5 ng/ml. 1.25 ng/ml, 0.625 ng/ml, 0.312 ng/ml, 0.156 
ng/ml and 0ng/ml, whereas samples were diluted 1:5 with the sample diluent 
provided. The standards and samples were prepared 15 minutes before running the 
experiment. Standard and samples were added into the appropriate wells and the 
plate was covered for two hours and incubated at 37°C. Then the diluted reagent A 
was added and the plate was incubated for one hour at 37°C. The plate was then 
washed, using a multi-channel pipette to aspirate each well three times with 350 µl of 
wash buffer (WB) that was supplied with the kit. 100μL of Detection B working 
solution was added into each well and the plate was incubated at 37°C for 30 min. 
After a second wash 90μL of Substrate Solution was added to each well and the 
plate was covered and incubated for 20 minutes at 37°C. During this incubation, TMB 
is oxidised to a dimine and the H2O2 reduced to water, catalysed by Detection B, the 
substrate TMB dimine gives a blue colour which is a measure of the amount of FN3K 
antibody. The reaction was then stopped by adding the stop solution which 
immediately turned the mixture yellow.   
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Using a Thermo Scientific Multiscan Ascent micro-plate reader (Thermo-
Fisher Scientific Inc, Illinois, USA) along with Thermo ScientificTM AscentTM software 
(Thermo-Fisher Scientific Inc, Illinois, USA), the optical density of the yellow solution 
in each well of the microplate was measured at a wavelength of 450nm.  
The sample concentration for FN3K in erythrocytes was calculated by using 
the standards with known concentration to draw a curve of best fit using the 4 
Parameter Logistic nonlinear regression model on Microsoft Office Excel 2013. The 
standard curve was used to interpolate the concentrations of the samples, using the 
equation of the line of best fit (figure 3.1.2a). 
2.1.2.3 Study 1, part 3: Measuring of FN3K levels in Human Plasma 
As described in section 1.2.1, plasma fructosamine is a measure of the 
glycated fraction of all plasma proteins. The predominant glycated protein of 
extracellular fructosamines in the circulation is glycated albumin, while HbA1c is the 
predominant intracellular fructosamine product of glycation (Cohen et al., 2003). 
According to Szwegold (2007) deglycation of glycated proteins can arise with 
specific enzymes occurring naturally to phosphorylate fructosamine residues 
(fructosamine-6-phosphates), which in turn are removed from the circulation by 
destabilizing them. A key enzyme is FN3K with its proposed deglycating role. The 
FN3K enzyme was reported by several studies to be existed intracellularly in human 
erythrocytes with its deglycating action on HbA1c (Delpierre, et al., 2002 and 
Delpierre & Van Schaftingen, 2003). Therefore, this part of the study aimed to 
investigate whether the FN3K enzyme is present in plasma and if it can deglycate 
glycated proteins in plasma such as glycated albumin. 
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The FN3K assay was performed using FN3K sandwich ELISA Kit (CSB-
EL008760HU) (Hölzel Diagnostika-50672 – Cologne, Germany). The procedure can 
be summarised as follows: 
This ELISA assay was a sandwich ELISA, a series of seven ELISAs were run, 
all reagents, wash buffer, reagent diluents were supplied, and the microtiter plate 
provided in this kit has been pre-coated with an antibody specific for the FN3K 
enzyme. The three reagents supplied in the kit (biotin antibody, HRP-avidin, 
standard - recombinant human FN3K) were all reconstituted and stored according to 
the instructions in the manual and were used within 60 days (storage time limit as 
instructed).   
Eight standard solutions of recombinant human FN3K were made via a serial 
dilution; 20 ng/ml, 10ng/ml, 5ng/ml. 2.5 ng/ml, 1.25 ng/ml, 0.625 ng/ml, 0.312 ng/ml 
and 0ng/ml whereas samples were diluted 1:4 with the sample diluent provided 
inside the kit box. The standards and samples were prepared 15 minutes before 
running the experiment. Standards and samples were added to the appropriate wells 
and the plate was covered for two hours at 37°C. Then the liquid was removed from 
each well, the Biotin-antibody added and the plate was incubated for one hour at 
37°C. The plate was then washed by using a multi-channel pipette to aspirate each 
well three times with 200 µl of the wash buffer (WB) supplied in the kit.  100μL of 
HRP-avidin (1x) working solution was added to each well and the plate was 
incubated at 37°C for 60 min. After additional washing, 90μL Substrate Solution was 
added to each well and the plate was covered and incubated for 20 minutes at 37°C 
in an incubator. During this incubation, the substrate is oxidised to a dimine and the 
H2O2 reduced to water, catalysed by detection B, the substrate TMB dimine gives the 
solution its blue colour which is quantitative to the amount of FN3K antibody. Once 
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the liquid turned into blue colour by the addition of substrate the reaction was 
stopped by adding the stop solution (50 µl) the blue colour was turned into yellow 
colour at once.   
By using a Thermo Scientific Multiscan Ascent micro-plate reader (Thermo-
Fisher Scientific Inc, Illinois, USA) along with Thermo ScientificTM AscentTM 
software (Thermo-Fisher Scientific Inc, Illinois, USA), the optical density of the yellow 
solution in each well of the microplate was measured at a wavelength of 450nm first 
then at 540nm. The reading at 540 nm was subtracted from the reading at 450nm to 
correct for optical imperfections in the plate. 
The sample concentration was calculated by using the standards with known 
concentration to draw a curve of best fit using the 4 Parameter Logistic nonlinear 
regression model on Microsoft Office Excel 2013. The standard curve was used to 
obtain the concentrations of the samples were calculated using the equation of the 
line of best fit (figure 3.1.4a). 
2.1.2.4 Study 1, part 4: Measuring of AGEs in Human Plasma 
Several methods may be adopted for measuring levels of AGEs. These are: 
1. ELISAs:  these can be run either by using monoclonal antibodies or polyclonal 
antibodies (Vlassara et al., 2002).  
2. Fluorescence spectroscopy dependent on the fluorescence characteristics of 
AGEs (Meerwaldt et al., 2004). 
3. HPLC or the most reliable forms of mass spectrometry (Mendez et al., 2010). 
We chose to measure plasma levels of AGEs by ELISA since it is simple and fast. 
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The assay was performed by using OxiSelect™ Advanced Glycation End Product 
(AGE) Competitive ELISA Kit (STA-817) which was purchased from Cambridge 
Bioscience Ltd. This assay was carried out according to the contained protocol 
supplied with the kit. This ELISA assay was a sandwich ELISA. 
A series of eight ELISAs was run. The six reagents supplied in the kit; AGE-BSA 
standard, AGE-conjugate, 100X Conjugate Diluent, anti-AGE antibody 
(1000X) and the assay diluent were all reconstituted and stored and were 
used within 60 days (storage time limit as instructed).  Ten standard solutions 
of recombinant human FN3K were made via a serial dilution; (100 µg/ml, 50 
µg/ml, 25 µg/ml. 12.5 µg/ml, 6.25 µg/ml, 3.13 µg/ml, 1.56 µg/ml, 0.78 µg/ml, 
0.39 µg/ml and 0 µg/ml) and samples were diluted 1:5 with the assay 
diluent provided in the kit. The plate was coated a day before running 
the assay with a 1:1 mixture of AGE Conjugate and 1X Conjugate 
Diluent by adding 100 µl of this mixture to each assigned well of 
the plate: after this, the mixture is refered to as the AGE conjugate.  
The next day, the AGE-conjugate was removed and each well was 
washed with a PBS 1X Solution. Then 200 μL of Assay Diluent was added to each 
well to block the wells for 1 hr in the fridge. The assay diluent was then removed 
without washing. Standards and samples were prepared 15 minutes before running 
the experiment. Then they were added into the appropriate wells and the plate was 
covered and incubated on an orbital shaker for 10 minutes at 37°C. 50 μl of the 
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diluted anti-AGE antibody was added to each well and the plate was incubated for a 
second time for one hour. 
The plate was then washed three times with wash buffer by adding 200 µL of the 
reconstituted wash buffer. 100 µL of secondary antibody-HRP conjugate was added 
to each well and the plate was incubated for one hour on an orbital shaker. After 
repeating the washing step again, 100 µl substrate was added to each well and the 
plate was incubated for 20 minutes on an orbital shaker at room temperature. 50 µl 
of stop solution was then added to each well, turning the solution yellow and the 
optical density was measured by using the same plate reader as in previous 
experiments, at a wavelength of 450nm. The sample concentration was calculated 
by using the standards with known concentration to draw a curve of best fit using the 
4 Parameter Logistic nonlinear regression model on Microsoft Office Excel 2013. 
The standard curve was then used to obtain the concentrations of the samples were 
calculated using the equation of the line of best fit (figure 3.1.5a). 
2.1.2.5 Study 1, part 5: Measuring of Markers of Endothelial Dysfunction 
According to Nadar et al. (2004) and Muniyappa and Sowers (2013),  indirect 
assessment of endothelial dysfunction is more reliable as it requires less patient 
contact, less complicated procedures and is relatively cheaper than direct 
assessment. We therefore chose to use the indirect approach to assess markers of 
endothelial dysfunction. 
The thrombomodulin and E-selectin assays were performed by using sandwich 
ELISA kits purchased from R&D Systems, UK. These kits are Human 
Thrombomodulin/BDCA-3 DuoSet ELISA (catalogue number DY3947) and Human 
E-Selectin/CD62E DuoSet ELISA (Catalogue number DY724). 
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2.1.2.5.1 Thrombomodulin Assay 
A series of seven ELISAs was carried out. The ELISA 96-well plate was incubated 
with 100µl of capture Ab for thrombomodulin at room temperature (RT) overnight. 
The plate was then washed by using a multi-channel pipette to aspirate each well 
three times with 400µl of wash buffer, followed by the addition of 300µl of reagent 
diluent (RD), comprised of 1% Bovine Serum Albumin (BSA) in PBS produced by 
dissolving 1g BSA (Sigma-Aldrich Co) in PBS. The plate was then incubated for 1.5 
hours in an incubator. The samples were diluted 1:7 with the reagent diluent (RD) 
whilst seven standard solutions of recombinant human thrombomodulin were made 
via a serial dilution; 6000pg/ml, 3000pg/ml, 1500pg/ml, 750pg/ml, 375pg/ml, 
187.5pg/ml and 0pg/ml in RD. The plate was then washed and 100µl of the 
standards and samples loaded into the appropriate wells in duplicate. After a further 
two hour incubation, the microplate was washed again before the detection Ab was 
diluted to its working concentration and added to each well and the plate incubated 
for another two hours. The washing process was then repeated. The Streptavidin 
conjugated HRP was diluted 1:100 in RD and 100µl added to each well and 
incubated for 20 minutes in an incubator. The washing process was repeated and a 
mixture of H2O2 and TMB was added to the microplate. The plate was incubated for 
20 minutes out of direct light. After the liquid in each well turned blue 50µl of a 
blocking solution of 2N HCL was added to each well to turn the colour of the liquid in 
each well yellow. Finally, the microplate was transferred to a microplate reader and 
the reading was measured at 450nm as described previously. 
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2.1.2.5.2 E-selectin Assay 
 
A series of seven ELISAs was carried out as per the protocol supplied with the kit. 
The samples were diluted 1:7 with RD whilst seven standard solutions of 
recombinant human E-selectin were made via a serial dilution; 6000pg/ml, 
3000pg/ml, 1500pg/ml, 750pg/ml, 375pg/ml, 187.5pg/ml and 0pg/ml in RD.  The E-
Selectin ELISA assay was performed as for the thrombomodulin assay in 2.1.2.5.1, 
with the kit-supplied standard solutions of E-selectin and E-selectin-detection 
antibody instead of thrombomodulin standard solutions and thrombomodulin-
detection antibody.   The microplate was transferred to a microplate reader and the 
optical density for E-selectin was measured at 450nm. 
2.1.2.6 Study 1, part 6: Measuring of Markers of Thrombosis (PAI-1 assay) 
This assay used a sandwich ELISA kit that was purchased from R&D Systems, UK: 
Human Serpin E1/PAI-1 DuoSet ELISA, DY1786. 
A series of seven ELISAs was carried out to cover the experiment samples. 
The ELISA 96-well plate was incubated with 100µl of capture Ab at room 
temperature (RT) overnight. The plate was then washed by using a multi-channel 
pipette to aspirate each well three times with 400µl of wash buffer, followed by the 
addition of 300µl of reagent diluent (RD) (1% Bovine Serum Albumin (BSA) in PBS 
produced by dissolving 1g BSA (Sigma-Aldrich Co) in PBS). The plate was 
incubated for 1.5 hours. The samples were diluted 1:8 with RD whilst seven standard 
solutions of recombinant human PAI-1 were made via a serial dilution; 20 ng/ml, 
10ng/ml, 5ng/ml, 2.5ng/ml, 1.25 ng/ml, 0.625ng/ml and 0.3125ng/ml (RD). The plate 
was then washed and 100µl of the standards and samples loaded into the 
appropriate wells in duplicate. After two hours of incubation, the microplate was 
washed again before the detection Ab was diluted to its working concentration with 
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normal goat serum and added to each well. The plate was incubated for a further two 
hours. The washing process was repeated and the Streptavidin conjugated HRP 
diluted 1:100 in RD and100µl added to each well. After 20 minutes of incubation, the 
washing process was repeated and a mixture of H2O2 and TMB was added to the 
microplate. The plate was incubated for 20 minutes out of direct light; after the colour 
of the liquid in each well turned to blue 50µl of a blocking solution of 2N HCL was 
added to each well to turn the colour of the liquid of each well yellow. Finally, the 
microplate was transferred to a microplate reader and the optical density measured 
at 450nm.  
 2.1.3 Study 1 Materials and Equipment  
Materials and equipment used in each part of this study are: 
1. Study 1, part1: Measurment of FN3K activity in human erythrocytes. As 
mentioned in section 2.1.2.1, the activity was measured by means of an 
HPLC system. Assays of this nature were conducted in the University of 
Wolverhampton Faculty of Science and Engineering, using a PerkinElmer 
Series 200 HPLC Systems UV/Vis Detector, MBI Refrigerated Centrifuge 
(max 24 x 2.0 mL), MiniMouse II Microcentrifuge (Cat #: C0801-NR), Red lid 
and FISHER SCIENTIFIC 220 DIGITAL WATER BATH.  
2. Study 2, part 2: Measurment of FN3K levels in erythrocyte lysate. PBS 
solution (Phosphate buffered saline) 10x concentrated (P5493-1L) was used 
for all immunoassays in this study when required. It was purchased separately 
from (Sigma-Aldrich Company Ltd. Dorset, England). The optical density of 
the yellow solution inside each well of the assay plate was read by using a 
Thermo Scientific Multiscan Ascent micro-plate reader (Thermo-Fisher 
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Scientific Inc, Illinois, USA) along with Thermo ScientificTM AscentTM 
software (Thermo-Fisher Scientific Inc, Illinois, USA), at a wavelength of 
450nm. This microplate-reader was used in all immunoassays in this study. 
3.  Study 1, part 3: Measurment FN3K enzyme levels in human plasma. The 
optical density was read at wavelength of 450nm and 540nm to enable 
correction of any background readings. The corrected readings, reading at 
450nm minus the reading at 540nm, were used to quantify the amount of 
FN3K in plasma samples.  
 
4.  Study 1, part 4: Measurment of AGEs  in human plasma. The optical density 
was read at a wavelength of 450nm using the microplate reader described 
previously. This study requires an orbital shaker: the model used was a PST-
60HL-4, Plate Shaker-Thermostat manufactured by Biosan Medical Biological 
research technologies, Riga, Latvia. 
5. Study 1, part 5 and part 6: Measurments of markers of endothelial dysfunction 
and thrombosis. The following items were prepared separately:  
 Wash buffer, which was prepared by dissolving 0.05% Tween® 20 in 
PBS produced by diluting a 10x concentrated solution in distilled water. 
The Tween sachet was purchased from Salimetrics, Pennsylvania, 
USA. 
 The reagent diluent (RD) was prepared by dissolving 1% Bovine 
Serum Albumin (BSA) in PBS. The BSA which was purchased (Sigma-
Aldrich Company Ltd. Dorset, England). 
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 The substrate solution was purchased from R&D Systems separately 
from the kits, catalogue number DY999 (as recommended by the kit 
manufacturer). 
 The Stop solution was 1M H2SO4, prepared in our lab. 
 Plate Sealers: ELISA Plate Sealers (Catalog # DY992) purchased from 
R&D Systems. 
 Finally, the microplates were purchased from R&D systems (as 
recommended in the kit), R&D Systems (Catalogue # DY990). 
 
All of microplates in these ELISA assays in study (1) were washed with wash buffer 
using a multi-channel pipette (purchased from Eppendorf UK Limited Eppendorf 
House-Stevenage). 
2.1.4 Statistical Analysis 
Statistical analyses of data were conducted using the statistical software, Graphpad 
Prism 6 (Graphpad software Inc., 2014; California, USA) to compare and analyse the 
difference between sample specimens with positive versus negative G-gaps. 
According to an initial analysis performed, the data were not normally distributed, 
and so the appropriate test for the collected data was determined to be a non-
parametric, two-tailed, unpaired test also known as the Mann-Whitney U test. 
Results for this statistical test are considered significant when  ≤ 0. 05 with 95% 
confidence interval.  
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2.2 Study 2: Measuring of FN3K levels in AECOPD patients treated with 
metformin and placebo 
2.2.1 Study Design  
A randomised double blind trial involving 23 patients with AECOPD and diabetes 
admitted to St George's Hospital (London) and treated with either metformin or 
placebo (16 treated with metformin and seven treated with placebo, Clinical trial # 
NCT01247870). Serum samples were collected at several different stages; upon 
entry (baseline), at discharge (7days after entry) and afterwards for follow up (29 
days after discharge).  These samples were immediately stored at -80˚C. 
2.2.2 Ethical Approval  
Ethical approval was obtained before samples were collected from St George’s 
University Hospitals NHS Foundation Trust, London, UK.  
2.2.3 Inclusion Criteria and Exclusion Criteria 
The patients recruited were required to be: patients with diabetes and COPD, 
smokers and healthy individuals. They were generally aged 40 and above with a 
well-documented record of their medication history and treatment. 
 Patients excluded from this study were those who were characterised as:   
1. Individuals without diabetes and non-COPD patients; 
2. Females who were pregnant at the time of the study ; 
3. Those diagnosed with renal diseases or renal dysfunctions (e.g. as 
indicated by serum creatinine levels greater than, or equal to, a value of 1.5 
mg/dL for males, and greater than or equal to 1.4 mg/dL for females. 
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Individuals with abnormal creatinine clearances which may result from 
conditions such as, cardiovascular collapse (shock), acute myocardial 
infarction, and septicaemia, were also excluded from the study; 
4. Patients with a known hypersensitivity to metformin hydrochloride; 
5. Those with acute or chronic metabolic acidosis, including diabetic 
ketoacidosis, with or without coma. 
2.2.4 Selection of Patients and Data Collection 
The patients were recruited for a wider study into COPD exacerbations and Type 2 
diabetes (study cohort n=130) who were admitted to St George’s hospital, (London, 
UK) between 1998 and 2010 and assigned International Classification of Diseases 
codes (ICD-10) for both COPD (J41-J44) and Type 2 diabetes mellitus (E10, E11, 
E14). These patients were identified from clinical coding data with our study. From 
those 130 patients, 23 serum samples were collected for our study at each stage 
(Entry (baseline), discharge and follow up)). See Appendix II for patients’ map. 
Hitchings et al. (2014) stated that the extracted data were written and 
electronic case notes that related to the patients’ co-morbidities, severity of illness, 
relevant investigations, treatment and survival. The quantification of comorbidity 
burden was achieved by utilising the Charlson comorbidity index and the severity of 
each patient’s illness was gauged using the APACHE (Acute Physiology and Chronic 
Health Evaluation) II scores (Knaus et al., 1985; Charlson et al., 1985). 
Glycated haemoglobin (HbA1c) levels were used to assess glycaemic control. 
This measurement was made daily for the 90 days of the index admission. The vital 
status and dates for each recorded death were obtained from the hospital electronic 
record system as a part of the national mortality data. 
114 
 
The follow-up period was identified as the time frame during which the patient was 
alive to record their last electronic review in September 2013.   
Patients were categorised into one of two groups upon entry to the hospital, 
metformin or non-metformin treated patients, based on their recorded drug histories 
indicating the administration, or lack thereof, of this drug (Hitchings et al., 2014). 
When considering the number of patient deaths that occurred at the hospital, an 
inquiry was conducted to determine and analyse whether the prescription of 
metformin therapy during the last week leading to their decline was a contributing 
factor to their death. Death after discharge from the hospital resulted in group 
assignment that was based on whether metformin was prescribed according to 
records of the patient’s prescription letter, written at the time of their discharge.  
2.2.5 Consent Forms and Information Sheets 
According to Hitchings et al. (2014), informed consent was not sought, as the data 
were collected in parallel with an audit of prescribing practices. In addition, the 
National Information Governance confirmed that support under Section 251 of the 
NHS (National Health Service/UK) Act 2006 was not required (accessing the 
identified data without consent). However, the South West London Research Ethics 
Committee provided a favourable opinion for the study. 
2.2.6 Samples 
As stated by  Hitchings et al., (2014), all patients were informed of the dates for 
which blood samples would be collected and that venepuncture would be used. After 
the collection of blood samples, the blood was left to clot by leaving it undisturbed at 
room temperature for approximately 20 minutes. The clot was removed by 
centrifuging at 2000xg for 10 minutes in a refrigerated centrifuge. The resulting 
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supernatant was designated as a serum. The liquid serum was transferred into a 
clean polypropylene tube using a Pasteur pipette and the samples were maintained 
at 2-8°C during the handling. The serum was apportioned into aliquots and stored at 
-20°C for performing assays on them later at St George’s University hospital. For this 
study, the 32 samples of serum which were collected from patients at all three 
stages mentioned in section 2.2.1 were received from Prof Emma Baker and Dr 
Andrew Hitchings from St George’s University Hospital in collaboration with Prof 
Paul Kirkham of the University of Wolverhampton. These samples were subjected to 
ELISA assays for measuring expression of FN3K.  
2.2.7 Study (2) Materials and Equipment 
The FN3K assay was performed by using FN3K sandwich ELISA Kit (CSB-
EL008760HU) manufactured by Cusabio Corp, purchased from: Hölzel Diagnostika-
50672 Cologne/Germany. This assay was performed for serum samples obtained 
from St George’s Hospital following the manufacturer’s recommended guidelines as 
stated in the protocol that accompanied the kit.  
This was a sandwich ELISA. A series of five ELISAs was run and the microtiter plate 
provided in this kit had been pre-coated with an antibody specific to the FN3K 
enzyme. Eight standard solutions of recombinant human FN3K were made via a 
serial dilution; 20 ng/ml, 10ng/ml, 5ng/ml. 2.5 ng/ml, 1.25 ng/ml, 0.625 ng/ml, 0.312 
ng/ml and 0ng/ml whereas samples were diluted 1:5 with the sample diluent 
provided inside the kit box. The standards and samples were prepared 15 minutes 
before running the experiment. Standard and samples were added into the 
appropriate wells and the plate was covered for 2 hours at 37°C. Then the liquid was 
removed from each well and the Biotin-antibody was added and the plate was 
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incubated for 1 hour at 37°C. The plate was then washed using a multi-channel 
pipette to aspirate each well 3 times with 200 µl of wash buffer (WB) which supplied 
inside the kit. 100μL of HRP-avidin (1x) working solution was added into each well 
and the plate was incubated at 37°C for 60 min. Once washing was repeated, 90μL 
of Substrate Solution was added to each well and the plate was covered and 
incubated for 20 minutes at 37°C in an incubator. During this incubation, the 
substrate (TMB) is oxidised to a dimine and the H2O2 reduced to water. Catalysed by 
detection B, the substrate TMB dimine gives the solution its blue colour which is 
quantitative to the amount of FN3K antibody. Once the liquid turned blue by the 
addition of the substrate the reaction was stopped by adding 50 µl of the stop 
solution. The blue colour was turned yellow at once.   
The optical density of the yellow solution in each well of the microplate was 
measured by microplate reader at a wavelength of 450nm first then at 540nm. The 
reading at 540 nm was subtracted from the reading at 450nm to correct for optical 
imperfections in the plate. 
The FN3K concentration of each sample was calculated by using the 
standards with known concentration to draw a curve of best fit using the 4 Parameter 
Logistic nonlinear regression model on Microsoft Office Excel 2013. The standard 
curve was used to obtain the concentrations of the samples were calculated using 
the equation of the line of best fit (graph 5.3.1). 
2.2.8 Statistical Analysis 
The statistical analyses of the data were performed using Graphpad Prism 6 
software (Graphpad software Inc., USA, 2014) to analyse differences in FN3K 
expression in serum samples for those patients who were treated with metformin at 
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each stage (entry, discharge and follow-up) and with patients who were treated with 
placebos at each of the three stages. According to the data collected for the initial 
analysis, FN3K expressions were not normally distributed. As a result, it was decided 
that the appropriate test for analysing the data collected would be the same Mann-
Whitney U test described in section 2.1.4. 
2.3 Study 3: Measurment of FN3K expression in human peripheral lung tissue 
2.3.1.1 Study design 
A double-blind study involving 36 human peripheral lung samples from healthy 
individuals, asymptomatic smokers and stable (GOLD 2) COPD patients were 
assessed for FN3K expression by means of immunohistochemistry on paraffin fixed 
lung tissue biopsies obtained following lung resection surgery.  
2.3.1.2 Ethical committee approval 
Subjects were recruited from the Section of Respiratory Medicine of the University 
Hospital of Ferrara, Italy, with approval by the local Ethics Committee.  
2.3.1.3 Inclusion and exclusion criteria  
Patients recruited were selected on the basis that they were patients living with 
diabetes and COPD, were smokers and cleared as healthy individuals, with their 
medication history and treatment available on record. Those patients that were 
excluded from this study were either: 
1.  Individuals negative for diabetes or non-COPD patients; 
2. Pregnant females; 
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None of the participants had received glucocorticoids, theophylline, antibiotics or 
antioxidants within the month preceding surgery or bronchodilators within the 
previous 48 hours. Patients had no history of asthma or other allergic diseases. 
Former smokers were classed as those who had not smoked for more than one 
year. Each patient had a medical history taken and received a physical examination, 
chest radiography, electrocardiogram, routine blood tests, and pulmonary function 
tests during the week prior to surgery. 
2.3.1.4 Patients Consent 
Tissue samples were acquired after written informed consent to thoracic surgery was 
obtained and pulmonary and pulmonary function tests were performed according to 
Marwick et al., (2009). All patients were informed about their right to withdraw from 
the study at any time without giving a reason.  
2.3.1.5 Samples    
COPD was defined according to international guidelines (post-bronchodilator 
FEV1/FVC ratio < 70%), and the severity of COPD was classed according to current 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria 
(www.goldcopd.org). All patients were stable at the time of the study and were free 
from acute exacerbations of symptoms and from upper respiratory tract infections in 
the 2 months preceding the study.  
Twenty subjects undergoing lung resection surgery for a solitary peripheral 
neoplasm were recruited. A further 20 subjects who were lifelong non-smokers with 
normal lung function 20 who were smokers with normal lung function and 16 
subjects who were smokers with COPD were also recruited. All former smokers had 
stopped smoking for more than one year. None of the subjects underwent 
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preoperative chemotherapy and/or radiotherapy and none had been treated with 
bronchodilators, theophylline, antibiotics, antioxidants and/or glucocorticoids in the 
month prior to surgery. Lung tissue processing was performed as previously 
described (Kirkham, 2011). Two to four randomly selected tissue blocks were taken 
from the sub pleural parenchyma of the lobe obtained at surgery, avoiding areas 
grossly invaded by tumour. Samples were fixed in 4% formaldehyde in phosphate-
buffered saline at pH 7.2 and, after dehydration, embedded in paraffin wax. Serial 
sections 4 µm thick were first cut and stained with haematoxylin-eosin (H&E) in order 
to visualize the morphology and to exclude the presence of microscopically evident 
tumour infiltration. Tissue specimens were then cut for immunohistochemical 
analysis and were placed on charged slides as previously reported (Kirkham et al., 
2011). 
After meeting inclusion criteria, the total number of patients who were recruited was 
36. (Table 2.3.1.5) shows the characteristics of recruited patients as follows: 
 
 
 
 
 
 
 
. 
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According to Table 2.3.1.5, the number of participants is equal among each group of 
non-smokers, smokers & COPDs, although there were more males than females (M: 
male subjects; F: female subjects).   
2.3.1.6 Materials and Equipment Used for Study 3  
In order to carry out this assay we collaborated with Prof Gaetano Caramori at 
University of Ferrara, Italy. This assay was carried out at in CEMICEF, University of 
Ferrara, Italy laboratories. The prepared 36 slides were assayed using 
Immunohistochemistry (IHC) techniques. 
Reagents and kits purchased: 
Subjects 
 
n Age Sex Smoking 
history 
Pack-
years 
Chronic 
bronchitis 
FEV1 
%pred 
FEV1/ 
FVC% 
Non-
smokers 
12 68.6 
(2.3) 
5M/7F ------- ------- 0 108.5 
(5.0) 
78.2 
(1.4) 
Smokers 12 69.8 
(2.6) 
9M/3F 11 Ex  
1 
Current  
30.8(8.4) 1  100.6(6.2) 77.1(1.4) 
COPD 12 71.3(1.5) 12M 9 Ex  
3 
Current  
41.2(4.4) 4 67.4(4.5) 54.6(2.7) 
Table 2.3.1.5: shows characteristics of subjects for the IHC studies for FN3K.  
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1. FN3K Antibody (N-term) Catalogue (T1993): Rabbit Polyclonal Antibody from 
Epitomics - an Abcam Company, 863 Mitten Road, Suite 103 Burlingame, California 
94010-1303.  
2. FN3K Antibody (N-term), source from rabbit, catalogue (AP7083a), was 
purchased from Abgent, Maidenhead, Berkshire, UK. 
3. Biotinylated Goat Anti-Rabbit IgG Antibody Catalogue Number: BA-1000, 
purchased from:  Vector Laboratories Ltd, Peterborough, United Kingdom. 
4. Vectastatin Elite ABC Kit (Rabbit IgG), Catalogue Number: PK-6101, purchased 
from:  Vector Laboratories Ltd, Peterborough, United Kingdom. 
5. Normal rabbit IgG: sc-2027, purchased from: Santa Cruz Biotechnology Inc, 
Bergheimer, Heidelberg, Germany. 
The immunohistochemistry microscope for parts of study was an OLYMPUS BX 60-
NRI-MCDP, at the University of Ferrara, Italy. 
 
The procedure for detection of FN3K expression in human lung slides, the 
appropriate dilution was obtained after several trials which are summarised in table 
2.3.1.6.  
The slides were rinsed with Xylene for 5 minutes then with 100% ethanol for 3 
minutes, then 95% ethanol for 3 minutes. After that they were transferred into a glass 
slide holder, and the rest of the rack was filled with empty slides to ensure even 
heating. Then the rack was placed in 600ml of 10mM sodium citrate (PH-6) in a 
glass beaker and the beaker then was put inside a microwave for 20 minutes 
(unmasking procedure). After cooling the slides for 20 minutes the slide were 
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washed four times with distilled water for 3 minutes and four times with 1x PBS for 3 
minutes. After washing the slides were blocked with peroxidase for 15 minutes and 
then the wash process was repeated according to the protocol. The slides were 
immersed in a dish containing blocking buffer (serum from rabbit of secondary 
antibody to be used, diluted 1:10 in PBS), followed by an incubation step at 37°C for 
20 minutes. The tissue section was covered with primary AB diluted in blocking 
buffer (1:300). The slides were then incubated for one hour at 37°C. The excess 
liquid was then blotted from slides and they were rinsed three times in PBS for 5 
minutes each wash. 
The tissue was covered with secondary antibody diluted in blocking buffer 
according to the protocol instructions, then they were incubated at 37°C for 30 
minutes.  The slides were then washed with PBS + Saponin for 5 minutes. After that 
the counterstaining step with Chromogen (DAB) was applied, and the slides were 
rinsed with tap water. After blotting the excess water from the slides, one drop of 
mounting medium was added to each slide and a coverslip applied. Then they were 
transferred to the microscope and the first measure was with 10x then 40x lenses. 
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2.3.1.7 Statistical Analysis 
The statistical analysis of our data was performed by using Graph-pad prism 6 
(Graphpad software Inc., California, USA, 2014) to analyse the difference in FN3K 
expression in serum among healthy individuals, smokers and COPD patients. The 
initial data analyses were not normally distributed.  Therefore, the Mann-Whitney U 
the 95% confidence interval. 
 
 
 
 
 
 
 
 
Antibody 
specificit
y 
Company 
Manufactur
er 
Catalogu
e code 
Source/ho
st 
Dilutio
n 
Unmaskin
g 
procedure 
Secondary 
antibody 
and 
amplificatio
n step 
Chromoge
n 
Positive 
control 
        
FN3K 
Abgent Co. AP7083a Rabbit 1:300 
(huma
n lung)  
Microwav
e, 10 mM 
citrate, pH 
6 
Vectastain 
Elite kit 
DAB Human 
bronchi
al rings 
(for 
human 
lung)  
Table 2.3.1.6 Summary of the immunohistochemical procedures used to detect 
FN3K in human lung. 
      DAB: 3, 3’-diaminobenzidine tetra hydrochloride. 
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Chapter 3 
 
Study 1  
 
FN3K (activity and protein levels) in relation to G- 
gap and AGEs in patients with diabetes    
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3.1 Results of Study 1, Parts 1, 2, 3 and 4 
3.1.1 Results for Study 1, Part 1: FN3K enzyme activity in relation to glycation 
gap (G-gap) 
According to Krause et al. (2006), the retention time for the product (BzG-phospho-
FruK) was around 18 minutes using the specified column (250 mm x 4.6 mm), and 
with our settings the retention time for the product was 18.5 minutes. The substrate 
(BzGFruK) retention time appeared to be 26 minutes. 
By calculating the area under the curve (AUC) of the eluted product at the 
specific retention time, the concentration of the product was obtained in relation to 
the known concentration of the standard (the substrate, BzGFruK). A calibration 
curve was drawn using Microsoft Excel (2013) for of BzGFruK, ranging from 6 to 100 
μM, and was used for quantification of formed BzGpFruK (Figure 3.1.1a).  
 
Figure 3.1.1a: Standard curve for BzGFruk 
 
After determining the concentration of BzGPFruk in each sample from the 
equation shown in Figure 3.1.1a, the activity of the enzyme FN3K was quantified 
y = 0.0002x + 7.3449 
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according to the method of Krause et al. (2006). FN3K activity was expressed as 
mU/g haemoglobin (Hb). 
 
The amount of Hb (g) in each sample was measured according to the method 
of Oshiru et al. (1980) (see Section 2.1.2.1.2). The Hb in each sample was quantified 
in relation to the known concentration of the standard Hb and the standard curve 
was drawn (Figure 3.1.1b). 
 
 
 
Figure 3.1.1b: Haemoglobin standard curve 
 
 
 
 
 
The concentration of the product, BzGpFruk, was measured in μM. Each unit 
was defined as the amount of FN3K enzyme needed to catalyse the formation of 1 
μmol BzGpFruK/min. First, the concentration of the product was changed from μM to 
mU as follows:1 μM (equal to 1μmol/L) was converted to μmol/μL (as our samples 
y = 0.0022x + 0.0028 
R² = 0.9998 
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sizes were in    μL) by dividing by 1,000,000. This was, in turn, converted to μmol by 
multiplying the value by the volume of the sample (200 μL). The result was the 
amount in μmol for each sample, thus the value was divided by 120 minutes (the 
incubation time) to obtain 1unit (μmol/min). Finally, to determine the activity, each 
unit was divided by 1000 to convert to mU which, in turn, was divided by the amount 
of Hb (in g), which was measured previously, to determine activity as mU/g.  
 
After measuring FN3K activity in each sample, statistical analysis was 
performed to examine whether the activity in each sample was correlated with the G-
gap value of each sample.  As mentioned in Chapter 2, this statistical analysis was 
performed using GraphPad Prism 6, which was used to produce Figures 3.1.1c and 
3.1.1d, and showed very significant differences in FN3K enzyme activity between 
subjects with high and low G-gap values (P < 0.001). Figure 3.1.1c shows mean ± 
standard deviation (SD) FN3K enzyme activity for the two G-gap groups. 
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Figure 3.1.1c: Scatter plot of mean ± SD FN3K activity by G-gap (negative and 
positive), and the median and quartiles of each group.  
P < 0.001 negative (n = 55) vs. positive (n = 43). 
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Overall, Figure 3.1.1c shows a significant difference between the two G-gap 
groups: the negative G-gap group had a mean of 4.078 mU/g compared with 0.7769 
mU/g for the positive G-gap group. The SD of the negative G-gap group was higher  
than that of the positive G-gap group (±7.393 mU/g vs. ±1.202 m U/g); therefore, 
when considering these findings together it was clear that this difference was highly 
significant, which was confirmed in the statistical analysis (P < 0.001).  
Table 3.1.1d shows the descriptive statistics for the measurement of FN3K 
enzyme activity in erythrocytes in patients with low and high G-gaps.  
Descriptive statistics of the separated cohort by G-gap, along with the P-value and 
Kolmogorov–Smirnov (KS) normality test, were calculated in the analysis of the 
distribution of the two data sets. The KS normality test showed that the data were not 
normally distributed when considering the negative and positive G-gap groups with 
P-values <0.05 for both. 
When taking into consideration the hypsographical plots of each data set, 
neither set followed the normal distribution curve and thus neither had a normal 
distribution. Therefore, a non-parametric test was carried out in the form of an 
unpaired, two-tailed Mann–Whitney U test which compares the median of the data 
as opposed to the mean which is compared in a Student’s t-test if the data are 
normally distributed.  A Mann–Whitney U test is shown in Table 3.1.1e which was 
produced by using GraphPad Prism 6 and gave a P-value of <0.0001 after 
adjustment for ties, with 95% confidence interval (CI). The result showed a highly 
significant difference in FN3K enzyme activity between subjects with high and low 
glycation, with those in the low G-gap group having higher mean and median FN3K 
enzyme activity than those with high G-gap values. Therefore, this finding confirms 
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our hypothesis that individuals with a low G-gap value have high FN3K activity and 
vice versa.  
 
 
 
 
 
 Negative GG Positive GG 
Number of values 55 43 
Minimum 0.2521 0.1975 
25% Percentile 0.9618 0.2727 
Median 1.368 0.33 
75% Percentile 4.907 0.607 
Maximum 49.82 6.11 
Mean 4.078 0.7769 
SD 7.393 1.202 
Standard Error of Mean (SEM) 0.9969 0.1833 
Lower 95% CI of mean 2.079 0.407 
Upper 95% CI of mean 6.077 1.147 
95% CI of median   
Actual confidence level 97.00% 96.85% 
Lower confidence limit 1.136 0.2993 
Upper confidence limit 1.916 0.4723 
Sum 224.3 33.41 
KS normality test   
KS distance 0.3075 0.3356 
P-value <0.0001 <0.0001 
Passed normality test (alpha = 0.05)? No No 
P-value summary **** **** 
 
 
 
 
 
 
 
 
 
 
Table 3.1.1d: Descriptive statistics of the cohort by G-gap, together with the P-value 
and KS normality test calculated in the analysis of the distribution of the two data 
sets. 
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Mann-Whitney U test (non-
parametric) 
  
Table analysed  Study 1 Part 1 
   
Column B  Positive G-gap 
vs  vs 
Column A  Negative G-gap 
   
Mann–Whitney U test   
P-value  <0.0001 
Exact or approximate P-value?  Exact 
P-value summary  **** 
Significantly different (P<0.05)?  Yes 
One- or two-tailed P-value?  Two-tailed 
Sum of ranks in columns A and B  3579, 1272 
Mann–Whitney U test  326 
   
Difference between medians   
Median of column A  1.368, n=55 
Median of column B  0.3300, n=43 
Table 3.1.1e: Mann–Whitney U test of normality in the form of a Student’s t-test. 
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3.1.2 Results of Study 1, Part 2: measurement of FN3K levels in erythrocytes in 
relation to G-gap 
As mentioned in Chapter 2, this measurement was performed by enzyme-linked 
immunosorbent assay (ELISA). A standard curve was drawn to obtain the 
concentration of FN3K. Figure 3.1.2a shows the standard curve for the first 
experiment (samples #2–44). The concentrations of the unknown samples were 
obtained from the standard curve. 
 
 
Figure 3.1.2a: The standard curve produced from the standard concentrations of 
human intracellular FN3K used in the first ELISA. The R2 value of the best fit curve is 
close to 1, which indicates a low level of deviation of the measurements plotted from 
the best fit curve to be the most accurate at predicting concentrations from the 
optical density.  
y = 6.9339x - 0.974 
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Optical density for FN3K standards 
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Statistical analysis was performed using GraphPad Prism 6 software which 
was also used to produce Figures 3.1.2b and 3.1.2c, both of which showed highly 
significant differences in FN3K protein levels between subjects with low and high G-
gap values (P = 0.0011).  
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Figure 3.1.2b: Differences in mean ± SD erythrocyte FN3K levels by G-gap 
(P<0.0011). 
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Overall, Figure 3.1.2b shows a significant difference between the two G-gap 
groups: mean FN3K levels of 223 ng/ml vs. 176 ng/ml for the negative and the 
positive G-gap groups, respectively. The corresponding SD values were ±77.5 ng/ml 
vs. ±60.15 ng/ml; therefore, it was clear that this difference was highly significant, 
which was confirmed in the statistical analysis (P < 0.0011). 
 
Table 3.1.2c shows the descriptive statistics for measurement of FN3K levels 
in erythrocytes in patients with low and high G-gap values. Descriptive statistics of 
the cohort by G-gap, along with the P-value, KS normality test and Wilcoxon signed 
rank test were calculated in the analysis of the distribution of the two data sets. The 
KS normality test showed a normal distribution of the data for the negative G-gap 
group (P < 0.0001) whereas the data for the positive G-gap group were not normally 
distributed (P < 0.0001). However, when considering both groups, the statistics 
showed that they were not normally distributed. A non-parametric Mann–Whitney U 
test (Table 3.1.2d) was carried out using GraphPad Prism 6, which showed, after 
adjustment for ties with 95% CI, a highly significant difference in FN3K enzyme 
levels between subjects with high and low glycation (P = 0.0011). In addition, those 
with low G-gaps had higher mean and median FN3K enzyme levels than those with 
high G-gaps (this significant difference was clarified in Figure 3.1.2b, which shows 
the mean ± SD). Therefore, this result confirmed our hypothesis that individuals with 
high G-gap values have low intracellular levels of FN3K and vice versa. 
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 Negative G-
gap 
 Positive G-gap 
n 55  43 
    
Minimum 70.86  82.87 
25% percentile 171.5  127.5 
Median 212.3  166.1 
75% percentile 288.0  201.7 
Maximum 412.7  319.9 
    
Mean 223.0  176.2 
SD 77.50   60.15 
SEM 10.45  9.173 
    
Lower 95% CI  202.0  157.7 
Upper 95% CI  243.9  194.8 
    
KS normality test    
KS distance 0.1135  0.1478 
P-value 0.0747  0.0192 
Passed normality test (alpha=0.05)? Yes  No 
P-value summary ns  * 
    
Wilcoxon signed rank test    
Theoretical median 0.0  0.0 
Actual median 212.3  166.1 
Discrepancy -212.3  -166.1 
Sum of signed ranks (W) 1540  946.0 
Sum of positive ranks 1540  946.0 
Sum of negative ranks 0.0  0.0 
P-value (two tailed) <0.0001  <0.0001 
Exact or estimate? Exact  Exact 
Significant (alpha=0.05)? Yes  Yes 
    
Sum 12265  7578 
Table 3.1.2c: Descriptive statistics of the cohort by G-gap for FN3K levels, 
together with the P-value and KS normality test calculated in the analysis 
of the distribution of the two datasets. 
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Man–Whitney U test (non-
parametric) 
 
  
  
Table analysed CFN3K-data 
  
Column B positive G-gap 
vs vs. 
Column A Negative G-gap 
  
Mann–Whitney U test  
P-value 0.0011 
Exact or approximate P-value? Exact 
P-value summary ** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P-value? Two-tailed 
Sum of ranks in column A, B 3173, 1678 
Mann–Whitney U 732 
  
Difference between medians  
Median of column A 212.3, n=55 
Median of column B 166.1, n=43 
Difference: Actual -46.27 
Difference: Hodges–Lehmann -46.27 
Man–Whitney U test (non-
parametric) 
 
  
  
Table analysed CFN3K-data 
  
Column B Positive G-gap 
vs. vs. 
Column A Negative G-gap 
  
Mann–Whitney U test  
P-value 0.0011 
Table 3.1.2 d: Mann–Whitney U test of normality in the form of a Student’s t-
test. 
137 
 
3.1.3 Statistical analysis of FN3K activity vs. concentration in erythrocytes 
This analysis was performed using SPSS software (IBM) to explore the relationship 
between FN3K activity and concentration by analysis of covariance (ANCOVA). 
 In order to normalise the otherwise skewed distribution, both measures were 
log10 transformed, and the ANCOVA test of log transformed FN3K activity showed a 
significant difference in FN3K activity between the negative and positive G-gap 
groups after controlling for log transformed concentration (r2 = 0.66, F = 90.68, P < 
0.001), with a significant slope parameter close to unity (B = 0.90, t = 9.219, P < 
0.001). Separate regression lines were fitted to the two groups which were 
significantly displaced from each other (F = 61.79, P < 0.001). 
The difference between the negative G-gap (mean = log10 248) and the positive G-
gap groups (mean = log10 -262) was log10 51 (SEM ±0.07, t = 7.861, P < 0.001) and 
(since this difference is log minus log) this represents the ratio of increased enzyme 
activity in the negative G-gap group compared with the positive G-gap group of 3.23 
(antilog) or 323% (see Figure 3.1.3.a). 
 
The magnitude of that ratio is consistent with the raw data outcomes of FN3K activity 
unadjusted (2.4/0.5 = 4.8) and adjusted (4.1/0.8 = 5.1) to Hb concentration and then 
further adjusted to FN3K concentration (0.013 /0.003 = 4.3) (Table 3.1.3b). 
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Figure 3.1.3a: Relationship of erythrocyte FN3K protein and enzyme activity in 
patients with diabetes with positive and negative G-gaps.  Patients with a negative 
G-gap (, n = 55) showed significantly higher FN3K enzyme activity in relation to 
FN3K protein compared with patients with a positive G-gap (, n = 43) (P < 0.001). 
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G-gap category Negative G-gap Positive G-gap P-value 
G-gap (% HbA1c) -1.4±0.7 +1.5±0.7 0.001 
Plasma FN3K 
concentration (ng/ml) 
3.3±3.5 2.3±2.5 ns 
Erythrocyte FN3K 
concentration (ng/ml) 
223±78 176±60 0.01 
Adjusted erythrocyte 
FN3K concentration 
(ng/g Hb) 
351±481 238±295 0.05 
FN3K activity 
(mU/ml) 
2.4±2.4 0.5±0.4 0.001 
Adjusted FN3K 
activity (mU/g Hb) 
4.1±7.4 0.8±1.2 0.001 
Ratio of FN3K 
activity/concentration 
0.013±0.017 0.003±0.002 0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3.1.3b: ANCOVA test for FN3K expression vs. concentration separated 
by the two G-gap groups. 
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3.1.4 Results of Study1, Part 3: measurement of plasma FN3K protein levels in 
relation to G-gap 
 As mentioned in Chapter 2, this measurement was performed by ELISA and a 
standard curve was drawn to determine the concentration of FN3K. The standard 
curve for the first experiment is shown in Figure 3.1.4a (samples #2–40). The 
concentrations of the unknown samples were obtained from the standard curve. 
 
 
 
Figure 3.1.4a: The standard curve produced from the standard concentrations of 
human plasma FN3K levels used in the first ELISA. The R2 value of the best fit curve 
is close to 1, which indicates a low degree of deviation of the measurements plotted 
from the best fit curve to be the most accurate at predicting concentrations from the 
optical density.  
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Statistical analysis was performed using GraphPad Prism 6 software. Figure 
3.1.4b clearly shows non-significant differences in mean ± SD for plasma FN3K 
levels between subjects with low and high G-gap values.  
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Figure 3.1.4b Differences in mean ± SD plasma FN3K levels by G-gap. 
 
Overall, Figure 3.1.4a shows a non-significant difference in mean plasma 
FN3K concentration between the two G-gap groups: 3.279 ng/ml vs. 2.317 ng/ml for 
the negative and positive G-gap groups, respectively. The corresponding SD values 
were ±3.505 ng/ml and ±2.478ng/ml. Therefore, when considering these findings 
together, it is clear that there is a non-significant difference in mean FN3K 
expression in plasma between the negative and positive G-gap groups, which was 
142 
 
confirmed in the statistical analysis (P = 0.0636) using the Student’s t-test (two-
tailed) to compare the controls and samples. 
The differences between the two groups are summarised in Table 3.1.4c, 
which shows the descriptive statistics for the measurement of FN3K levels in plasma 
in patients with low and high G-gap values. Descriptive statistics of the cohort by G-
gap are shown along with the P-value, KS normality test and Wilcoxon signed rank 
calculated in the analysis of the distribution of the two data sets. The KS normality 
test showed that the data were not normally distributed when considering both 
negative and positive G-gap groups with P-values <0.0001 for both. A non-
parametric Mann–Whitney U test (Table 3.1.4d) was carried out using GraphPad 
Prism 6, and showed a non-significant difference after adjustment for ties with 95% 
CI (P = 0.0636) in FN3K enzyme levels between subjects with high and low glycation 
with those in the low G-gap group. The mean and median FN3K concentration 
between the two groups were not significantly different (Figure 3.1.4b, Table 3.1.4d). 
Therefore, this result showed that the plasma levels of FN3K enzyme were not 
correlated with differences in G-gap values.   
 
 
 
 
 
 
 
 
 
143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Negative G-gap Positive G-gap 
n 81 67 
   
Minimum 0.0200 0.1645 
25% Percentile 0.8314 0.6500 
Median 2.270 1.440 
75% Percentile 4.088 3.051 
Maximum 17.35 14.26 
   
Mean 3.279 2.317 
SD 3.505 2.478 
SEM 0.3894 0.3028 
   
Lower 95% CI of mean 2.504 1.712 
Upper 95% CI of mean 4.054 2.921 
   
KS normality test   
KS distance 0.1860 0.2189 
P value < 0.0001 < 0.0001 
Passed normality test 
(alpha=0.05)? 
No No 
P value summary **** **** 
   
Wilcoxon Signed Rank 
Test 
  
Theoretical median 0.0 0.0 
Actual median 2.270 1.440 
Discrepancy -2.270 -1.440 
Sum of signed ranks 
(W) 
3321 2278 
Sum of positive ranks 3321 2278 
Sum of negative ranks 0.0 0.0 
P value (two tailed) < 0.0001 < 0.0001 
Exact or estimate? Exact Exact 
Significant 
(alpha=0.05)? 
Yes Yes 
Sum 265.6 155.2 
Table 3.1.4c: Descriptive statistics of the cohort by G-gap for plasma FN3K levels 
together with the P-value and KS normality test calculated in the analysis of the 
distribution of the two datasets. 
144 
 
 
 
Mann–Whitney U test (non-
parametric) 
 
  
  
  
Table analysed Data (FN3K plasma) 
  
Column B Positive G-gap 
vs. vs. 
Column A Negative G-gap 
  
Mann–Whitney U test  
P-value 0.0636 
Exact or approximate P-value? Exact 
P-value summary ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P-value? Two-tailed 
Sum of ranks in column A, B 6516, 4510 
Mann–Whitney U test 2232 
  
Difference between medians  
Median of column A 2.270, n = 81 
Median of column B 1.440, n = 67 
Difference: Actual -0.8300 
Difference: Hodges–Lehmann -0.5255 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1.4d:  Mann–Whitney U test of normality in the form of Student’s t-
test. 
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3.1.5 Results of study1 part 4: measuring of AGEs in plasma in relation to G-
gap 
As mentioned in Chapter 2, this measurement was performed by competitive ELISA; 
the standard curve was drawn to determine the concentration of AGEs. The standard 
curve for the first experiment is shown in figure 3.1.5a (samples #2–42). The 
concentrations of the unknown samples were obtained from the standard curve. 
 
 
Figure 3.1.5a: The standard curve produced from the standard concentrations of 
human AGE–bovine serum albumin (BSA) used in the first ELISA. The R2 value of 
the best fit curve is close to 1, which indicates a low degree of deviation of the 
measurements plotted from the best fit curve to be the most accurate at predicting 
concentrations from the optical density. 
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The statistical analysis was performed using GraphPad Prism 6 software and 
showed significant differences in mean ± SD plasma AGE–BSA levels by G-gap 
(Figure 3.1.5b). 
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Figure 3.1.5b Differences in mean ± SD plasma AGE levels by G-gap (P = 0.0109). 
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Figure 3.1.5b shows a significant difference in mean plasma AGE 
concentration between the two G-gap groups: 63.13 µg/ml vs. 78.93 µg/ml for the 
negative and positive G-gap groups, respectively. The corresponding SDs were 
±42.45 µg/ml and ±43.12 µg/ml.  This significance in the differences of mean AGE 
levels between the two G-gaps was confirmed in the statistical analysis (P = 0.0109) 
using a Student’s t-test (two-tailed) to compare controls and samples. 
This finding is summarised in Table 3.1.5c, which shows the descriptive 
statistics for measurement of AGE–BSA plasma levels in patients with low and high 
G-gap values. Descriptive statistics of the cohort by G-gap are shown along with the 
P-value, KS normality test and Wilcoxon signed rank calculated in the analysis of the 
distribution of the two data sets. The KS normality test showed that the data were not 
normally distributed when considering both negative and positive G-gap groups (P = 
0.0030 and P < 0.0001, respectively). A non-parametric Mann–Whitney U test (Table 
3.1.5d) was carried out using GraphPad Prism 6, which showed a significant 
difference (P = 0.0109), after adjustment for ties with 95% CI, in AGE–BSA levels 
between subjects with high and low glycation, with  those in low G-gap group having 
higher mean and median values than those in the high G-gap group. Therefore, 
plasma levels of AGE–BSA are correlated with G-gap values and proved our 
hypothesis that subjects with high G-gap values and low FN3K enzyme activity have 
high levels of AGE–BSA, whereas those with low G-gap values and high FN3K 
enzyme activity have low levels of AGE–BSA. 
 
 
 
 
148 
 
 
 
 
 
 
 
 Negative G-Gap Positive G-Gap 
n 81 67 
   
Minimum 0.8040 4.422 
25% Percentile 30.57 54.27 
Median 51.43 83.22 
75% Percentile 91.81 98.69 
Maximum 208.2 261.5 
   
Mean 63.13 78.93 
SD 42.45 43.12 
SEM 4.717 5.268 
   
Lower 95% CI of mean 53.75 68.42 
Upper 95% CI of mean 72.52 89.45 
   
KS normality test   
KS distance 0.1591 0.1376 
P-value <0.0001 0.0030 
Passed normality test 
(alpha = 0.05)? 
No No 
P-value summary **** ** 
   
Wilcoxon Signed Rank 
Test 
  
Theoretical median 0.0 0.0 
Actual median 51.43 83.22 
Discrepancy -51.43 -83.22 
Sum of signed ranks (W) 3321 2278 
Sum of positive ranks 3321 2278 
Sum of negative ranks 0.0 0.0 
P-value (two tailed) <0.0001 <0.0001 
Exact or estimate? Exact Exact 
Significant (alpha = 
0.05)? 
Yes Yes 
Sum 5114 5288 
Table 3.1.5c: Descriptive statistics of the cohort by G-gap for AGE–BSA 
plasma levels together with the P-value and KS normality test calculated in 
the analysis of the distribution of the two data sets. 
 
149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
Table analysed AGE–BSA 
Column B Positive G-gap 
vs. vs. 
Column A Negative G-gap 
  Mann–Whitney U test  
P-value 0.0109 
Exact or approximate P-value? Exact 
P-value summary * 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P-value? Two-tailed 
Sum of ranks in column A,B 5376, 5651 
Mann-Whitney U 2055 
Difference between medians  
Median of column A 51.43, n = 81 
Median of column B 83.22, n = 67 
Difference: Actual 31.79 
Difference: Hodges–Lehmann 20.47 
Table 3.1.5d:  Mann–Whitney U test of normality in the form of a 
Student’s t-test. 
150 
 
3.2. Results of Study1, Part 5: Markers of endothelial dysfunction in relation to 
G-gap  
3.2.1   Result of the thrombomodulin assay 
As described in Chapter 2, this assay was performed by ELISA and the standard 
curve was drawn to interpolate the concentration of thrombomodulin. Figure 3.2.1a 
shows the standard curve for the first experiment (samples # 2–40). The 
concentrations of the unknown samples were obtained from the standard curve. 
 
 
Figure 3.2.1a: The standard curve produced from the standard concentrations of 
human thombomodulin levels used in the first ELISA. Regarding the goodness of fit 
model, the R2 value of the best fit curve is close to 1, which indicates low deviation of 
the measurements plotted from the best fit line. This suggests the predicted 
concentrations from the optical density will be interpolated accurately.  
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Statistical analysis of this assay was performed by using Graphpad Prism 6 
software showed non-significant differences in mean+/- SD for plasma 
thrombomodulin levels separated by G-gap.  
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Figure 3.2.1b:  Mean plasma +/-SD concentrations of thrombomodulin and the SD 
above the mean for the negative and positive for G-gap groups (P = 0.2351). 
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Figure 3.2.1b indicates that there is a non-significant difference in mean plasma 
thrombomodulin concentration between the two G-gap groups. The negative G-gap 
had a mean of 6.108 ng/ml vs. 5.913ng /ml for the positive G-gap, although the SD 
of the negative G-gap group was higher (±2.583ng/ml) than the SD for the positive 
G-gap (±3.387ng/ml). This non-significant difference in mean plasma 
thrombomodulin levels between the two G-gap groups was confirmed with using a 
Mann-Whitney U test to compare samples (p= 0.2351). 
Table 3.2.1c shows descriptive statistics for measurement of plasma 
thrombomodulin levels in patients with low and high G-gap values, and a KS 
normality test calculated in the analysis of the distribution of the two data sets. The 
KS normality test showed that the data were not normally distributed for the positive 
G-gap group, whereas the negative G-gap group data were normally distributed (P = 
0.0008 and P > 0.1 for the positive and negative G-gap groups, respectively). 
Therefore, a non-parametric Mann–Whitney U test was performed using Graph-pad 
prism 6 (Table 3.2. 1d), and showed P = 0.2351 after adjustment for ties with 95% 
CI.  The results showed a non-significant difference in plasma thrombomodulin levels 
between subjects with high and low glycation in the low G-gap group. The mean and 
median between the two groups were not significantly different, and therefore shows 
that the plasma levels of thrombomodulin were not correlated with differences in G-
gaps values (see Figure 3.2.1a). 
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 Negative G-gap Positive G-gap 
Number of values 81 67 
Minimum 1.400 1.347 
25% Percentile 4.190 3.683 
Median 6.304 5.151 
75% Percentile 7.733 6.947 
Maximum 12.76 21.00 
Mean 6.108 5.913 
SD 2.583 3.387 
SEM 0.2870 0.4138 
Lower 95% CI of mean 5.537 5.087 
Upper 95% CI of mean 6.679 6.740 
KS normality test   
KS distance 0.06390 0.1491 
P-value >0.1000 0.0008 
Passed normality test (alpha = 0.05)? Yes No 
P-value summary ns *** 
Sum 494.8 396.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2.1c: Descriptive statistics for thrombomodulin in the cohort separated by 
G-gap, together with the P-value and KS normality test calculated based upon the 
analysis of the distribution of the two data sets. 
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Mann–Whitney U test   
Table analysed Data 1 
Column B Positive G-gap 
vs. vs. 
Column A Negative G-gap 
Mann–Whitney U test  
P-value 0.2351 
Exact or approximate P-value? Exact 
P-value summary ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P-value? Two-tailed 
Sum of ranks in column A, B 6344, 4683 
Mann–Whitney U test 2405 
Difference between medians  
Median of column A 6.304, n = 81 
Median of column B 5.151, n = 67 
Difference: Actual -1.153 
Difference: Hodges–Lehmann -0.5914 
Table 3.2.1d: Mann–Whitney U test for thrombomodulin assay.   
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3.2.2 Results of the E-selectin assay  
As described in Chapter 2, this assay was performed by ELISA, and a standard 
curve was drawn to get the concentration of E-selectin. Figure 3.2.2a shows the 
standard curve for the first experiment (samples #2–40). The concentrations of the 
unknown samples were obtained from the standard curve. 
 
 
 
Figure 3.2.2a: The standard curve produced from the standard concentrations of 
human E-selectin levels used in the first ELISA. Regarding the goodness of fit 
model, the R2 value of the best fit curve is close to 1, which indicates low deviation of 
the measurements plotted from the best fit line. This suggests the predicted 
concentrations from the optical density will be interpolated accurately. 
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The statistical analysis for this assay was performed as in previous 
experiments by using Graphpad prism 6 software. This showed non-significant 
differences in mean +/-SD concentrations of E-selectin separated by G-gap, as 
shown in Figure 3.2.2b 
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Figure 3.2.2b: Mean plasma E-selectin concentration of and the SD above the mean 
for the negative and positive G-gap groups. P = 0.7332. 
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Figure 3.2.2b shows minimal differences in the mean plasma E-selectin 
concentration; although the negative G-gap group had a slightly higher mean 
(30,527 pg/mL vs. 28,753 pg/mL). The SD of the group was also higher (±1686 
pg/mL vs. ±1561 pg/mL); however, this difference was not statistically significant (P > 
0.05). 
The summary statistics of the two data sets are shown in Table 3.2.2c alongside the 
result of the KS normality test which was carried out for each data set. A Shapiro–
Wilk normality test showed a normal distribution of the data when considering the 
positive G-gap group (P > 0.05), and the data of the negative G-gap group was not 
normally distributed (P < 0.05). Considering the histographical plots of each data set, 
neither set followed the normal distribution curve. Thus, a non-parametric test was 
carried out in the form of an unpaired, two tailed Mann–Whitney U test (Table 3.2.2d) 
to compare the median and mean between the two G-gap groups. A Mann–Whitney 
U test was carried out using Graphpad Prism 6 and showed P = 0.7332 after 
adjusting for ties with 95% CI, and thus significance was taken at P ≤ 0.05 for H1 to 
be true. With P > 0.05, H1 is unlikely to be true and any difference is due to chance, 
therefore, H0 cannot be rejected as it is likely true that the changes in G-gap value 
do not affect E-selectin concentration. Figure 3.2.3.2 shows the difference between 
the two groups. 
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 Negative G-gap Positive G-gap 
Number of values 81 67 
   
Minimum 4560 8510 
25% Percentile 18880 17010 
Median 27280 28400 
75% Percentile 40435 39088 
Maximum 73680 58480 
   
Mean 30527 28753 
SD 15176 12776 
SEM 1686 1561 
   
Lower 95% CI of mean 27172 25637 
Upper 95% CI of mean 33883 31870 
   
Sum 2472710 1926477 
   
KS normality test   
KS distance 0.09988 0.07474 
P-value 0.0444 0.1000 
Passed normality test (alpha=0.05)? No Yes 
P-value summary * ns 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2.2c: Descriptive statistics for E-selectin assay with Shapiro–Wilk normality 
test. 
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Table analysed E-selectin  
Column B Positive G-gap 
vs. vs. 
Column A Negative G-gap 
Mann–Whitney U test  
P-value 0.7332 
Exact or approximate P-value? Exact 
P-value summary Ns 
Significantly different? (P < 0.05) No 
One- or two-tailed P-value? Two-tailed 
Sum of ranks in columns A, B 6124, 4903 
Mann–Whitney U 2625 
Difference between medians  
Median of column A 27,280, n = 81 
Median of column B 28,400, n = 67 
Difference: Actual 1120 
Difference: Hodges-Lehmann -1063 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2.2d: shows Mann–Whitney U test for E-selectin assay. 
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3.2.3 Results of Study 1, Part 6: measurement of plasma plasminogen activator 
inhibitor-1 (PAI-1) in relation to G-gap 
As described in Chapter 2, this assay was performed by ELISA and a standard curve 
was drawn to determine the concentration of PAI-1. The standard curve for the first 
experiment is shown in Figure 3.2.3.3a (samples # 2–40). The concentrations of the 
unknown samples were interpolated from the standard curve. 
 
Figure 3.2.3a: The standard curve produced from the standard concentrations of 
plasma human PAI-1 levels used in the first ELISA. Regarding the goodness of fit 
model, the R2 value of the best fit curve is close to 1, which indicates low deviation of 
the measurements plotted from the best fit line. This suggests the predicted 
concentrations from the optical density will be interpolated accurately. 
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The statistical analysis showed highly significant differences in mean +/-SD 
for plasma PAI-1 concentrations separated by G-gap status (P < 0.0001) (Figure 
3.2.3b). 
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Figure 3.2.3b: Mean plasma concentrations of PAI-1 and the SD for the negative and 
positive G-gap groups. P < 0.0001. 
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Figure 3.2.3b shows a huge difference in the mean +/- SD for PAI-1between the two 
G-gap groups.  The positive G-gap had a higher mean than the negative G-gap 
group (93.06 ng/mL vs.17.27 ng/mL). The SD of the positive group was also higher 
(±55.72 pg/mL) vs. (±17.7 ng/mL for the negative G-gap group). This result indicated 
highly significant differences in plasma PAI-1 levels between these two groups which 
was confirmed in the statistical analysis (P < 0.0001). 
The descriptive statistics are summarised in Table 3.2.3c alongside the result 
of the Shapiro–Wilk normality test which was carried out on each data set. The KS 
normality test showed both groups were unlikely to be normally distributed, and the 
histographical plots of each data set showed neither set followed the normal 
distribution curve. Therefore, a non-parametric test was carried out in the form of an 
unpaired, two tailed Mann–Whitney U test to compare the mean and the median of 
each data set. A Mann–Whitney U test was carried out using Graphpad prism which 
gave P < 0.0001 (Table 3.2.3 d) after adjusting for ties with 95% CI. Thus, 
significance taken at P ≤ 0.05 for H1 to be true, with P < 0.05, H1 is likely to be true 
and any difference is due to chance, therefore, H0 can be rejected as it is likely true 
that the G-gap affects plasma PAI-1 concentrations. This means PA-1 levels are 
significantly correlated with difference in G-gap levels. Figure 3.2.3b shows the 
difference between the two groups. Elevated PAI-1 levels are associated with a 
positive G-gap status, suggesting that reduced deglycation may account for 
increased macrovascular disease and other diabetic complications in these patients. 
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 Positive G-gap Negative G-gap 
Number of values 67 81 
Minimum 20.04 0.4112 
25% Percentile 53.5 5.527 
Median 76.59 9.45 
75% Percentile 125.8 22.87 
Maximum 285.8 75.68 
Mean 93.06 17.27 
SD 55.72 17.7 
SEM 6.807 1.967 
Lower 95% CI of mean 79.47 13.35 
Upper 95% CI of mean 106.7 21.18 
95% CI of median   
Actual confidence level 95.02% 95.52% 
Lower confidence limit 67.21 6.586 
Upper confidence limit 87.2 16.2 
Sum 6235 1399 
KS normality test   
KS distance 0.178 0.1813 
P-value <0.0001 <0.0001 
Passed normality test (alpha = 0.05)? No No 
P-value summary **** **** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2.3c: Descriptive statistics for PAI-1 assay with KS normality test.  
 
164 
 
 
 
Table analysed PA-1 plasma 
Column B Positive G-gap 
vs. vs. 
Column A Negative G-gap 
Mann Whitney U test  
P-value <0.0001 
Exact or approximate P-value? Exact 
P-value summary **** 
Significantly different? (P < 0.05) Yes 
One- or two-tailed P-value? Two-tailed 
Sum of ranks in column A,B 3531, 7495 
Mann–Whitney U 210 
Difference between medians  
Median of column A 9.450, n = 81 
Median of column B 76.59, n = 67 
Difference: Actual 67.14 
Difference: Hodges–Lehmann 62.69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2.3d: Mann–Whitney U test for plasma PAI-1 assay. 
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3.3. Discussion 
3.3.1 Discussion of study 1 parts 1 and 2: intracellular FN3K activity and levels 
in relation to G-gap 
As mentioned in Chapter 1, non-enzymatic glycation is one of the major mechanisms 
by which hyperglycaemia contributes to cellular damage (Monnier et al., 2008). An 
enzymatic defence mechanism reducing glycation may act to suppress this cellular 
damage. It has been proposed that FN3K acts as a protein repair enzyme that is 
responsible for intracellular protein deglycation which in turn may decrease the risk 
of developing diabetes-related complications due to its ability to convert protein-
bound fructosamines into unstable 3-phospho derivatives (Delpierre et al., 2000; 
Delpierre et al., 2002).  In addition, the G-gap has been reported to be associated 
with a variation in risk of diabetic complications, and is a measure of deviation of 
measured HbA1c levels from the expected value in relation to the average degree of 
glycaemia.  A positive G-gap thus represents a higher level of glycation of proteins 
than expected whereas a negative G-gap relates to a lower than expected level 
(Nayak et al., 2013). Previous studies suggest that a positive G-gap correlates with a 
higher incidence of diabetes-related complications, whereas a negative G-gap in 
diabetic patients correlates with a lower incidence of such complications (Cohen, et 
al., 2003; Nayak, et al., 2013). Thus, in our study, the G-gap represents an important 
predictor of risk of diabetes-related complications. 
When comparing FN3K enzymatic activity and levels in erythrocytes of 
subjects with positive and negative G-gaps (figure 3.1.1c & figure 3.1.2b 
respectively), we observed very significant differences in the activity and protein 
expression of FN3K in the two groups (P<0.0001 for the mean FN3K activity and 
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P=0.0011 for FN3K expression for negative vs positive G-gaps). Therefore, whether 
the G-gap is negative or positive, it affects FN3K activity and expression.  These 
results support our hypothesis that patients with a positive G-gap appear to have a 
greater level of intracellular erythrocyte glycation (higher HbA1c levels in relation to 
the average degree of glycaemia) which may result from lower FN3K activity and 
expression compared to those with a negative G-gap. Thus, patients with a positive 
G-gap have a greater potential for more negative effects of glycation with higher risk 
of developing diabetes-related complications than those with a negative G-gap. 
Hence our results are consistent with our prediction, namely that higher activity and 
expression of FN3K is associated with less diabetic complications whereas lower 
activity of FN3K is associated with a higher incidence of diabetic complications. 
These findings also provide support for the concept that FN3K acts as a protein 
repair enzyme against damage caused by glycation. 
There have been many attempts over the years to find a good indicator that 
reflects glycaemic level and the presence of any complications related to diabetes; 
G-gap has been introduced as a good indicator that is associated with alteration of 
diabetic complications (Nayak et al., 2013; Cohen et al., 2008).  However, Sack et 
al., (2011) believed that in spite of the fact that the G-gap has been reported to be 
associated with various diabetic complications it is still not an ideal indicator because 
fructosamine is an indirect measure of glycation in plasma protein and does not 
predict glucose haemostasis if Hb is glycated.     
The activity of FN3K has been reported to be higher in human erythrocytes 
than in those of other species such as chicken and pig when the concentration of 
intracellular glucose in erythrocytes is low. Taking into consideration the fact that 
hyperglycaemia is associated with a higher incidence of diabetes-related 
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complications (Monnier et al., 2008) and since HbA1c is a standard indicator of 
hyperglycaemia, this means that higher intracellular glucose levels are associated 
with low FN3K activity and increased risk of diabetic complications (Delplanque et 
al., 2004). This is consistent with our findings. 
A study in FN3K gene knock-out mice showed an increase in glycation of proteins 
which provides support for the role of FN3K in the physiological deglycation process 
in erythrocytes (Veiga-da-Cunha et al., 2006).  The decrease in FN3K activity was 
shown to be associated with intracellular protein damage which in turn was 
associated with a higher risk of developing diabetes-related complications (Delpierre 
et al., 2002). Such association was also confirmed by Veiga-da-Cunha et al., (2006) 
in animal models by demonstrating that the concentrations of Hb-bound 
fructosamine and other intracellular proteins are higher in tissue and erythrocytes of 
FN3K-deficient mice than in those of healthy control mice. 
This is the first time that this clear distinction has been reported and offers strong 
support for the hypothesis that FN3K may play a role in protein deglycation in 
patients with diabetes. It is likely therefore that the average degree of glycaemia 
would be underestimated in patients with a negative G-gap (high FN3K activity), and 
it is also possible that these patients, who we have shown to have a lower incidence 
of diabetic complications (Nayak et al., 2013), would have lower levels of AGEs and 
of markers of diabetes-related complications. This was supported by the results of 
the assay of AGEs. 
One possible explanation for the variations in the activity of FN3K might be 
differences in SNPs in the FN3K gene such as rs1056534 between patients in the 
different G-gap groups. Several studies have reported genetic variants in FN3K. For 
instance, Delpierre et al., (2006) investigated a possible association between FN3K 
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enzymatic activity in erythrocytes and polymorphisms in the FN3K gene in a cohort 
of type1 diabetics and controls (n=58). They found that a decrease in FN3K activity 
in erythrocytes was associated with two SNPs in addition to gene variants {(CC of 
the c.900C/G (rs1056534) in exon 6 and GG of the c.–385A/G (rs3859206)}, 
although they did not find a direct correlation between FN3K SNPs and HbA1c 
levels. However, one of main limitations in this study was the small sample size. 
Later Mohas et al., (2010), investigated large cohorts of type 2 diabetic patients who 
were analysed for the presence of the polymorphism rs 1056534 of FN3K gene, 
reported an association between the C allele of rs 1056534 and low HbA1c levels. 
However, these authors did not identify an association between this polymorphism 
and diabetic complications. In contrast, more recently, Tanhäuserová et al., (2014) 
indicated that there is an association between polymorphism of the FN3K gene (rs 
1056534) and the development of nephropathy and cardiovascular morbidity.  
Therefore, our study provides novel insights into exploring the relationship between 
variations in FN3K activity as well as intracellular levels and discrepancies in G-gap 
values among individuals.  
3.3.2 Discussion of study 1 part 3: FN3K plasma levels in relation to G-gap 
values      
The results from the present assay showed a non-significant correlation between 
changes in G-gap values and variation in FN3K plasma levels (figure 3.1.4b, table 
3.1.4d); in other words, patients with a negative G-gap who were previously shown 
to have higher intracellular activity and concentration of FN3K than those with 
positive G-gaps were unlikely to have a significant difference in their mean FN3K 
plasma proteins levels (2.317ng/ml and 3.279ng/ml  for positive and negative G-gaps 
respectively, P=0.0636). We initially expected to have this result due to the fact that 
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G-gap reflects the intensity of glycation inside the erythrocyte rather outside it. 
Taking into consideration that the value of HbA1c is a principal measurement in the 
calculation of the G-gap due to the concept of G-gap is defined as: G-gap = 
intracellular HbA1c – the standardized fructosamine-derived HbA1c equivalent 
(FHbA1c).  Therefore, it can be concluded from this equation that when HbA1c level 
is high, the value of G-gap would be high (Nayak et al., 2013). Along with  what was 
proved in previous results of both part 1 and part 2 of this study, we can conclude 
that  high level of HbA1c (or high G-gap value)  is associated with  low values of both  
intracellular FN3K activity and protein level  rather than  plasma FN3K protein level 
which is unlikely to be associated with changes in HbA1c levels. Thus, whether the 
G-gap is negative or positive, it is unlikely to be associated with plasma FN3K levels 
due to the fact that the FN3K concentration itself has been reported by several 
groups to be mainly active inside rather than outside erythrocytes (Avemaria et al., 
2015; Delpeirre et al., 2002; Delplanque et al., 2004; Payne et al., 2008).  Thus, we 
expected that there would not be much variation in FN3K protein levels in plasma 
since the G-gap value is associated more with intracellular glycation than with 
plasma protein glycation. This would lead us to suppose that the main effect of FN3K 
is to deglycate intracellular proteins.   
The presence of FN3K in plasma might be understood as a response to 
glycation activity on plasma proteins such as albumins. However no previous studies 
have investigated the actions of FN3K in plasma. The reason for our measurement 
of FN3K in plasma in relation to G-gap was the significant correlation (found in study 
2 which was performed at earlier time) between serum FN3K concentration and 
treatment with metformin in patients with AECOPD under different settings.  
Therefore, we assumed that there would be a possible link between G-gap and 
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FN3K levels in our plasma samples from the cohorts of study 1 despite the fact that 
the degree of deglycation in plasma and serum is less than in erythrocytes (Delpierre 
et al., 2001). Therefore, in the present study, we attempted to investigate the 
presence of FN3K as a deglycating enzyme in the plasma and any correlation 
between both plasma and intracellular levels of FN3K and G-gap levels. Further 
studies are needed to investigate how FN3K in plasma is regulated and what factors 
affect its presence.  
3.3.3 Discussion of study 1 part 4: plasma AGEs levels in relation to G-gap 
values  
When analysing the results of the AGE-BSA assay in plasma samples with positive 
and negative G-gaps(figure 3.1.5b, table 3.1.5d), there was a significant difference in 
the mean plasma levels of AGE-BSA in correlation with G-gaps (78.9 ng/ml vs 63.13 
ng/ml for positive and negative G-gaps respectively, p=0.01). This means the 
difference in G-gap values correlate positively with plasma AGEs levels.When 
considering the strong correlation between erythrocyte FN3K activity and protein 
levels with G-gap values in the results of study 1 parts 1 and 2 along with the results 
of this part, we concluded that changes in G-gap values correlate with both 
intracellular FN3K activity and levels along with plasma AGEs levels.  This supports 
the hypothesis that a positive G-gap suggests a greater level of intracellular 
erythrocyte glycation of Hb than the predicted from the level of circulating 
fructosamine. This also means higher levels of AGEs with low activity and 
expression of FN3K with more negative effects of glycation with a higher risk of 
developing diabetic complications. Thus, our results confirm our prediction as well as 
previous findings that high levels of AGEs contribute to a higher risk of complications 
(Gkogkolou and Bohm, 2012; Peppa, et al., 2003; Schurman et al., 2008). 
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Considering that AGEs are the final products of the non-enzymatic glycation process 
that are formed from the amadori product via dicarbonyl intermediates (Ahmed et al., 
2005), a positive G-gap simply means higher glycated Hb than predicted from 
fructosamine which in turn means a higher degree of protein glycation (Nayak et al., 
2013). Thus, it seems intuitive that patients with positive G-gaps are likely to have 
higher levels of AGEs and lower FN3K activity than those with negative G-gaps. This 
was confirmed in our study. The higher activity of FN3K with lower levels of AGEs in 
patients with negative G-gaps compared to those with positive G-gaps can be 
explained by the role of FN3K as it is able to break down the second intermediate of 
the non-enzymatic glycation by phosphorylating FL to FL3P, which in turn prevents 
formation of AGEs when it is active (Szwergold et al., 2001). Such correlation 
between FN3K activity and AGE levels was proven by Skhra et al., (2014). These 
authors reported that there is a significant association between the FN3K SNPs 
rs1056534 and rs3848403 and sRAGE concentration in diabetic patients.  
3.3.4 Discussion of study 1 part 4: endothelial dysfunction markers in relation 
to G-gap 
3.3.4.1 Discussion of Thrombomodulin levels in relation to G-gap results 
When examining the results, there was no significant difference in plasma 
thrombomodulin levels between the two groups (negative or positive G-gap) with a p 
value >0.05(figure 3.2.1b, table 3.2.1d), thus whether the value of G-gaps is positive 
or negative is unlikely to alter the levels of plasma thrombomodulin. Considering 
thrombomodulin is an important marker for endothelial dysfunction (Takahashi et al., 
1992) and the results of the assay suggest that there is no difference in endothelial 
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dysfunction occurrence with G-gap, this means G-gap may neither effect nor predict 
the occurrence of endothelial dysfunction.  
As discussed in the introduction chapter, the rate of glycation is connected to 
the production of AGEs and ROS, both of which contribute to damage. Therefore, a 
positive G-gap means a higher level of intracellular glycated haemoglobin than the 
predicted level from fructosamine, which can be translated as greater chance of 
having endothelial dysfunction. Our findings are contrary to our prediction. 
As thrombomodulin is only one marker of endothelial dysfunction, therefore it 
was recommended to measure more makers of endothelial damage which might 
show a different conclusion.   In other words, it might show the expected relationship 
between incidence of endothelial dysfunction and G-gap values. Therefore we 
decided to measure other markers associated with endothelial damage such as E-
selectin and PAI-1, although the result of this assay may have some power in the 
prediction of   many cardiovascular events that are associated with diabetes, of 
which endothelial dysfunction is a precursor.  
Identification of endothelial damage as an early precursor of several diabetic 
complications can help identify the predictive importance of G-gap on endothelial 
dysfunction and can also have important benefits for prediction of CVD 
complications. 
3.3.4.2 Discussion of E-selectin in relation to G-gap results 
In the E-selectin immunoassay there was no significant difference in plasma E-
Selectin levels between the two groups (negative or positive G-gap) with a p value 
>0.05 (figure 3.2.2b). This means G-gaps status is unlikely to affect the 
concentrations of plasma E-selectin.  
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As described in the introduction chapter, E-selectin is an important marker of 
endothelial dysfunction alongside thrombomodulin (Muniyappa & Sowers, 2013). Our 
findings showed a non-significant difference in E-selectin levels between the two 
glycation gap groups which means there will be no difference in the presence of 
endothelial dysfunction between those two groups. As we predicted that a positive 
G-gap means a higher level of intracellular glycated haemoglobin than the predicted 
level from fructosamine, which in turn can be translated as greater chance of having 
endothelial dysfunction, our findings are therefore contrary to our prediction. 
According to Endemann & Schiffrin (2004), E-selectin is a well know marker of 
endothelial dysfunction and an increase in its concentration is well connected to the 
presence of endothelial dysfunction, E-selectin is expressed on the surface of the 
cell for cell adhesion, a small proportion of it also found in the circulation which can 
be measured via immunoassays and this make it an important candidate of 
endothelial damage.  
Despite our results showing no difference in Plasma E-selectin and 
thrombomodulin levels between the two glycation groups, many studies have 
reported contradictory results. For example, glycation gap status has been used in 
patients with diabetes for disease monitoring and prediction of diabetic 
complications, i.e.  When the value is positive it is associated with certain diabetes-
related complications, positive G-gap associated-retinopathy, nephropathy and some 
CVD diseases (Hempe et al., 2002, McCarter et al., 2000 and Cohen et al., 2003).  
In general, several studies have reported that the G-gap value is correlated 
with various diabetic complications. As an example, Cohen et al., (2008) studied a 
cohort for 4 years with random measurements of G-gaps, blood glucose levels and 
glycated haemoglobin and found that an increased risk of diabetic nephropathy was 
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associated with positive G-gap but not with negative G-gap. In regard to other 
diabetes-related complications such as nephropathy, both Cohen et al., (2003) and 
Rodriguez-Segade, et al., (2011) found that the risk of nephropathy is higher with 
positive G-gap rather negative G-gap (positive G-gap was defined as >1% whereas 
the negative was defined <-1%): both studies show that G-gap is a predictor of 
nephropathy in NIDDM patients, taking into consideration that nephropathy is an 
important link to microvascular diseases.  
Despite the previous studies found that positive G-gap was associated with 
diabetic complication such as nephropathy and neuropathy, Nayak et al., (2013) 
found that the risk of mortality is increased in both positive and negative G-gaps, 
indicating a lack of correlation between mortality rate and the variation of G-gap 
values. This study describes a U shape quadratic relationship, proposing that neither 
positive nor negative G-gap status is linked with improving mortality rate. This result 
agrees with our findings that there is no link between difference in G-gap with 
plasma levels of thrombomodulin and E-selectin.  
 As both thrombomodulin and E-selectin are well known established markers 
of endothelial damage with previous studies showed that individuals exhibiting 
positive G-gaps have high risk of diabetes related complication and considering that 
ED is a well-known precursor of these complications, it could be assumed that those 
two markers of endothelial dysfunction are increased with positive G-gap (Cohen, et 
al. 2003, Nayak, et al., 2013). However, our findings did not support this assumption. 
This finding suggests that G-gap is not associated with the early phases of 
developing CVD complications. Considering larger cohort might demonstrate a link 
between ED and G-gap variation, or these two markers alone are insufficient to 
support this assumption.  
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3.3.5 Discussion of PAI-1 in relation to G-gap results 
When considering the results of PAI-1 immunoassay(figure 3.2.3b) there was a very 
significant difference in plasma PAI-1 levels between the positive and negative G-
gap groups (p value < 0.0001). This means the difference in G-gap values correlate 
positively with plasma PAI-1 concentration. 
As discussed in the introduction chapter, PAI-1 is considered both as a 
marker of endothelial damage and is linked to thrombosis via its role as a partial 
inhibitor of fibrolysis (Nadar et al., 2004). Our results show a highly significant 
change in plasma PAI-1 levels between the two groups in contrast to the previous 
two markers of endothelial dysfunction, which were not significantly different 
between the two G-gap groups. 
 This result agrees with previous studies which showed that individuals with positive 
G-gaps have high risk of diabetes related complication such as endothelial 
dysfunction with PAI-1 as a well-established marker of endothelial dysfunction. This 
contradiction between PAI-1 assay results with E-selectin and thrombomodulin 
assay results can be explained due to several factors, for example the small cohorts’ 
size in our study might not be sufficient to support a positive correlation between 
positive G-gap and the chance of having endothelial dysfunction. A larger cohort 
might produce different results. However, the results of the PAI-1 assay showed a 
very significant difference in plasma PAI-1 level between positive G-gap and 
negative G-gap whereas the results of E-selectin and thrombomodulin did not 
produce a significant difference. This means the change in G-gap values might not 
influence the risk of having endothelial dysfunction, or that those two markers are 
insufficient to present such correlation between positive G-gap and endothelial 
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damage, unlike the result of PAI-1. Despite this, the powerful significance in the 
difference of PAI-1 levels between the groups is enough to support our prediction.  
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Chapter 4 
 
Study 2  
 
The effect of metformin therapy on FN3K expression 
in  
AECOPD patients   
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4.1 Results of study2: Measuring of FN3K enzyme levels in serum of AECOPDs 
patients 
4.1.1 Obtaining of FN3K enzyme serum concentration 
As described in Chapter 2 this assay was performed by means of ELISA. The 
standard curve was drawn to get the concentration of FN3K; below is the standard 
curve for the first experiment (figure 4.1.1a: samples # 1-23). From the standard 
curve the concentrations of the unknown samples were interpolated. 
 
 
Figure 4.1.1a The standard curve produced from the standard concentrations of 
human serum FN3K levels used in the first ELISA. Regarding the goodness of fit 
model, the R2 value of the best fit curve is close to 1, which indicates low of 
deviation of the measurements plotted from the best fit curve. This indicates the 
accuracy of the interpolation for predicting concentrations from the optical density. 
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4.1.2 Statistical analysis 
4.1.2.1 Metformin treatment 
The statistical analysis performed by using Graph-pad Prism 6 software showed very 
significant differences in mean serum FN3K levels between discharge and follow up 
stages, which can be seen clearly in (Figure 4.1.2.1b).  
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Figure 4.1.2.1b: Impact of metformin on FN3K expression for each subject 
(****p<0.0001 relative to entry) separated by the 3 stages (entry discharge- follow 
up) on x axis. P<0.0001. 
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Figure 4.1.2.1b: shows the differences in mean FN3K levels +/- SD is plotted as a 
scatterplot to show the impact of metformin treatment in FN3K expression in each 
patient at every stage. This shows an increase in the mean of serum FN3K at each 
stage: (83.45, 110.3 & 124.4) ng/ml for entry, discharge and follow up, respectively. 
The standard deviation was also increased (+/-25.27, +/-27.78, +/-32.44) ng/ml for 
entry, discharge & follow-up periods respectively. It can be concluded that metformin 
has an impact on FN3K expression in those patients. Therefore, when considering 
these together it is clearly show that this difference is significant, which was 
confirmed in the statistical analysis with P<0.0001. 
 Table 4.1.2.1c shows the descriptive statistics for measurement of FN3K 
levels in serum of patients treated with metformin separated by 3 stages (entry-
discharge-follow up).  Descriptive statistics of the separated cohort by 3 stages along 
with the p-value and a KS normality test were calculated in the analysis of the 
distribution of the three data sets. The KS normality test showed a normal 
distribution of the data for the entry, discharge and the follow up groups with non-
significant p values for each (0.9972, 0.9430, 0.8667).  As we have FN3K serum 
levels values for each metformin treated individual taken at each point, we do need 
to compare the mean of FN3K concentrations among each point of entry. This was 
performed by the two- way ANOVA test table 4.1.2.1d:  the test showed (p<0.0001), 
with R squared 66.68% and Geisser-Greenhouse’s epilson test (to correct the 
degrees of freedom of the F-distribution) value of 0.72, which indicates a very 
significant difference in FN3K expression between entry and discharge stages with 
homogenous variance between data in the two stages. When considering discharge, 
and follow up stages, p <0.0001 R squared was 59.16%, indicating a very significant 
difference in FN3K expression between discharge and follow up period. To then test 
181 
 
multiple variances (table 4.1.2.1e) a Tukey test with 95% confidence interval was 
used and this result showed a very significant difference in FN3K levels between all 
stages. This indicates that metformin treatment enhances FN3K expression (Figure 
4.1.2.1b). 
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 entry discharge follow up 
Number of values 16 16 16 
    
Minimum 31.06 66.24 69.91 
25% Percentile 70.12 85.19 101.9 
Median 81.96 107.2 123.0 
75% Percentile 101.2 132.5 155.1 
Maximum 132.5 166.4 182.9 
    
Mean  83.45 110.3 124.4 
Std. Deviation 25.27 27.78 32.44 
Std. Error of Mean 6.317 6.946 8.109 
    
Lower 95% CI of mean 69.98 95.51 107.2 
Upper 95% CI of mean 96.91 125.1 141.7 
Actual confidence level 97.87% 97.87% 97.87% 
Lower confidence limit 69.21 81.53 100.1 
Upper confidence limit 101.6 134.6 155.1 
KS normality test    
KS distance 0.09907 0.09985 0.1379 
P value 0.9972 0.9430 0.8667 
Passed normality test 
(alpha=0.05)? 
Yes Yes Yes 
P value summary ns ns ns 
Sum 1335 1765 1991 
Table 4.1.2.1c: Descriptive statistics of the separated cohort by stages (entry-
discharge-follow up) for treated patients with metformin together with the p-value 
and KS normality test calculated in the analysis of the distribution of the three data 
sets. 
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Repeated measures ANOVA summary   
Assume sphericity? No     
F 30.26     
P value < 0.0001     
P value summary ****     
Statistically significant (P < 
0.05)? 
Yes     
Geisser-Greenhouse's 
epsilon 
0.72     
R square 0.6686     
      
Was the matching effective?    
F 8.741     
P value < 0.0001     
P value summary ****     
Is there significant 
matching (P < 0.05)? 
Yes     
R square 0.5916     
      
ANOVA table SS DF MS F (DFn, DFd) P 
value 
Treatment (between 
columns) 
13874 2 6937 F (1.440, 
21.60) = 30.26 
P < 
0.0001 
Individual (between rows) 30058 15 2004 F (15, 30) = 
8.741 
P < 
0.0001 
Residual (random) 6877 30 229.2   
Total 50810 47    
      
Data summary     
Number of treatments 
(columns) 
3     
Number of subjects (rows) 16     
Table 4.1.2.1d: ANOVA test for analysing data of study2.  
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Number of 
families 
1        
Number of 
comparisons per 
family 
3        
Alpha 0.05        
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95% CI of 
diff. 
Significant
? 
Summ
ary 
    
entry vs. 
discharge 
-26.86 -39.92 to -
13.81 
Yes ***  A-
B 
  
entry vs. follow 
up 
-40.99 -58.52 to -
23.46 
Yes ****  A-
C 
  
discharge vs. 
follow up 
-14.13 -24.24 to -
4.016 
Yes **  B-
C 
  
Test details Mean 1 Mean 2 Mean Diff. SE of 
diff. 
n
1 
n2 q D
F 
entry vs. 
discharge 
83.45 110.3 -26.86 5.027 1
6 
16 7.5
57 
1
5 
entry vs. follow 
up 
83.45 124.4 -40.99 6.749 1
6 
16 8.5
90 
1
5 
discharge vs. 
follow up 
110.3 124.4 -14.13 3.892 1
6 
16 5.1
32 
1
5 
Table 4.1.2.1e: 2way ANOVA multiple comparisons for FN3K serum expression. 
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4.1.2.2 Statistical analysis for placebo treated patients  
The statistical analysis performed by using Graph-pad Prism 6 software showed 
non-significant differences in serum FN3K levels among patients treated with 
placebo, separated into 3 stages (entry discharge- follow up). 
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Figure 4.1.2.2a: Impact of placebo on FN3K expression in serum of patients treated 
with placebo separated by 3 stages (entry discharge- follow up) on x axis. It can be 
noticed that there is no significant change in FN3K expression among the three 
stages.  
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Figure 4.1.2.2a: shows the differences in mean FN3K levels +/- SD is plotted as a 
scatterplot to show the impact of placebo treatment in FN3K expression in each 
patient at all stages. It shows differences in the mean of serum FN3K at each stage: 
(155.1, 127.9 & 143.3) ng/ml for entry, discharge &follow up, respectively. The 
standard deviation was also increased (+/-55.49, +/-35.12, +/-45.22) ng/ml for entry, 
discharge & follow-up periods respectively. From these data, it can be concluded 
that placebo is unlikely to affect FN3K expression in those patients. Therefore, when 
considering these together it is clearly show that this difference is non-significant, 
which was confirmed in the statistical analysis with p= 0.4692. 
Table 4.1.2.2b summarises the descriptive statistics for measurement of 
FN3K levels in serum of patients treated with placebo separated by 3 stages (entry-
discharge-follow up). Descriptive statistics of the separated cohort by 3 stages along 
with the p-value and a KS normality test were calculated in the analysis of the 
distribution of the three data sets.  The KS normality test showed a normal 
distribution of the data for the entry, discharge and the follow up with non-significant 
p value for each (0.5214, 0.8411, 0.9934).   
 As we have FN3K serum levels values for each placebo-treated individual 
taken at each point, we do need to compare the mean of FN3K concentrations 
among each point of entry.  This was performed by the two- way ANOVA test table 
4.1.2.2c, the test showed (p=0.4692), with R squared 11.65%, Geisser-
Greenhouse’s epilson test (to correct the degrees of freedom of the F-distribution) 
value of 0.9366, indicating a non-significant difference in FN3K expression between 
entry and discharge stages with non-homogenous variance between data in all two 
stages. When considering discharge, and follow up stages p= 0.1697 as with R 
squared 45.1%, indicates a non-significant difference in FN3K expression between 
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discharge and follow up period. Then to test multiple variances table 4.1.2.2d a 
Tukey test with 95% confidence interval was used and this result showed a non-
significant difference in FN3K levels between all stages. This indicates that placebo 
treatment has no effects on FN3K expression (figure 4.1.2.2a). 
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 Entry discharge follow up 
Number of values 7 7 7 
    
Minimum 75.4 66.44 78.44 
25% Percentile 133.5 109.9 104.1 
Median 139.3 124.8 145.8 
75% Percentile 203.1 160.4 182.4 
Maximum 248.5 172.5 211.5 
    
Mean 155.1 127.9 143.3 
Std. Deviation 55.49 35.12 45.22 
Std. Error of Mean 20.97 13.28 17.09 
    
Lower 95% CI of mean 103.8 95.44 101.5 
Upper 95% CI of mean 206.5 160.4 185.1 
    
95% CI of median    
Actual confidence level 98.44% 98.44% 98.44% 
Lower confidence limit 75.4 66.44 78.44 
Upper confidence limit 248.5 172.5 211.5 
    
Sum 1086 895.5 1003 
    
KS normality test    
KS distance 0.2532 0.1615 0.1292 
P value 0.5214 0.8411 0.9934 
 
Passed normality test (alpha=0.05)? Yes Yes Yes 
P value summary ns ns ns 
 
 
 
 
 
 
 
Table 4.1.2.2b: Descriptive statistics of the separated cohort by stages (entry-
discharge-follow up) for treated patients with placebo together with the p-value and 
KS normality test calculated in the analysis of the distribution of the three data sets. 
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Number of comparisons 
per family 
3        
Alpha 0.05        
Tukey's multiple 
comparisons test 
Mea
n 
Diff. 
95% 
CI of 
diff. 
Significa
nt? 
Summar
y 
    
Entry vs. discharge 27.2
2 
-37.58 
to 
92.01 
No ns  A-B   
Entry vs. follow up 11.8
4 
-62.49 
to 
86.17 
No ns  A-C   
discharge vs. follow up -
15.3
7 
-75.12 
to 
44.37 
No ns  B-C   
Test details Mea
n 1 
Mean 
2 
Mean 
Diff. 
SE of 
diff. 
n
1 
n2 q DF 
Entry vs. discharge 155.
1 
127.9 27.22 21.12 7 7 1.8
23 
6 
Entry vs. follow up 155.
1 
143.3 11.84 24.22 7 7 0.6
91
3 
6 
discharge vs. follow up 127.
9 
143.3 -15.37 19.47 7 7 1.1
17 
6 
Table 4.1.2.2 c: Two-way ANOVA test for analysing data of study2 
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Table analysed    Placebo  
Repeated measures ANOVA 
summary 
     
Assume sphericity? No     
F 0.7913     
P value 0.4692     
P value summary ns     
Statistically significant (P < 
0.05)? 
No     
Geisser-Greenhouse's epsilon 0.9366     
R square 0.1165     
Was the matching effective?      
F 1.860     
P value 0.1697     
P value summary ns     
Is there significant matching (P 
< 0.05)? 
No     
R square 0.4510     
ANOVA table SS D
F 
MS F (DFn, DFd) P value 
Treatment (between columns) 2607 2 130
3 
F (1.873, 11.24) = 
0.7913 
P = 
0.4692 
Individual (between rows) 18381 6 306
3 
F (6, 12) = 1.860 P = 
0.1697 
Residual (random) 19767 1
2 
164
7 
  
Total 40754 2
0 
   
Data summary      
Number of treatments 
(columns) 
3     
Number of subjects (rows) 7     
Table 4.1.2.2d: Two-way ANOVA multiple comparison for FN3K serum expression of 
placebo.  
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4.1.2.3 Statistical analysis for placebo vs metformin treated patients 
In order to confirm the impact of metformin on FN3K expression, a multiple 
comparison (two-way ANOVA) for FN3K expression was made between patients 
with metformin treatment with those with placebo. Figure 4.1.2.3a 
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Figure 4.1.2.3a:  Impact of metformin versus placebo on mean+/-SD   serum FN3K 
levels in AECOPD (*p<0.05 relative to placebo at each sampling point). 
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Figure 4.1.2.3a: shows the differences in mean FN3K levels +/- SD for the metformin 
treatment vs. placebo. It shows the differences in the mean of serum FN3K at each 
stage (entry, discharge &follow up) and it shows that these differences are significant 
at the discharge and follow up stages, which suggests that metformin has a relative 
impact of on FN3K serum expression in AECOPD patients. This was show as p 
<0.05.  
Table 4.1.2.3b summarize this comparison by using two-way ANOVA test for 
multiple comparisons. The statistical analysis showed a significant difference 
between expressions of FN3K in metformin treatment at discharge vs. follow up 
stage compared with placebo figure 4.1.2.3a. For more powerful analysis the data 
was additionally analysed by Holm-Sidak method to allocate the differences at what 
stage table 4.1.2.3c. These results indicate that metformin may reduce this risk in 
COPD by raising FN3K levels. 
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Compare each 
cell mean with 
the other cell 
mean in that 
row. 
         
Number of 
families 
1         
Number of 
comparisons per 
family 
3         
Alpha 0.05         
          
Sidak's multiple 
comparisons 
test 
Mean 
Diff. 
 95% 
CI of 
diff. 
Significant? Summary     
metformin - 
Placebo 
         
Entry 0.0  -
53.14 
to 
53.14 
No ns     
Discharge 49.01  -
4.133 
to 
102.2 
No ns     
Follow up 57.26  4.117 
to 
110.4 
Yes *     
          
          
          
Test details Mean 
1 
 Mean 
2 
Mean Diff. SE of 
diff. 
N1 N2 t DF 
metformin - 
Placebo 
         
Entry 0.0  0.0 0.0 21.67 16 7 0.0 63 
Discharge 41.44  -
7.571 
49.01 21.67 16 7 2.262 63 
Follow up 60.69  3.429 57.26 21.67 16 7 2.643 63 
 
 
Table 4.1.2.3b: Two-way ANOVA multiple comparisons for FN3K serum expression in 
metformin vs placebo. 
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Table 4.1.2.3c One unpaired t test (Holm-Sidak method) of  FN3K expression for  
metformin vs placebo  
 Significa
nt? 
P value Mean
1 
Mean
2 
Differe
nce 
SE of 
difference 
t ratio df 
Entry  1.0 0.0 0.0 0.0 21.6651 0.0 63.0 
Dischar
ge 
* 0.02714
91 
41.43
75 
-
7.571
43 
49.008
9 
21.6651 2.2621
1 
63.0 
Follow 
up 
* 0.01035
79 
60.68
75 
3.428
57 
57.258
9 
21.6651 2.6429
1 
63.0 
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4.2 Discussion 
When analyzing the results of this study (figure 4.1.2.1b), there was a very significant 
difference in FN3K serum concentration when comparing FN3K serum concentration 
among all three stages (entry, discharge and follow up) with p< 0.0001 for FN3K 
concentration in entry vs discharge & p<0.0001 for discharge vs. follow up. When 
performing multiple comparisons using an ANOVA test, there was a very significant 
difference in FN3K concentration among all stage, with highest mean at the follow up 
and lowest at the entry (table 4.1.2.1d). This means the admission of metformin 
increase the concentration of FN3K in AECOPD patients. 
When considering placebo admission, the results showed a non-significant 
difference in FN3K levels after placebo treatment among all stages  (entry, 
discharge, and follow up). When applying a Tukey post-hoc test with 95% confidence 
interval (table 4.1.2.2c) the result showed a non-significant difference in FN3K levels 
between all stages. This indicates that placebo treatment has no effects on FN3K 
expression (figure 4.1.2.2b).  
The above result encouraged us to re-analyze the data by applying a multiple 
comparison of FN3K serum expression for metformin vs placebo treatment at all 
stages by using a two-way ANOVA test for multiple comparison. This showed a 
significant difference between expressions of FN3K in metformin treated patients at 
discharge and follow up stage compared with placebo-treated patients’ (figure 
4.1.2.3a). This means metformin has an impact on FN3K serum concentration, which 
might be attributed to a defensive mechanism against protein glycation in COPD, or 
as a part of its role in reducing the frequency and severity of diabetes related 
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complications along with formation of AGE (Beisswenger & Lopez, 2003 and Stirban 
et al., 2014).   
This study was designed to investigate the effect of metformin treatment on 
FN3K enzyme expression in AECOPD patients. We found that the serum FN3K 
concentrations increased with metformin treatment. This increase in FN3K 
concentration continued throughout the metformin treatment. Moreover, this 
relationship between metformin treatment and FN3K serum concentration was 
confirmed when we measured FN3K concentration in patients who underwent 
placebo treatment and found no correlation between placebo treatment and serum 
FN3K concentration.  Thus, metformin treatment may raise FN3K concentration in 
patients with COPD as part of its beneficial effect in decreasing diabetes related 
complication (Zhou et al., 2001).   
 Despite the known mechanisms behind the beneficial effects of metformin on 
protein glycation, it is still not clear how it has an impact on FN3K action in COPD 
patients. However, several authors have reported a role of metformin in inhibition of 
protein glycation through inhibition of AGEs formation (Beisswenger & Lopze, 2003, 
Tanaka et al., (1997), Ishibashi et al., 2012, and Ishibashi et al., 2013). 
The main effect of metformin is that of reducing hepatic glucose production 
throughout activation of AMPK, which is a major cellular regulator for glucose and 
lipid metabolism (Zhou et al., 2001). Moreover, various authors have shown the 
beneficial effects of metformin administration in inhibiting adipose tissue lipolysis, 
decreasing formation of AGEs, reducing circulating levels of free fatty acids, and 
improving insulin sensitivity (Kirpichnikov et al., 2002). Furthermore, metformin 
lowers blood pressure in patients with type2 diabetes and impaired glucose 
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tolerance (Verma et al., 1994). Metformin was also reported to decrease morbidity 
and mortality rates in patients with type 2 diabetes when administered alone or with 
sulphonylurea (McDonald et al., 2010 & Eurich and McAllister, 2010).  
On the other hand, AGE is considered as one of the main pathogenic factors 
of diabetic vascular complications (Yamagishi et al., 2005). AGEs are formed from 
non-enzymatic glycation of amino groups in proteins in vivo, which then produces 
highly reactive carbonyl groups (alpha-dicarbonyls or oxoaldehydes), including 3-
deoxyglucosone, glyoxal, and methylglyoxal (Brownlee et al., 2006).  
As the methylglyoxal (MG) is one of the main sources of formation of AGEs, 
any changes in MG levels can alter AGE formation (Beisswenger et al., 1995, 
Monnier et al., 1986 and Biesswenger et al., 1997). Metformin is thought to decrease 
AGE formation by reducing MG levels in the tissues of diabetic patients 
(Beisswenger et al., 1999), which in turn decreases the incidence of diabetic 
vascular and neuropathic complications (Monnier et al., 1986 and Biesswenger et 
al., 1997). Metformin also decrease AGE levels in animal tissues such as in the eye 
lens, kidney and nerves of diabetic animals (Tanaka et al., 1999). It is reported that 
metformin can reduce MG levels by formation of specific condensation products that 
result from the reaction of metformin with MG; an example of those compounds 
being triazepinone (TZP) (Ruggiero-Lopez et al., 1999).  
In a study by Zhao et al., (2014) on rats, it was found that metformin 
significantly restored AGE-impaired IKca and Skca (intermediate-conductance and 
small-conductance Ca (2+)-activated potassium channels)-mediated vasodilators in 
mesenteric arteries of Streptozotocin-induced type 2 diabetic rats.  
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One of the important mechanisms by which AGEs contribute to diabetic 
complications is related to tissue inflammation and oxidative stress (Cai et al., 2002). 
It is widely accepted that oxidative stress is a major aetiological factor in the 
pathogenesis of COPD (Mirrakhimov, 2012). Both oxidative stress and 
hyperglycaemia can accelerate the production of AGEs (Schmidt et al., 2001). 
As FN3K has been demonstrated to decrease levels of AGEs in Chapter 3 
and the increase in oxidative stress levels in COPD patients leads to the formation of 
carbonyl stress that is linked to AGEs formation, it is therefore axiomatic that this 
increase in oxidative stress decreases FN3K expression. In summary, metformin 
treatment, which has been proved by many studies to inhibit glycation and formation 
of AGE, may enhance the expression of FN3K, and as a protective mechanism act 
against deleterious effects of oxidative stress, as was demonstrated in this study. 
Furthermore, metformin was reported to have more effects in reducing oxidative 
stress in COPD patients than lifestyle modifications (Esteghamati et al., 2013).  
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Chapter 5 
 
 
Measurement of FN3K protein levels in COPD airways  
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5.1 Results of study 3 measurement of FN3K expression in human peripheral 
lung tissue 
The statistical analysis was performed using GraphPad Prism software; figure 5.1a 
shows FN3K expression in airway epithelial cells.  
 
Figure 5.1a: FN3K expression in airway epithelial cells. Data were also used to 
calculate the percentage of positive (high) FN3K expressers. 
Y-axis: percentage of epithelial cells staining positive for FN3K (epi) /total number of 
epithelial cells (epi) in each cohort. 
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Figure 5.1b: Percentage of subjects positive for FN3K expression in airways. This 
figure was prepared by plotting the percentage of patients who were FN3K positive 
(as the number of FN3K patients’ positive / total number patients). 
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Immunohistochemistry of bronchial biopsies was used to determine expression of 
FN3K in airway epithelial cells. In each cohort (healthy non-smokers, control 
smokers and patients with COPD) individuals were grouped in one of two categories, 
low or high FN3K expressers as described in figure 5.1a. In healthy non-smokers, 
83% (10 of 12) of subjects expressed FN3K at low levels with only 2.2 ± 1.4% of 
airway epithelial cells expressing FN3K. In contrast, 75% (9 of 12) of smokers 
exhibited a significant increase in FN3K expression with 31.3 ± 6.3% of epithelial 
staining positive for FN3K. However, in the COPD group, 67% (8 of 12) of subjects 
had low levels of FN3K expression with only 4.1 ± 2% of epithelial cells expressing 
FN3K (see table 5.1d). On the other hand, with regard to the percentage of subjects 
positive for FN3K expression in airways, the highest expression of FN3K is clearly 
observed in the control smokers followed by COPD patients and the healthy non-
smokers (figure 5.1b).   
  Table 5.1c shows the descriptive statistics for the study. The Shapiro-Wilk 
normality test was applied and showed that the data were not normally distributed, 
with non-significant P-values (P<0.0001 for non-smokers, P=0.0222 for control 
smokers and P=0.0084 for COPD patients). Table 5.1d shows the descriptive 
statistics for the two categories in each cohort (high and low percentage FN3K 
expression, see figure 5.1a). In the newly categorised groups, the data were not 
normally distributed (table 5.1d).  
In order to compare FN3K expression among all groups, a one-way ANOVA 
for multiple comparisons was applied (table 5.1e) and showed non-significant 
differences among all groups (P=0.5222). When applying the Tukey test for multiple 
comparison (table 5.1f) we also found a non-significant difference in FN3K 
expression among the three cohorts.  However, the highest mean FN3K expression 
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was observed in the control smokers group (table 5.1c). This can be explained if 
FN3K expression is upregulated in the airways of smokers, presumably as a 
protective mechanism to prevent or limit the impact of increased carbonyl stress as a 
result of increased exposure to oxidative stress from cigarette smoking. In COPD, 
however, this protective mechanism of increased FN3K expression is lost. This can 
be confirmed in (table 5.1g) by categorising the individuals in each cohort into two 
categories high and low FN3K expressers. This conclusion confirms our hypothesis 
that patients with COPD may have low FN3K expression due to certain factors 
oxidative and chronic inflammation).  
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 Non-smokers Control smokers COPD 
n 12 12 12 
Minimum 0.0 0.0 0.0 
25% Percentile 0.0 6.500 0.0 
Median 0.5000 22.85 10.00 
75% Percentile 11.75 31.50 35.00 
Maximum 73.00 77.00 82.00 
Mean 12.83 23.95 19.83 
Std. Deviation 25.33 20.22 25.80 
Std. Error of Mean 7.313 5.838 7.447 
Lower 95% CI of mean -3.263 11.10 3.443 
Upper 95% CI of mean 28.93 36.80 36.22 
Shapiro-Wilk normality test    
W 0.5780 0.8320 0.7960 
P value < 0.0001 0.0222 0.0084 
Passed normality test (alpha=0.05)? No No No 
    
P value summary **** * ** 
Sum 154.0 287.4 238.0 
Table 5.1c: Descriptive statistics for study 3.  
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 NS low  NS high  CS low CS high  COPD  
low 
COPD 
high  
Total 
number 
of values 
10 2 3 9 8 4 
Number 
of 
excluded 
values 
0 0 0 0 0 0 
Number 
of binned 
values 
10 2 3 9 8 4 
       
Minimum 0 59 0 17 0 29 
25% 
Percentile 
0 59 0 22.35 0 31 
Median 0 66 3 25 2.5 44.5 
75% 
Percentile 
2.75 73 3 32.35 11 74.5 
Maximum 14 73 3 77 13 82 
Mean 2.2 66 2 31.26 4.16 50 
Std. 
Deviation 
4.44 9.89 1.73 17.90 5.62 23.36 
Std. Error 
of Mean 
1.40 7 1 5.96 1.98 11.68 
Lower 
95% CI of 
mean 
-0.97 -
22.94343 
-2.30 17.49 0.047 12.818456 
Upper 
95% CI of 
mean 
5.37 154.94 6.30 45.03 9.45 87.18 
       
Table 5.1d: Descriptive statistics for the two categories (high and low FN3K expressers) in 
study 3. NS low (non- smokers/low FN3K expressers group), NS high (non-smokers /high 
FN3K expressers), CS low (controlled smokers/low FN3K expressers group), CS high 
(controlled smokers/high FN3K expressers group), COPD low (COPD patients with low 
FN3K expression group) and CS high (COPD Patients with high FN3K expression group). 
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Table analysed  % total FN3K 
+ve epi cells/tot 
epi cells nr 
  
      
ANOVA summary      
F 0.6626     
P-value 0.5222     
P-value summary ns     
Are differences among 
means statistically significant 
(P<0.05)? 
No     
r2 0.03861     
      
Brown–Forsythe test      
F (DFn, DFd) 0.2244 (2, 33)     
P-value 0.8002     
P-value summary ns     
Significantly different SD 
(P<0.05)? 
No     
      
Bartlett's test      
Bartlett's statistic (corrected) 0.7334     
P-value 0.6930     
P-value summary ns     
Significantly different SD 
(P<0.05)? 
No     
      
ANOVA table SS DF MS F (DFn, DFd) P-value 
Treatment (between columns) 758.1 2 379.1 F (2, 
33)=0.6626 
P=0.5222 
Residual (within columns) 18879 33 572.1   
Total 19637 35    
      
Data summary      
Number of treatments 
(columns) 
3     
Number of values (total) 36     
 
 
 
 
 
 
Table 5.1e: One-way ANOVA test for study 3 data. 
207 
 
 
1        
Number of 
comparisons per 
family 
3        
Alpha 0.05        
Tukey's multiple 
comparisons test 
Mean 
Diff. 
95.% 
CI of 
diff. 
Significa
nt? 
Summ
ary 
Adjusted 
P Value 
   
Non-smokers vs. 
Control smokers 
-11.12 -35.08 
to 
12.84 
No ns 0.4977 A-
B 
  
Non-smokers vs. 
COPD 
-7 -30.96 
to 
16.96 
No ns 0.7553 A-
C 
  
Control smokers vs. 
COPD 
4.117 -19.84 
to 
28.08 
No ns 0.9070 B-
C 
  
Test details Mean 1 Mean 
2 
Mean 
Diff. 
SE of 
diff. 
n1 n2 q DF 
Non-smokers vs. 
control smokers 
12.83 23.95 -11.12 9.765 12 12 1.6
1 
33 
Non-smokers vs. 
COPD 
12.83 19.83 -7 9.765 12 12 1.0
14 
33 
Control smokers vs. 
COPD 
23.95 19.83 4.117 9.765 12 12 0.5
962 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1f: Tukey’s multiple comparison test for study 3 data. 
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Number of families 1     
Number of comparisons per 
family 
3     
Alpha 0.05  2   
Dunn's multiple comparisons 
test 
Mean rank 
diff. 
Significant
? 
Summary   
NS vs. NS -23.65 Yes **  A-
B 
Smoker vs. Smoker -15.22 No ns  C-
D 
COPD vs. COPD -19.31 Yes **  E-
F 
Test details Mean rank 1 Mean rank 
2 
Mean rank 
diff. 
n
1 
n2 
Non-smoker vs. Non -smoker 9.85 33.5 -23.65 1
0 
2 
Smoker vs. Smoker 11.67 26.89 -15.22 3 9 
COPD vs. COPD 12.19 31.5 -19.31 8 4 
Table 5.1g: One-way ANNOVA for multiple comparisons with Dunn’s test for each 
category test in each cohort of study 3 data. 
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5.2 Discussion  
 
In the preceding chapter we explored the correlation between metformin treatment 
and FN3K serum concentration in AECOPD patients. The results showed that FN3K 
concentration was enhanced by metformin treatment with time. In this chapter, the 
statistical analysis using one-way ANOVA showed non-significant differences in 
FN3K expression among three groups: healthy non-smokers, control smokers and 
COPD patients (P=0.522, r2=0.03861; table 5.1.e; figure 5.1b). However, there was a 
slight difference in the mean FN3K expression which was highest in control smokers 
followed by COPD patients then non-smokers (23.95, 19.83 and 12.83 respectively). 
This difference can be explained by upregulation of FN3K enzyme expression in the 
airways of smokers, presumably as a protective mechanism to prevent or limit the 
impact of increased carbonyl stress as a result of increased exposure to oxidative 
stress from cigarette smoking. In COPD, however, this protective mechanism of 
increased FN3K expression is lost. 
It has been demonstrated that chronic inflammation, as a result of inhaled 
particles during smoking or from other sources, causes disruption in the normal 
repair and defence mechanism thus limiting airflow (Chung, 2005). In addition, AGEs 
and carbonyl stress formations can be resulted from the presence of both oxidative 
stress and systemic inflammation (Gopal et al., 2014 & Goldin et al., 2006), ), and 
FN3K is assumed to be the enzyme that deglycates glycated proteins in erythrocytes 
and other tissue including the lung (Delpierre et al., 2000). Thus, in our study the 
mean FN3K expression in control healthy smokers is higher than that of COPD 
patients possibly due to the presence of two factors: chronic inflammation and 
oxidative stress in these COPD patients.  Both factors lead to the formation of AGEs 
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which might affect FN3K expression due to the inability of FN3K to deglycate all 
elevated AGE levels. Another reason might be the fact that the level of NRF2 (which 
regulates the expression of antioxidant proteins that protect against oxidative stress) 
is decreased in COPD patients and therefore the level of oxidative stress is high 
(Boutten et al., 2011). In healthy smokers, however, it seems that the FN3K enzyme 
expression might be enhanced to resist protein damage caused by chronic 
inflammation as a result of smoking. Thus, this enhances the expression of FN3K 
enzyme to resist disruption of the normal repair defence mechanism. Therefore, 
mean FN3K expression in control smokers was higher than in COPD patients due to 
the fact that in control smokers only one deleterious factor was developed (systemic 
inflammation)   whereas in COPD patients, two factors were developed (chronic 
inflammation and oxidative stress).  This explains why the mean FN3K expression 
was in COPD patient lower than that of smokers as the FN3K cannot overcome the 
presence of these two factors together in those COPD patients (see figure 1.4.8). 
However, one of the main limits in this study is the sample size, and perhaps using 
more samples of human peripheral lung tissue to detect FN3K expression might 
either lead to a different conclusion or confirm the present findings.  
  As mentioned in chapter 1, smoking is an important risk factor for diabetes 
and COPD, causing an increase in serum levels of inflammatory markers (Arcavi and 
Benowitz, 2004; Gan et al., 2005). Moreover, smoking was demonstrated to 
contribute to cardiovascular events via induction of endothelial dysfunction. Cigarette 
smoking is linked to formation of oxidative stress which is widely considered to be a 
mediator of endothelial dysfunction (Morrow et al., 1995; Cai and Harrison, 2000; 
Sambola et al., 2003). ). Endothelial dysfunction itself is widely considered to be an 
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important precursor for other cardiovascular complications in diabetes (Green and 
Turner, 2017; Meigs, et al., 2004; Sena et al., 2013; Hadi and Al Suwaidi, 2007).  
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Chapter 6 
 
Final discussion and conclusion  
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6.1 Discussion  
The International Diabetes Federation (IDF) estimated that 415 million people 
around the world had diabetes in 2015 and this number was projected to increase to 
642 million by 2040 (IDF, 2015). Several studies have shown an association 
between diabetes and COPD; the prevalence of diabetes among COPD patients is 
as high as 18% (Cazzola et al., 2010). The presence of diabetes has been reported 
to be associated with poorer lung function (Van den Borst et al., 2010) with smoking 
being a known risk factor for developing type 2 diabetes in the absence of COPD 
(Xie et al., 2009). Moreover, smoking has been considered as a risk factor for both 
diabetes and COPD (Manson et al. 2000; Rimm et al. 1995). Diabetes, hypertension, 
ischaemic heart disease and heart failure are the main comorbidities associated with 
COPD (Moussas et al., 2008).  Several studies have reported that type 2 diabetes is 
a risk factor for macrovascular disease (Fowler, 2008), and COPD outcome might be 
altered by some of the effects of diabetes which may be related to increased 
cardiovascular morbidity and mortality. In addition, the lung itself is targeted by 
microvascular diseases (Mirrakhimov, 2012).  Glycation is defined as a non-
enzymatic reaction by which carbohydrates (such as glucose) can bind to proteins 
(Popova et al., 2010).  
AGEs are formed via non-enzymatic glycation. Their presence was reported 
to be associated with complications related to diabetes and ageing and have 
deleterious effects on several tissues such as skin and bones (Gkogkolou & Bohm 
2012; Schurman et al., 2008). It has been reported that an increase in the levels of 
glucose and its transporter (GLUT-1) can also glycate proteins in other cells such as 
those of the vascular endothelium which are unable to regulate intracellular glucose. 
Such glycation is a possible contributory factor in the development of complications 
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associated with diabetes such as CVD and COPD (Sing et al., 2014). Glycation is 
controlled by an enzymatic process thought to involve a key enzyme (FN3K) which 
can deglycate the glycated haemoglobin in red blood cells and other glycated 
proteins in other tissues (Szwergold et al., 2002). The main aim of our research is to 
investigate the role of FN3K enzyme in diabetes related complications.  
The G-gap has been reported to be associated with an alteration of the risk of 
diabetic complications; a positive G-gap is defined as a higher level of glycation of 
proteins than expected whereas a negative G-gap denotes a lower than expected 
level of glycation (Nayak et al., 2013). Therefore, it was assumed that a positive G-
gap correlates with a higher incidence of diabetes-related complications, whereas a 
negative G-gap in diabetic patients correlates with lower incidence of such 
complications (Cohen, et al. 2003, Nayak, et al., 2013).  
              No previous study has investigated the possible correlation between FN3K 
activity or expression and G-gap values.  Few previous studies have measured the 
activity and expression of FN3K in human and animal models. Very few studies have 
reported the reasons behind the variations in the activity of FN3K among individuals; 
these reasons were owe to presence of two possible polymorphisms in FN3K gene 
(Delpierre et al., 2006, Mohas et al., 2010, and Tanhäuserová et al., 2014).  
Furthermore, none of the previous studies has highlighted any possible correlation 
between metformin treatment and FN3K expression in either COPD or diabetic 
patients though it has been reported that metformin inhibits both glycation and AGE 
formation (Beisswenger & Lopze, 2003; Tanaka et al., 1997; Ishibashi et al., 2012; 
Ishibashi et al., 2013). Finally, few studies have examined the relationship between 
variations in FN3K activity and AGE levels (Skhra et al., 2014). Thus, this is the first 
study to highlight the role of FN3K in diabetes, to investigate any correlation between 
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FN3K and G-gap as an indicator of the risk of diabetes-related complications, and to 
explore the role of FN3K in COPD patients. 
We have described for the first time a significant relationship between FN3K 
activity or levels and G-gaps, showing that erythrocyte activity and level of FN3K are 
inversely correlated with G-gaps. This striking result leads to new questions about 
the role of FN3K in diabetes-related complications as this interesting relationship 
between FN3K and G-gap values has not been investigated previously. 
 Moreover, the significant relationship between G-gap and plasma AGEs  as 
show in figure 3.1.5b has provided further confirmation for the role of FN3K as a 
deglycating enzyme as the results of the AGE assay showed a direct correlation 
between AGEs and G-gaps, both correlating inversely with FN3K activity (study 1 
parts 1 and 2).   
          However, results from the FN3K plasma assay showed a non-significant 
correlation between G-gap and plasma FN3K level because the G-gap value reflects 
the intensity of glycation inside the erythrocytes as the value of HbA1c is a principal 
measurement in the calculation of G-gaps (Nayak et al., 2013). 
No previous studies have examined the correlation between G-gaps and 
markers of endothelial dysfunction, therefore one of the aims of the present study 
was to explore the possibility of a correlation between G-gaps and markers of 
endothelial dysfunction which is considered an important precursor for other 
diabetes-related cardiovascular complications (Hadi & Al Suwaidi, 2007; Meigs et al., 
2004; Sena et al., 2013). Although we showed non-significant differences in plasma 
thrombomodulin and E-selectin levels between positive and negative G-gaps 
(chapter 3), the PAI-1 assay showed a very significant difference in plasma PAI-1 
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between negative and positive G-gaps (figure 3.2.3b, p<0.0001). As mentioned in 
chapter 1, PAI-1 is also considered a marker of endothelial damage and partially 
controls inhibition of fibrinolysis so that it is linked to thrombosis (Nadar et al., 2004). 
Therefore, the results of the PAI-1 assay suggest that patients with positive G-gaps 
are more likely to develop endothelial damage and/or thrombosis and tend to 
develop CVD complications associated with diabetes. It would have been assumed 
that these two markers of endothelial dysfunction (E-selectin and thrombomodulin) 
are increased with positive G-gaps but the results did not support this assumption 
(Cohen, et al. 2003; Nayak, et al., 2013) suggesting that the G-gap is not associated 
with the early phases of development of CVD complications and/or these two 
markers are not enough to support this assumption. Perhaps investigating a larger 
cohort might demonstrate a link between endothelial dysfunction and G-gap on the 
one hand and FN3K on the other. 
The results of the PAI-1 assay are consistent with the previous finding that 
individuals with positive G-gaps have a high risk of diabetes-related complication 
such as endothelial dysfunction, taking into consideration the fact that PAI-1 is a 
well-established marker of endothelial dysfunction. This contradiction between the 
PAI-1 and the E-selectin and thrombomodulin assay results suggests that the 
change in G-gap values might not affect the risk of endothelial dysfunction or that 
these two markers (E-selectin and thrombomodulin) might not reflect such 
correlation between positive G-gap and endothelial damage By contrast, statistical 
analysis showed a highly significant difference in PAI-1 levels between the two G-
gap groups can overcome the debate arising from both E-selectin and 
thrombomodulin  results.  
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                When examining the results of study 2, the statistical analysis showed very 
strong correlations between metformin treatment and FN3K serum levels in 
AECOPD patients  for metformin vs. placebo treatment (figure 4.1.2.3a, p<0.05). 
This suggests that metformin may enhance FN3K levels in COPD patients; however 
how metformin acts on the deglycation process dictated by FN3K remains 
controversial. Even though metformin reduced MG levels, it can inhibit the formation 
of AGEs and thereby inhibit the glycation reaction. The underlying mechanism of this 
role is still not completely understood (Beisswenger et al., 1999; Tanaka et al., 
1999). However, treatment with metformin was also shown to decrease oxidative 
stress (Esteghamati et al., 2013), a key aetiological factor in the pathogenesis of 
COPD through which in turn formation of AGEs is decreased (Kirkham et al., 2013). 
This is the first time that the correlation between metformin treatment and FN3K 
expression has been investigated. Our findings could suggest potential clinical 
approaches. Future studies are required to explore the link between metformin and 
FN3K activity and expression, and how to control FN3K expression in COPD 
patients in a way to prevent diabetes-related CVD complications. 
           With regards to the findings of study 3, FN3K expression was slightly 
increased in healthy control smokers compared to subjects with stable COPD. This 
might be due to an inability of FN3K to initiate protective mechanisms to resist the 
damage caused by chronic inflammation plus oxidative stress among those patients 
with stable COPD. This damage results in development of carbonyl stress that 
contributes to the formation of AGEs (Gopal et al., 2014 & Goldin et al., 2006). 
Moreover, in COPD the level of NRF2 (which regulates the expression of antioxidant 
proteins that protect against oxidative stress) declines, which raises the level of 
oxidative stress in patients (Boutten et al., 2011).   Whereas,  FN3K expression in 
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control smokers was higher than in COPD patients due to the fact that in control 
smokers only one deleterious factor was developed (chronic inflammation)   whereas 
in COPD patients, two factors were developed (chronic inflammation and oxidative 
stress).  Therefore the FN3K enzyme was enhanced to resist disruption of the 
normal repair defence mechanism in control smokers.  Further studies of this 
pathway are needed in COPD patients to investigate factors, especially genetic 
factors that regulate FN3K expression and their control.  
Most studies on the FN3K were based on identifying its biochemical role 
either in vitro or in vivo using human or animal models rather than its involvement in 
diabetes and associated comorbidities (Delpierre et al., 2000; Delplanque et al., 
2004; Monnier et al., 2006; Szwergold et al., 1990; Szwergold et al., 2002; Veiga-da-
Cunha et al., 2006). 
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6.2 Conclusion 
The primary aims of the present research were to answer the questions posed in 
chapter 1 that were raised through reviewing the literature and to investigate several 
issues that have not been explored previously.   Thus, we sought to explore the role 
of FN3K in the development of diabetes-related complications by understanding the 
process through which the enzyme utilises the deglycation process.  This was 
achieved by measuring FN3K activity and level with relation to G-gaps in diabetic 
patients and also by measuring levels of markers of endothelial dysfunction. The 
results demonstrated that FN3K plays an important role in the protein repair system 
which protects against damage caused by non-enzymatic glycation.   Thus, patients 
with positive G-gaps exhibit lower FN3K activity than those with negative G-gaps, 
which in turn they are more susceptible to develop diabetes-related complications.  
The role of FN3K in phosphorylating fructosamines situated on the third carbon of 
their sugar moiety makes them unstable and therefore, results in their detachment 
from proteins. This process provides protection against protein damage. Moreover, 
we demonstrated that high FN3K enzyme activity was associated with low levels of 
AGEs as well as low carbonyl stress levels among patients with diabetes and COPD. 
The lack of significant differences found for plasma concentrations of both E-
selectin and thrombomodulin between the positive and negative G-gap groups in this 
research does not mean that an association between ED and the G-gap does not 
exist.  On the contrary, it paves the way for future studies to determine whether an 
association between ED and G-gap exists by using other methods for detecting ED, 
and whether the G-gap is a useful tool for predicting ED and other diabetic 
complications. The G-gap is potentially useful for reflecting variation in the 
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occurrence of some diabetes-related complications when its predictive value is 
identified. 
On the other hand, COPD patients tend to have a low degree of protection by 
FN3K against protein damage in comparison to the general population. They tend to 
be at risk of developing more complications, particularly CVD complications, than 
normal healthy individuals.  
 Metformin was also proven to have beneficial effects in reducing protein 
damage caused by carbonyl stress resulting from increased exposure to oxidative 
stress from smoking cigarettes by enhancing FN3K action, presumably as a 
protective enzyme, in addition to its role in decreasing lipid and glucose levels.  
6.3 Limitations 
One of the major limitations of this research is that the participants in study 1 were 
recruited from a single NHS trust hospital situated in Wolverhampton which limits 
how translatable the results are to a wider population. Furthermore, working with a 
small population decreases the probability of accounting for the influences of genetic 
and lifestyle factors that are more apparent among wider populations in multicentre 
research. The idea of limited genetic variability is confounded when considering that 
the ethnic background of the cohort is limited, with a mainly white population and a 
relatively unspecific ethnic background with unknown country of origin. In addition to 
these considerations, the collection of data from participants of a single centre is not 
an accurate depiction of a country’s ethnic diversity and thus limits the ability to 
make appropriate interpretations about the impact that genetic variability has on the 
medical conditions of diabetic patients. Ethnicity is an important factor that affects 
the variable expression of a medical condition, as well as responses to antidiabetic 
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drug management.  For instance, it was reported that approximately 60% of the 
global diabetic population were of Asian ethnicity (Hu, 2011; Oldroyd et al., 2005).  
Another disadvantage of working with the small sample size of patients 
recruited for this study is the introduction of gender bias.  In the present study, there 
was a disproportionate number of males compared to females (92 versus 65; 
p<0.05). Consequently, the results cannot be generally applied to both genders in 
this analysis as some measurements are related to gender-specific variation to some 
degree; however, there was a consistent gender bias in both groups of study 1 so 
that they were comparable. The lack of an ethnically diverse sample population and 
the effects of gender bias may affect variations in G-gap values as the findings of 
several studies suggest that gender and ethnicity are likely to be associated with 
potential variation in G-gap values (Cohen et al., 2006; Nayak et al., 2011).  
Therefore, the validity for the cohort to represent the global population may be 
questioned.   
Another limitation of study 1 is the lack of details regarding patient age and 
the amount of time since diagnosis of the disease.  Both are important as the longer 
the duration of diabetes, the greater the exposure of a patient to uncontrolled blood 
glucose levels and the higher the likelihood of developing diabetes-related 
complications such as endothelial dysfunction.  
Previous authors have demonstrated that G-gap values are affected by the 
type of diabetes (Cohen et al., 2002; Nayak et al., 2013). Although the majority of the 
patients in study 1 had Type 2 diabetes, some had Type 1 diabetes. It was not clear 
in this study precisely how many and which patients had type 1 diabetes.  
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 Because most the participants in studies 1 and 2 were classified as type 2 
diabetics, the antidiabetic drug therapy should be taken into consideration.  In 
particular, drugs such as metformin, an antidiabetic agent which lowers glycaemic 
and lipid levels (see chapter 1), can lower HbA1c levels (Jager et al., 2014). This in 
turn affects the G-gap value.  Thus, metformin can be  a confounding factor in 
usefulness of  G-gap.  Moreover, it has been shown that metformin has beneficial 
effects on cardiovascular events (Inzucchi, 2005; Lamanna et al., 2011; Sasali & 
Leahy, 2003). In addition, metformin may decrease levels of markers of endothelial 
dysfunction by decreasing AGE levels (Jager et al., 2014). Furthermore, metformin 
has been shown to have anti-inflammatory effects by reducing levels of pro-
inflammatory cytokines which in turn improves endothelial function (Fidan, et al. 
2011; Jager, et al. 2014). Therefore, metformin can be considered a limiting factor in 
study 1.  
Another potential limitation is the use of several freeze–thaw cycles which 
may alter the activity and protein levels of FN3K as well as the levels of other 
measured proteins (i.e. markers of endothelial dysfunction) in relation to G-gap value 
over time. 
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6.4 Future studies   
Larger studies are necessary to obtain a better understanding of the role of 
FN3K in the deglycation process, including studies involving the measurement of 
FN3K genetic variants and their correlation with diabetes progression, and how this 
variation can be utilised in the management of the disease and its complications. 
Observing whether polymorphisms of FN3K (SNPs) can predict diabetic 
complications would also provide valuable information. Furthermore, assessment of 
the correlation between the activity of FN3K, markers of endothelial dysfunction and 
G-gap values through comparison of negative, positive and neutral values may be 
informative. 
For study 2, it was important to examine whether levels of AGEs were 
significantly correlated with FN3K levels in subjects treated with metformin. Studies 
of such correlations are ongoing at St George’s University Hospital. Moreover, 
further studies are needed to determine whether FN3K expression correlates with 
improvements in other clinical parameters of CVD and whether individuals with a 
high expression of FN3K have less severe exacerbated episodes and/or comorbidity 
with diabetes and other vascular disorders. Finally, further studies need to be carried 
out to identify the mechanisms responsible for promoter(s) that have an impact on 
the FN3K gene and activity for catalysing deglycation in larger cohorts.  
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Appendices 
Appendix I 
 
List of purchased materials for preparation of HEPES buffered erythrocyte lysate 
solution: 
Name of item  SKU-Pack Size 
 
Company name  
HEPES 
≥99.5% (titration) 
 
H3375-100G  Sigma-aldrich 
Leupeptin 
microbial, ≥90% 
(HPLC) 
 
L2884-.5MG Sigma-aldrich 
Dithiotreitol DTT D0632-1G Sigma-aldrich 
Antipain 50000 U/mg 10791-5MG Sigma-aldrich 
Sodium chloride 
BioXtra, ≥99.5% (AT) 
S7653-250G Sigma-aldrich 
Adenosine 5′-
triphosphate disodium 
salt hydrate 
A7699-1G Sigma-aldrich 
Trichloracetic acid Trichloracetic acid Sigma-aldrich 
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Appendix II  
Study 2 patients recruitment information: 
  Metformin in COPD: serum sample 
map 
 CI: Prof Emma Baker  
  Box ID: 5 Visit 1 (study entry)      Study 
contact: 
Dr Andrew 
Hitchings 
 
           ahitchin@sgul.ac.uk  
  Samples for Paul Kirkham, University of Wolverhampton   +44 (0)20 8725 
5380 
 
           +44 (0)7811 045 
737 
 
          Return 
address: 
Andrew Hitchings  
  Please refreeze and return residual serum     Clinical Research Facility 
           St George's, Univ of London 
  Key: 1 Participant number     Cranmer Terrace  
   JG Participant initials     London SW17 0RE  
           United Kingdom  
              
   1 2 3 4 5 6 7 8 9 10  
  A 1 2 3 4 5 17 18 29 36 37 
V
isit 1
 (stu
d
y e
n
try) 
  JG GC BA MM FH BRL RP GB JP IS 
  B 41 51 52 53 54 58 63 69 70 72 
  JC RW LC NJ PJ DG SW VS GP NC 
  C 73 74 75 76 77 78 79 80 81 82 
  RR RF WKP BP DR DS BG RB PE IW 
  D 83 87 93 94 95 96 97 101 102 103 
  LA AR CAM KT JC CR JL LCC DJ JK 
  E 105 106 107 108             
  TLB MF PN MW             
  F                     
 
                      
 
  G                      
                       
  H                      
                       
  I                      
                       
  J                      
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Metformin in COPD: serum sample map  CI: Prof Emma Baker  
Box ID: 6 Visits 2 (discharge) and 3 (follow-
up) 
 Study 
contact: 
Dr Andrew 
Hitchings 
 
         ahitchin@sgul.ac.uk  
Samples for Paul Kirkham, University of Wolverhampton   +44 (0)20 8725 
5380 
 
         +44 (0)7811 045 
737 
 
        Return 
address: 
Andrew Hitchings  
Please refreeze and return residual 
serum 
    Clinical Research Facility 
         St George's, Univ of London 
Key: 1 Participant number     Cranmer Terrace  
 JG Participant initials     London SW17 0RE  
         United Kingdom  
            
 1 2 3 4 5 6 7 8 9 10  
A 2 4 5 17 35 37 41 51 52 53 V
isit 2
 (h
o
sp
ital d
isch
arge
 7
d
ays after 
e
n
try) 
GC MM FH BRL RPW IS JC RW LC NJ 
B 54 58 63 70 74 75 76 77 78 79 
PJ DG SW GP RF WKP BP DR DS BG 
C 80 81 83 87 93 95 96 97 105 107 
RB PE LA AR CAM JC CR JL TLB PN 
D 108                   
MW                   
E                     
                    
F 1 4 5 17 18 29 35 37 41 51 
V
isit 3
 (fo
llo
w
-u
p
 2
9
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ays afte
r d
isch
arge) 
JG MM FH BRL RP GB RPW IS JC RW 
G 52 53 54 58 69 70 73 74 75 76 
LC NJ PJ DG VS GP RR RF WKP BP 
H 77 78 79 80 83 93 95 96 97 100 
DR DS BG RB LA CAM JC CR JL JT 
I 101 105 106 107 108           
LCC TLB MF PN MW           
J                     
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Appendix III 
Conference presentations 
1. Abstract: 0048-PD:                                                                                                 
A. Alderawi, S. Dunmore, A. Majebi, J. Brown, A. Narshi, A. Nayak, B. Singh4. 
Risk markers of macrovascular disease are related to the "Glycation Gap" in 
patients with diabetes. DOI: 10.13140/RG.2.1.3426.6961 Conference: World 
Diabetes Congress-International diabetes federation, At Vancouver.   
2. Abstract: 0017-PD                                                                                                                      
Simon Dunmore, Amr Alderawi, Aruna Narshi, James Brown, Paul Kirkham, 
Ananth Nayak, Baldev Singh. Fructosamine-3-kinase activity in erythrocytes is 
related to the "Glycation Gap" in patients with diabetes. Conference: World 
Diabetes Congress-International diabetes federation, At Vancouver. 
3.  Abstract: PA886 01 September 2015; volume 46, issue suppl 59.                    
Amr Alderawi, Simon Dunmore, Gaetano Caramori, Andrew Hitchings, Emma 
Baker and Paul Kirkham. Fructosamine-3-Kinase: A molecular link between 
COPD and diabetes regulating carbonyl stress and the impact of metformin 
treatment. Published in 2015 in European Respiratory Journal 46 (suppl 59). 
4. Abstract : 468-P 08 June  2017; Simon J. Dunmore, Amr S. Alderawi, Aruna 
Narshi, Fakhra Naseem, James E.P Brown, Alan Nevill, Ananth Nayak, 
Baldev M Singh: Evidence of the Role of Fructosamine-3-Kinase in the 
Glycation Gap and in Protection against Complications in Patients with 
Diabetes.  
